
<html lang="en"     class="pb-page"  data-request-id="e4ca02f8-69ab-4788-a68a-f95fb1ae4ac7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.1c00674;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-13;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis" /></meta><meta name="dc.Creator" content="Dana M.  Klug" /></meta><meta name="dc.Creator" content="Eftychia M.  Mavrogiannaki" /></meta><meta name="dc.Creator" content="Katherine C.  Forbes" /></meta><meta name="dc.Creator" content="Lisseth  Silva" /></meta><meta name="dc.Creator" content="Rosario  Diaz-Gonzalez" /></meta><meta name="dc.Creator" content="Guiomar  Pérez-Moreno" /></meta><meta name="dc.Creator" content="Gloria  Ceballos-Pérez" /></meta><meta name="dc.Creator" content="Raquel  Garcia-Hernández" /></meta><meta name="dc.Creator" content="Cristina  Bosch-Navarrete" /></meta><meta name="dc.Creator" content="Carlos  Cordón-Obras" /></meta><meta name="dc.Creator" content="Claudia  Gómez-Liñán" /></meta><meta name="dc.Creator" content="Andreu  Saura" /></meta><meta name="dc.Creator" content="Jeremiah D.  Momper" /></meta><meta name="dc.Creator" content="Maria Santos  Martinez-Martinez" /></meta><meta name="dc.Creator" content="Pilar  Manzano" /></meta><meta name="dc.Creator" content="Ali  Syed" /></meta><meta name="dc.Creator" content="Nelly  El-Sakkary" /></meta><meta name="dc.Creator" content="Conor R.  Caffrey" /></meta><meta name="dc.Creator" content="Francisco  Gamarro" /></meta><meta name="dc.Creator" content="Luis Miguel  Ruiz-Perez" /></meta><meta name="dc.Creator" content="Dolores  Gonzalez Pacanowska" /></meta><meta name="dc.Creator" content="Lori  Ferrins" /></meta><meta name="dc.Creator" content="Miguel  Navarro" /></meta><meta name="dc.Creator" content="Michael P.  Pollastri" /></meta><meta name="dc.Description" content="Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic ince..." /></meta><meta name="Description" content="Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic ince..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 22, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00674" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00674" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00674" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00674" /></link>
        
    
    

<title>Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00674" /></meta><meta property="og:title" content="Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0019.jpeg" /></meta><meta property="og:description" content="Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic incentive to develop new treatments for these diseases has meant that existing therapeutics have serious shortcomings in terms of safety, efficacy, and administration, and better therapeutics are needed. We now report a series of 3,5-disubstituted-7-azaindoles identified as growth inhibitors of Trypanosoma brucei, the parasite that causes HAT, through a high-throughput screen. We describe the hit-to-lead optimization of this series and the development and preclinical investigation of 29d, a potent antitrypanosomal compound with promising pharmacokinetic (PK) parameters. This compound was ultimately not progressed beyond in vivo PK studies due to its inability to penetrate the blood–brain barrier (BBB), critical for stage 2 HAT treatments." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00674"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00674">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00674&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00674&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00674&amp;href=/doi/10.1021/acs.jmedchem.1c00674" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 9404-9430</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00669" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00696" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Dana M. Klug</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dana M. Klug</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry & Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dana+M.++Klug">Dana M. Klug</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8982-0640" title="Orcid link">https://orcid.org/0000-0002-8982-0640</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eftychia M. Mavrogiannaki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eftychia M. Mavrogiannaki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry & Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eftychia+M.++Mavrogiannaki">Eftychia M. Mavrogiannaki</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katherine C. Forbes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katherine C. Forbes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry & Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katherine+C.++Forbes">Katherine C. Forbes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lisseth Silva</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisseth Silva</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry & Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisseth++Silva">Lisseth Silva</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rosario Diaz-Gonzalez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rosario Diaz-Gonzalez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rosario++Diaz-Gonzalez">Rosario Diaz-Gonzalez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guiomar Pérez-Moreno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guiomar Pérez-Moreno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guiomar++P%C3%A9rez-Moreno">Guiomar Pérez-Moreno</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gloria Ceballos-Pérez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gloria Ceballos-Pérez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gloria++Ceballos-P%C3%A9rez">Gloria Ceballos-Pérez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Raquel Garcia-Hernández</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Raquel Garcia-Hernández</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Raquel++Garcia-Hern%C3%A1ndez">Raquel Garcia-Hernández</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cristina Bosch-Navarrete</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cristina Bosch-Navarrete</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cristina++Bosch-Navarrete">Cristina Bosch-Navarrete</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carlos Cordón-Obras</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carlos Cordón-Obras</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carlos++Cord%C3%B3n-Obras">Carlos Cordón-Obras</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Claudia Gómez-Liñán</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claudia Gómez-Liñán</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claudia++G%C3%B3mez-Li%C3%B1%C3%A1n">Claudia Gómez-Liñán</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andreu Saura</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreu Saura</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreu++Saura">Andreu Saura</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeremiah D. Momper</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeremiah D. Momper</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, La Jolla, San Diego, California 92093, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeremiah+D.++Momper">Jeremiah D. Momper</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria Santos Martinez-Martinez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria Santos Martinez-Martinez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos 28760, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria+Santos++Martinez-Martinez">Maria Santos Martinez-Martinez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pilar Manzano</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pilar Manzano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos 28760, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pilar++Manzano">Pilar Manzano</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ali Syed</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ali Syed</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, La Jolla, San Diego, California 92093, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ali++Syed">Ali Syed</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nelly El-Sakkary</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nelly El-Sakkary</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, La Jolla, San Diego, California 92093, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nelly++El-Sakkary">Nelly El-Sakkary</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Conor R. Caffrey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Conor R. Caffrey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, La Jolla, San Diego, California 92093, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Conor+R.++Caffrey">Conor R. Caffrey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Francisco Gamarro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francisco Gamarro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francisco++Gamarro">Francisco Gamarro</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luis Miguel Ruiz-Perez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luis Miguel Ruiz-Perez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luis+Miguel++Ruiz-Perez">Luis Miguel Ruiz-Perez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dolores Gonzalez Pacanowska</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dolores Gonzalez Pacanowska</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dolores++Gonzalez+Pacanowska">Dolores Gonzalez Pacanowska</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4303-5209" title="Orcid link">https://orcid.org/0000-0002-4303-5209</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lori Ferrins</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lori Ferrins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry & Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#87eba9e1e2f5f5eee9f4c7e9e8f5f3efe2e6f4f3e2f5e9a9e2e3f2"><span class="__cf_email__" data-cfemail="fd91d39b988f8f94938ebd93928f8995989c8e89988f93d3989988">[email protected]</span></a>. Phone: 617-373-3715.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lori++Ferrins">Lori Ferrins</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-8992-0919" title="Orcid link">https://orcid.org/0000-0001-8992-0919</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Miguel Navarro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Miguel Navarro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Miguel++Navarro">Miguel Navarro</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Michael P. Pollastri</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael P. Pollastri</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry & Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+P.++Pollastri">Michael P. Pollastri</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9943-7197" title="Orcid link">https://orcid.org/0000-0001-9943-7197</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00674&amp;href=/doi/10.1021%2Facs.jmedchem.1c00674" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 9404–9430</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 22, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 April 2021</li><li><span class="item_label"><b>Published</b> online</span>22 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00674" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00674</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9404%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDana%2BM.%2BKlug%252C%2BEftychia%2BM.%2BMavrogiannaki%252C%2BKatherine%2BC.%2BForbes%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D13%26contentID%3Dacs.jmedchem.1c00674%26title%3DLead%2BOptimization%2Bof%2B3%252C5-Disubstituted-7-Azaindoles%2Bfor%2Bthe%2BTreatment%2Bof%2BHuman%2BAfrican%2BTrypanosomiasis%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9430%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00674"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">764</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00674" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Dana&quot;,&quot;last_name&quot;:&quot;M. Klug&quot;},{&quot;first_name&quot;:&quot;Eftychia&quot;,&quot;last_name&quot;:&quot;M. Mavrogiannaki&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;C. Forbes&quot;},{&quot;first_name&quot;:&quot;Lisseth&quot;,&quot;last_name&quot;:&quot;Silva&quot;},{&quot;first_name&quot;:&quot;Rosario&quot;,&quot;last_name&quot;:&quot;Diaz-Gonzalez&quot;},{&quot;first_name&quot;:&quot;Guiomar&quot;,&quot;last_name&quot;:&quot;Pérez-Moreno&quot;},{&quot;first_name&quot;:&quot;Gloria&quot;,&quot;last_name&quot;:&quot;Ceballos-Pérez&quot;},{&quot;first_name&quot;:&quot;Raquel&quot;,&quot;last_name&quot;:&quot;Garcia-Hernández&quot;},{&quot;first_name&quot;:&quot;Cristina&quot;,&quot;last_name&quot;:&quot;Bosch-Navarrete&quot;},{&quot;first_name&quot;:&quot;Carlos&quot;,&quot;last_name&quot;:&quot;Cordón-Obras&quot;},{&quot;first_name&quot;:&quot;Claudia&quot;,&quot;last_name&quot;:&quot;Gómez-Liñán&quot;},{&quot;first_name&quot;:&quot;Andreu&quot;,&quot;last_name&quot;:&quot;Saura&quot;},{&quot;first_name&quot;:&quot;Jeremiah&quot;,&quot;last_name&quot;:&quot;D. Momper&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Santos Martinez-Martinez&quot;},{&quot;first_name&quot;:&quot;Pilar&quot;,&quot;last_name&quot;:&quot;Manzano&quot;},{&quot;first_name&quot;:&quot;Ali&quot;,&quot;last_name&quot;:&quot;Syed&quot;},{&quot;first_name&quot;:&quot;Nelly&quot;,&quot;last_name&quot;:&quot;El-Sakkary&quot;},{&quot;first_name&quot;:&quot;Conor&quot;,&quot;last_name&quot;:&quot;R. Caffrey&quot;},{&quot;first_name&quot;:&quot;Francisco&quot;,&quot;last_name&quot;:&quot;Gamarro&quot;},{&quot;first_name&quot;:&quot;Luis&quot;,&quot;last_name&quot;:&quot;Miguel Ruiz-Perez&quot;},{&quot;first_name&quot;:&quot;Dolores&quot;,&quot;last_name&quot;:&quot;Gonzalez Pacanowska&quot;},{&quot;first_name&quot;:&quot;Lori&quot;,&quot;last_name&quot;:&quot;Ferrins&quot;},{&quot;first_name&quot;:&quot;Miguel&quot;,&quot;last_name&quot;:&quot;Navarro&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;P. Pollastri&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;9404-9430&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00674&quot;},&quot;abstract&quot;:&quot;Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic incentive to develop new treatments for these diseases has meant that existing therapeutics have serious shortcomings in terms of safety, efficacy, and administration, and better therapeutics are needed. We now report a series of 3,5-disubstituted-7-azaindoles identified as growth inhibitors of Trypanosoma brucei, the parasite that causes HAT, through a high-throughput screen. We describe the hit-to-lead optimization of this series and the development and preclinical investigation of 29d, a potent antitrypanosomal compound with promising pharmacokinetic (PK) parameters. This compound was ultimately not progressed beyond in vivo PK studies due to its inability to penetrate the blood–brain barrier (BBB), critical for stage 2 HAT treatments.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00674&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00674" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00674&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00674" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00674&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00674" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00674&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00674&amp;href=/doi/10.1021/acs.jmedchem.1c00674" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00674" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00674" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00674%26sid%3Dliteratum%253Aachs%26pmid%3D34156862%26genre%3Darticle%26aulast%3DKlug%26date%3D2021%26atitle%3DLead%2BOptimization%2Bof%2B3%252C5-Disubstituted-7-Azaindoles%2Bfor%2Bthe%2BTreatment%2Bof%2BHuman%2BAfrican%2BTrypanosomiasis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D13%26spage%3D9404%26epage%3D9430%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292365" title="Electromagnetic radiation">Electromagnetic radiation</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic incentive to develop new treatments for these diseases has meant that existing therapeutics have serious shortcomings in terms of safety, efficacy, and administration, and better therapeutics are needed. We now report a series of 3,5-disubstituted-7-azaindoles identified as growth inhibitors of <i>Trypanosoma brucei</i>, the parasite that causes HAT, through a high-throughput screen. We describe the hit-to-lead optimization of this series and the development and preclinical investigation of <b>29d</b>, a potent antitrypanosomal compound with promising pharmacokinetic (PK) parameters. This compound was ultimately not progressed beyond <i>in vivo</i> PK studies due to its inability to penetrate the blood–brain barrier (BBB), critical for stage 2 HAT treatments.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Human African trypanosomiasis (HAT) is designated by the World Health Organization as a neglected tropical disease (NTD), one of a group of 20 communicable diseases that are prevalent in tropical climates and disproportionately affect populations living in poverty.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> HAT is caused by infection with either of two subspecies of the parasite <i>Trypanosoma brucei</i> (<i>T. brucei gambiense</i> or <i>T. brucei rhodesiense</i>) and is fatal if untreated.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The disease proceeds in two stages; in the first stage, patients exhibit milder, flu-like symptoms and thus often go undiagnosed. In the second stage, the parasite crosses the blood–brain barrier (BBB) and causes more serious neurological symptoms, such as the severe disruption of sleep patterns from which the disease takes the colloquial name “African sleeping sickness.”<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Historically, the treatments available for HAT have been suboptimal in terms of efficacy, safety, and route of administration.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Recent advances include a combination therapy called nifurtimox–eflornithine combination therapy (NECT), which reduces the dose requirement for eflornithine, a repurposed cancer drug requiring hours-long intravenous infusions to administer, by combining it with nifurtimox, an oral treatment first used to treat Chagas disease (a related NTD).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Even more recently, the orally available drug fexinidazole has been approved to treat both stages of <i>T. brucei gambiense</i> HAT and has been added to the WHO treatment guidelines;<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and acoziborole, formerly known as SCYX-7158, has been advanced to Phase II/III clinical trials for HAT.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a></div><div class="NLM_p">However, as with any infectious disease, resistance to current therapies may develop, and it is important to fill the pipeline with backup compounds. As much of the drug discovery for NTDs is done by academic laboratories with limited resources, repurposing strategies (including but not limited to drug repurposing)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> are used to quickly identify chemical matter that may be suitable for further development. Such strategies take advantage of target function shared between human and parasite and assess compounds that were optimized against human targets as starting points for antiparasitic agents. In this instance, we exploited the fact that trypanosomes are known to express essential kinases by repurposing compounds originally designed as inhibitors of human kinases.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> A high-throughput screen (HTS) of over 40 000 kinase inhibitors, drawn largely from the published kinase inhibitor set (PKIS) and in-house GSK compounds, was undertaken and resulted in the identification of 797 compounds that showed <i>Trypanosoma brucei</i> growth inhibition (pEC<sub>50</sub> > 6.0) and 100× selectivity over HepG2 cells.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> These hits were then clustered by structural similarity, and the most promising were selected for further optimization.</div><div class="NLM_p">Due to a patient population that is likely to have limited access to health care facilities and the lack of effective therapeutics for stage 2 HAT, we sought a lead compound likely to be orally available and brain penetrant. Therefore, in addition to potency against <i>T. brucei</i> and mammalian cell toxicity, physicochemical properties and metrics such as the lipophilic ligand efficiency (LLE) and central nervous system-multiparameter optimization (CNS-MPO) score were used to prioritize clusters for further optimization.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> One of the clusters identified through this HTS comprised a series of 3,5-disubstituted-7-azaindoles. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> highlights the properties of three compounds in this series: <b>NEU-1207</b>, −<b>1208</b>, and −<b>1209</b>. Both <b>NEU-1207</b> and <b>NEU-1208</b> display pEC<sub>50</sub> > 7.0 against <i>T. brucei</i>; <b>NEU-1209</b> is ≥0.5 log units less potent. The longer aliphatic chain and primary amine of <b>NEU-1209</b> translate to suboptimal physicochemical properties, such as high molecular weight and topological polar surface area (TPSA), and a low CNS-MPO score; however, the other two compounds had properties in acceptable ranges, and we felt the series warranted further investigation.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Targeted versus Measured and Calculated Values for the Properties of Interest<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0008.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0009.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last"><i>nd</i> = no data. Values highlighted in green meet or exceed targeted values; values highlighted in yellow indicate acceptable values, and values highlighted in red indicate values that are well outside the target. <sup>†</sup>Kinetic aqueous solubility.</p></div></div><div></div></div><div class="NLM_p">In addition to these data, we also obtained pharmacokinetic (PK) data for <b>NEU-1207</b>. <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> shows the plasma concentration of this compound over time following a 5 mg/kg oral dose. The compound concentration was below the lower limit of quantitation after an average of 4.7 h <i>in vivo</i>, which is consistent with the observed high <i>in vitro</i> human liver microsome intrinsic clearance (HLM Cl<sub>int</sub>) for this compound (190 μg/min/mg protein). Metabolism was therefore identified as a key liability of this series going forward. Given the data on the initial hits and the PK profile of <b>NEU-1207</b>, our major goals for the series were to maintain or improve potency against <i>T. brucei</i> while improving the ADME properties of <b>NEU-1207</b> (in particular, its clearance and solubility) to develop an effective, orally available HAT therapeutic.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Plasma concentrations of <b>NEU-1207</b> over time after a 5 mg/kg oral dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We first sought to establish structure–activity relationships (SAR) around the 7-azaindole core of the series. The biological activity of these analogues is shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> (preparation described in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Schemes S1–S5</a>). Methylation (<b>1</b>) or tosylation (<b>2</b>) of the indole −NH resulted in a loss of activity against <i>T. brucei</i>, as did replacing the azaindole with a pyridofuran (<b>3</b>) or indole (<b>4</b>). These analogues demonstrated that the hydrogen bond donor/acceptor pair of the azaindole core was required for potency. The methylated-core analogue <b>5</b>, which we anticipated might increase solubility by virtue of breaking the planarity of the molecule, maintained potency without any improvement in clearance or solubility. The substituents at the 3- and 5-positions of the core were interchangeable without sacrificing substantial activity (<b>6</b> vs <b>NEU-1207</b>), while removing either one (<b>7</b> and <b>8</b>) rendered the compound inactive.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Biological Activity of Core-Replacement Analogues<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0010.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last"><i>nd</i> = no data. All pEC<sub>50</sub> SD within ±0.17.</p></div></div><div></div></div><div class="NLM_p">The HLM Cl<sub>int</sub> of the core-replacement analogues was also assessed, but only compound <b>2</b> showed a significant reduction compared to <b>NEU-1207</b>. To better understand the high clearance of these compounds, predictive software was used to determine likely sites of metabolism. <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> shows the most likely metabolites for <b>NEU-1207</b> as predicted by MetaSite 5.0 (Molecular Discovery Ltd.). Both are the products of oxidation at substituents on either the 3- or 5-position substituents of the 7-azaindole core, consistent with the clearance data presented in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. We therefore focused further efforts on varying substituents at these positions.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Predicted metabolites of <b>NEU-1207</b> using MetaSite software.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of analogues varied at the 3-position is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. By maintaining the pyrazole at the 5-position, we employed a parallel-enabled synthetic route. The pyrazole was installed by reacting 5-bromo-7-azaindole <b>9</b> with 1-methyl-4-pyrazoleboronic acid pinacol ester under Suzuki conditions to afford intermediate <b>7</b>. This compound was iodinated using NIS and subsequently tosylated to afford intermediate <b>11</b>, which could then undergo a second Suzuki reaction with the desired boronic acid or ester to afford the protected products <b>12</b>. Under basic conditions, the tosyl group was removed to afford the final products <b>13a-aa</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 3-Position Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (a) 1-methyl-4-pyrazoleboronic acid pinacol ester, K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/water, 85 °C, 4 h (93%). (b) NIS, acetonitrile, 50 °C, 2 h (69%). (c) Tosyl chloride, 4-dimethylaminopyridine (DMAP), triethylamine (TEA), dichloromethane (DCM), rt, 12 h (89%). (d) Aryl boronic acid or pinacol ester, K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/water, 120 °C, μw, 30 min (24–85%). (e) NaOH (2 M aq), dioxane, 150 °C, μw, 1–10 min (10–83%). Ar = aryl group.</p></p></figure><div class="NLM_p">The <i>T. brucei</i> activity, <i>in vitro</i> clearance, and thermodynamic aqueous solubility of the aromatic benzonitrile replacements are shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Moving the nitrile to the 2- (<b>13a</b>) or 4- (<b>13b</b>) position of the benzene ring resulted in ∼10-fold reduction in potency; an unsubstituted benzene ring (<b>13c</b>) was slightly more potent. 4-Chloro, -methyl, and -trifluoromethyl substituents (<b>13d–f</b>, <b>13i</b>) were detrimental to antitrypanosomal activity compared to the parent compound, while the methoxy group (<b>13g</b>) fared slightly better. A series of fluorinated analogues (<b>13j–o</b>), both with and without a nitrile group, maintained submicromolar potency, but only two of these compounds, 3-fluoro (<b>13j</b>) and 3-cyano-5-fluoro (<b>13n</b>), were equipotent to <b>NEU-1207</b>. Although some of these compounds did show improved clearance over <b>NEU-1207</b>, all of them remain in the “high clearance” category (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Table S1</a>) and only a few were soluble at concentrations >10 μM.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biological Activity, HLM Cl<sub>int</sub>, and Aqueous Solubility of Aromatic Benzonitrile Replacement Analogues<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0011.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0012.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last"><i>nd</i> = no data. All pEC<sub>50</sub> SD within ±0.17.</p></div></div><div></div></div><div class="NLM_p">Further nitrile replacements included the amide (<b>13p</b>), carboxylic acid (<b>13q</b>), amine (<b>13r</b>), and nitro (<b>13t</b>) groups. In addition, the 4-<i>N</i>,<i>N</i>-dimethylmethanamine (<b>13s</b>) and 4-hydroxy (<b>13u</b>) substituents, both included in another azaindole-derived HTS cluster, were synthesized. Of these analogues, the amine and hydroxy substituents were equipotent to <b>NEU-1207</b>, and the nitro substituent showed an increase in potency (pEC<sub>50</sub> 7.6). Although <b>13r</b> showed vastly improved solubility, the HLM Cl<sub>int</sub> remained problematic, and both <b>13t</b> and <b>13u</b> showed signs of toxicity in mammalian cells (a known liability of nitrobenzenes and phenols; see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Table S2</a>). The benzoxadiazole (<b>13v</b>) and indole (<b>13w</b>) were designed as bioisosteres of the nitro and hydroxy groups, respectively, in an attempt to recapitulate the improved potency and solubility of the parent compounds; however, both resulted in decreased activity against trypanosomes.</div><div class="NLM_p">In a final attempt to improve the ADME properties by modification of the benzonitrile substituent, insertion of a heteroatom led to 3-pyridyl (<b>13x</b>) and 4-pyridyl (<b>13y</b>) analogues. Although these compounds did show a decrease in HLM Cl<sub>int</sub> and an increase in solubility as compared to <b>NEU-1207</b>, they had lower antitrypanosomal activity. Seeking additive SAR, we synthesized nitrile-substituted pyridyl groups (<b>13z-aa</b>) based on the previous SAR (cf. <b>NEU-1207</b> vs <b>13c</b>). However, these analogues lost activity compared to the unsubstituted pyridyl compounds and the beneficial ADME properties were lost as well. Although <b>13y</b> showed the best combination of potency, clearance, and solubility, none of the aromatic groups installed at the 3-position had values within the desirable range for all three properties simultaneously.</div><div class="NLM_p">In addition to aromatic substituents, aliphatic groups were also installed at the 3-position. The synthesis of these analogues is shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The 5-bromo-7-azaindole starting material <b>9</b> was converted to the dihalide <b>14</b> and subsequently tosylated to afford intermediate <b>15</b>. A Suzuki reaction with 5- and 6-membered cyclic amine boronic acids produced the olefin compounds <b>16</b>, and a second Suzuki reaction to install <i>N</i>-methylpyrazole at the 5-position afforded disubstituted intermediates <b>17</b>. The olefin was reduced via transfer hydrogenation using ammonium formate to produce intermediates <b>18</b>, which were subsequently deprotected to afford the final products <b>19a–c</b> and <b>20a–c</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Aliphatic 3-Position Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (a) NIS, acetonitrile, 50 °C, 2 h (83%). (b) Tosyl chloride, Et<sub>3</sub>N, DMAP, DCM, rt, 12 h (78%). (c) Boronic ester, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 3:1 dioxane/water, 80 °C, 10 min, μw (56–73%). (d) 1-Methyl-4-pyrazoleboronic acid pinacol ester, K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/water, 85 °C, 4 h (83–93%). (e) NH<sub>4</sub>COO, 10% Pd/C, EtOH, 85 °C, 1.5 h (59–68%). (f) 2 M aq NaOH, dioxane, 150 °C, 15 min, μw (44–75%). (g) HCl, dioxane, 1–3 h, rt (78–97%).</p></p></figure><div class="NLM_p">The biological activity, clearance, and solubility of analogues containing an aliphatic group at the 3-position are shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. These compounds were designed to increase the Fsp<sup>3</sup>, a known strategy to increase the solubility of highly aromatic, “flat” compounds.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> None of these compounds displayed submicromolar activity against <i>T. brucei</i>, indicating that aromaticity in this position is essential for antitrypanosomal activity. However, those compounds that possessed a basic amine showed a consistent and dramatic improvement in HLM Cl<sub>int</sub> and aqueous solubility, the latter likely due to increased ionization at physiological pH.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Biological Activity, HLM Cl<sub>int</sub>, and Aqueous Solubility of Aliphatic Benzonitrile Replacement Analogues<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0013.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0014.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">All pEC<sub>50</sub> SD within ±0.17.</p></div></div><div></div></div><div class="NLM_p">We next turned our attention to the pyrazole at the 5-position of the azaindole, also identified as a potential metabolic hotspot. Aromatic substituents were installed according to <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> using the advanced intermediate <b>15</b>. Short reaction times in a microwave reactor enabled selective Suzuki coupling of the aryl iodide with (3-cyanophenyl)boronic acid to afford intermediate <b>21</b>. A second Suzuki reaction at the 5-position yielded intermediates <b>22</b>, which were detosylated to afford final products <b>23a–f</b>. Alternatively, intermediate <b>21</b> was subjected to palladium-mediated coupling conditions to afford 5-amino-substituted azaindoles <b>24</b>, where the tosyl group was deprotected under the reaction conditions. The syntheses of compounds <b>25</b>–<b>28</b> are presented in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Schemes S7 and S8</a>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 5-Position Aromatic and Cyclic Amine Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (a) (3-cyanophenyl)boronic acid, K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/water, 120 °C, μw, 5 min (60%). (b) Aryl boronic acid or pinacol ester, K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/water, 85 °C, 4 h (31–84%). (c) NaOH (2 M aq), dioxane, 150 °C, μw, 1–10 min (10–83%). (d) Amine, LiHMDS (1.0 M in tetrahydrofuran (THF)), RuPhos, RuPhos Pd G1, 65 °C, 5 h (12–30%).</p></p></figure><div class="NLM_p">The biological activity, clearance, and solubility data of the pyrazole replacement analogues are shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. Many of the analogues with aromatic substituents (<b>23a,b</b>, <b>23d</b>, and <b>23f</b>), as well as compounds with an intervening <i>N</i> atom (<b>27</b>, <b>28</b>), were approximately equipotent with respect to <b>NEU-1207</b>, although the trisubstituted pyrazole (<b>23c</b>) and pyrimidine (<b>23e</b>) were almost 10-fold less potent. In general, aliphatic replacements of the pyrazole were inactive, except for the methylsulfonylpiperazine analogue (<b>25</b>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Biological Activity, HLM Cl<sub>int</sub>, and Aqueous Solubility of Aromatic and Aliphatic Pyrazole Replacement Analogues<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0015.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0016.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last"><i>nd</i> = no data. All pEC<sub>50</sub> SD within ±0.17.</p></div></div><div></div></div><div class="NLM_p">The clearance of pyrazoles <b>23a–c</b> remained quite high, whereas replacement with methylsulfonyl benzene or pyrimidine significantly lowered the clearance, though poor aqueous solubility was still generally an issue, with <b>23a</b> being the exception (aqueous solubility: 26 μM). In addition, most aliphatic substituents also had improved clearance over <b>NEU-1207</b>. Insertion of an intervening −NH resulted in improved solubility of compound <b>27</b>. This was thought to be due to the inclusion of an ionizable group, although <b>28</b> was no more soluble than its matched pair <b>23d</b>. Aliphatic substituents containing a basic nitrogen distal to the azaindole core (<b>24c</b>, <b>24e</b>, and <b>26</b>) resulted in significantly improved solubility; aliphatic substituents without this feature (<b>24a, b</b>) or those where the basicity of the distal nitrogen was attenuated by further substitution (<b>24d</b>, <b>25</b>) did not show similar improvement.</div><div class="NLM_p">Finally, we explored a variety of substituted pyrazoles at the 5-position, including tetrahydropyran (<b>29a</b>), <i>N</i>-boc-piperidine (<b>29b</b>), and <i>N</i>-methyl piperidine (<b>29c</b>). The synthesis of these compounds is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Scheme S9</a>. Of these, <b>29a</b> showed a significant (10-fold) improvement in potency, becoming the most potent compound to date for this series, which was reflected in its high LLE. In addition, both <b>29a</b> and <b>29c</b> showed a significant reduction in HLM Cl<sub>int</sub>, suggesting that the <i>N</i>-alkyl pyrazole moiety constitutes the major metabolic liability of this chemotype. This reduction in clearance represented a major step forward in resolving a critical issue for this series. However, all three of these substituted pyrazoles displayed poor solubility (<10 μM), prompting further optimization efforts.</div><div class="NLM_p">We sought to improve the solubility of <b>29a</b> using insights from the established SAR. Previously, both pyridyl and saturated groups at the 5-position had resulted in higher solubility. The synthesis of these compounds with the tetrahydropyran-substituted pyrazole in the 5-position is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Schemes S10 and S11</a>. In this case, the inclusion of the pyridine (<b>30</b>) did not result in significant solubility improvement, and the inclusion of a saturated group (<b>31</b>) while improving both solubility and HLM clearance, was significantly detrimental to potency, despite the presence of the <i>N</i>-tetrahydropyran-2-yl (THP)-substituted pyrazole. Replacement of the tetrahydropyran moiety with a piperidinyl group (<b>29d</b>) to incorporate an additional H-bond donor resulted in a compound with the best combination of potency, solubility, and clearance thus far.</div><div class="NLM_p">In a final effort to improve the ADME properties of <b>29a</b>, we returned to the strategy of making further modifications to the core (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>; synthesis shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Scheme S12</a>). It was hypothesized that increasing the polarity of the azaindole may improve clearance and solubility; as such, the azaindole core was replaced with a pyrazolopyridine (<b>32</b>). In addition, <i>ortho-</i>methylation is known to improve the aqueous solubility of compounds,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and we had previously demonstrated that this change did not impact the potency of the series (cf. compound <b>5</b>). We reasoned that the installation of methyl at the 4-position of <b>29d</b> (compound <b>33</b>) could increase aqueous solubility due to a steric clash with the tetrahydropyran that would twist the substituent out of plane. However, neither of these modifications produced the desired improvement in ADME properties.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Biological Activity, HLM Cl<sub>int</sub>, and Aqueous Solubility of Substituted Pyrazoles and Related Analogues<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0017.gif" alt="" id="fx10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0018.gif" alt="" id="fx11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">All pEC<sub>50</sub> SD within ±0.17.</p></div></div><div></div></div><div class="NLM_p">Given its combination of high potency, improved LLE, low clearance, and reasonable (>10 μM) solubility, we obtained additional data on compound <b>29d</b> (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). In addition to its pEC<sub>50</sub> of 7.2, this compound is nontoxic in MRC5 cells (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Table S2</a>), has an LLE of 4.8, and a CNS-MPO score of 4.4, indicating a likelihood of brain penetration. In addition, it is stable in mouse plasma and its plasma protein binding is below the threshold of 95%. The major potential liabilities with this compound continue to be related to metabolism: although its HLM Cl<sub>int</sub> is low, the clearance in rat hepatocytes and mouse liver microsomes (MLM) is higher, and this discrepancy could potentially pose issues when evaluating safety and efficacy in rodent animal models.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Overall Profile of <b>29d</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="center" char=".">targeted value</th><th class="colsep0 rowsep0" align="center" char="."><b>29d</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T.b.b</i>. pEC<sub>50</sub></td><td class="colsep0 rowsep0" align="char" char=".">≥7</td><td class="colsep0 rowsep0" align="char" char=".">7.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein-binding-adjusted <i>T.b.b</i>. EC<sub>50</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">256</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRC5 pTC<sub>50</sub></td><td class="colsep0 rowsep0" align="char" char=".">≤5</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LLE</td><td class="colsep0 rowsep0" align="char" char=".">≥4</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CNS-MPO score</td><td class="colsep0 rowsep0" align="char" char=".">≥4</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aq. sol. (μM)</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HLM Cl<sub>int</sub> (μL/min/mg protein)</td><td class="colsep0 rowsep0" align="char" char="."><9</td><td class="colsep0 rowsep0" align="char" char="."><3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat hepatocyte Cl<sub>int</sub> (μL/min/10<sup>6</sup> cells)</td><td class="colsep0 rowsep0" align="char" char="."><5</td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse plasma stability <i>t</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">>120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MLM <i>t</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="char" char=".">>60</td><td class="colsep0 rowsep0" align="char" char=".">34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB</td><td class="colsep0 rowsep0" align="char" char="."><95</td><td class="colsep0 rowsep0" align="char" char=".">91</td></tr></tbody></table></div></div><div class="NLM_p">Despite the concerns about rodent clearance, we felt that the potency of <b>29d</b> combined with its other, more favorable ADME properties, justified the progression of this compound to <i>in vivo</i> pharmacokinetic (PK) studies. Continuous sampling at a 10 mg/kg intraperitoneal (ip) dose showed an average <i>C</i><sub>max</sub> of 4413.3 ng/mL 1 h after dosing (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Calculation of the protein-binding-adjusted EC<sub>50</sub> (EC<sub>50</sub>/<i>f</i><sub>u</sub>, 256 ng/mL) reveals that exposure over the adjusted EC<sub>50</sub> is maintained for ∼8 h, which is a marked improvement over <b>NEU-1207</b> (which, when accounting for PPB, did not achieve levels over the EC<sub>50</sub> (378 ng/mL) for the duration of the study). However, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>, compound <b>29d</b> is not appreciably brain penetrant. We sought to gain a better understanding of the permeability and efflux of <b>29d</b> using a Caco-2 assay (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Table S3</a>), which revealed that <b>29d</b> had low permeability and is likely a substrate for P-gp or other active transporters. Given this information and the PK data, we concluded that the series was not likely to yield a compound appropriate for treating stage 2 HAT and did not undertake further optimization or pursue efficacy studies on compound <b>29d</b>.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Plasma concentration versus time profile of <b>29d</b> in mice (<i>n</i> = 3) following a single 10 mg/kg ip dose. The blue dashed line shows the average concentration and the shaded area represents the standard deviation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Sparse Sampling Brain and Plasma Concentration of <b>29d</b> after a 10 mg/kg, ip Dose<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">time (h)</th><th class="colsep0 rowsep0" align="center" char=".">mean plasma concentration (ng/mL)</th><th class="colsep0 rowsep0" align="center">mean brain concentration (ng/mg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">3193.7</td><td class="colsep0 rowsep0" align="left"><LLOQ</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">426.3</td><td class="colsep0 rowsep0" align="left">0.22</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">LLOQ = 9.77 ng/mL.</p></div></div></div><div class="NLM_p">It should be noted that a lack of CNS penetration was observed for another compound in this series (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Table S4</a>), which also had a high CNS-MPO score (>5; see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Table S5</a>). Although unavailable to us at the time, we have since calculated a BBB score<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> for both compounds, according to which neither compound is predicted to penetrate the CNS (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Table S6</a>). The BBB score differs from the CNS-MPO score in the properties it takes into account, the functions used to assign T0 values to those properties, and the weight given to each, and higher sensitivity and specificity have been reported for the BBB score over the CNS-MPO score.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">For compound <b>29d</b>, the components that are most detrimental to the overall BBB score are the number of aromatic rings, which is not factored into the CNS-MPO score calculation, and the TPSA, which gives a T0 of 1 using the CNS-MPO calculator and a T0 of 0.43 using the BBB calculator. Thus, analysis of the BBB score of <b>29d</b> would suggest that a reduction in the number of aromatic rings and a reduction in the TPSA would improve its brain penetration, although it is unclear whether this would be effective if <b>29d</b> is indeed a P-gp substrate. One limitation of both metrics in our hands is the use of predicted p<i>K</i><sub>a</sub> values, which can vary depending on the programs used to calculate them. Another is the general lack of guidance for the physicochemical properties required for therapeutics that are both orally available and brain penetrant, of great importance for stage 2 HAT therapeutics. However, it appears that the BBB score is a better predictor of brain penetration than the CNS-MPO score for this series and may be of greater use for HAT drug discovery going forward.</div><div class="NLM_p last">Finally, as part of an ongoing cross-screening effort by our group, the compounds synthesized during this optimization campaign were screened against <i>Trypanosoma cruzi</i>, <i>Leishmania donovani</i>, and <i>Schistosoma mansoni</i>, the causative parasites of Chagas disease, leishmaniasis, and schistosomiasis, respectively. Although compounds active against <i>T. brucei</i> are not assumed to have broad antiparasitic activity, we have had some success with this approach as a way of generating new lead series against other pathogens by screening all compounds synthesized as part of our HAT medicinal chemistry campaigns against multiple parasites.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The data are presented in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">Tables S7 and S8</a>). None of the compounds in this series showed activity against <i>L. donovani</i>, and only one showed submicromolar activity against <i>T. cruzi</i>. To adjudicate the potency of compounds against adult <i>S. mansoni</i>, we employed a severity scoring system (0–4 (severest)),<a onclick="showRef(event, 'ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22">(19−22)</a> which encapsulates many phenotypic changes (e.g., motility, density, shape, and inability to adhere to the bottom of the assay dish) that this parasite is capable of as a function of time and compound concentration.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> At 10 μM for 48 h, compounds <b>1</b> and <b>13o</b> demonstrated modest activity, whereby both yielded a severity score of 2.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60128" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60128" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Using a lead repurposing approach, we identified a series of 3,5-disubstituted-7-azaindoles with antitrypanosomal activity through an HTS of human kinase inhibitor chemotypes. Through a detailed SAR study, we identified <b>29d</b> which retained submicromolar activity against<i>T. brucei</i> while showing improved aqueous solubility and dramatically improved HLM Cl<sub>int</sub> over the original HTS hit. This compound was progressed to <i>in vivo</i> PK studies and maintained a free plasma concentration greater than or equal to EC<sub>50</sub> for ∼8 h after a 10 mg/kg ip dose. However, the low brain penetration of this series precluded it from progression as a HAT therapeutic, as the resulting low brain concentrations mean that the compounds would not be effective in the target tissue for stage 2 of the disease. Similar limitations were observed for a related compound and, therefore, work on the series discontinued for HAT. Cross-screening against <i>T. cruzi</i>, <i>L. donovani</i>, and <i>S. mansoni</i> did not result in potent inhibitors against any of these pathogens.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20072" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20072" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> <i>In Vitro</i> Biology</h3><div class="NLM_p last">To determine the <i>T. b. brucei</i> EC<sub>50</sub> values, 4 μL per well from compound master plates was dispensed into a new plate, and 96 μL of HMI-9 per well was added to generate a 4% dimethyl sulfoxide (DMSO) intermediate plate. Mid-log phase growth <i>T. b. brucei</i> was diluted to a working cell density of 2750 cells/mL, and 90 μL/well was dispensed into 96-well flat-bottom transparent assay plates (Nunc). From intermediate plates, 10 μL/well was added so that the final cell concentration was 2500 cells/mL, and the final top concentration of compounds was 40 μM in 0.4% DMSO per well. Assay plates were incubated for 72 h at 37 °C and 5% CO<sub>2</sub>. Four hours prior to the end of the incubation, 20 μL of a 440 μM resazurin solution in prewarmed HMI-9 was added to each well and incubated for another 4 h. Fluorescence was then measured in an Infinite F200 plate reader (Tecan) at 550 nm (excitation filter) and 590 nm (emission filter). A four-parameter equation was employed to fit the dose–response curves and determine the EC<sub>50</sub> value using SigmaPlot 13.0 software. Assays were performed in duplicate at least twice to achieve a minimal <i>n</i> = 2 per dose–response.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Pharmacokinetic Protocols</h3><div class="NLM_p"><i>In vivo</i> pharmacokinetics were evaluated in BALB/c mice (<i>n</i> = 3). Each mouse received a 10 mg/kg dose of the test compound by intraperitoneal injection. Blood samples (50 μL) were taken via retro-orbital bleeds at 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h postdose. Plasma concentrations were determined using liquid chromatography with tandem mass spectrometry (LCMS-MS).</div><div class="NLM_p last">Animal studies for <b>NEU-1207</b> were ethically reviewed and carried out in accordance with European Directive 2010/63/EEC and the GSK Policy on the Care, Welfare and Treatment of Animals; meanwhile, the study for <b>29d</b> was conducted under animal use protocols approved by the University of California, San Diego Institutional Animal Care and Use Committee.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Chemistry</h3><div class="NLM_p">Reagents purchased were used as received unless otherwise noted. Purification of intermediates and final compounds was performed using silica gel chromatography using the Biotage Isolera One flash purification system. When required, preparative high-performance liquid chromatography (HPLC) was conducted for final compounds on a Waters FractionLynx system using acetonitrile/water and 0.1% formic acid gradient and collected based on UV monitoring at 254 nm. LCMS analysis was performed using a Waters Alliance reverse phase HPLC (columns Waters SunFire C18 4.6 × 50 mm<sup>2</sup>, 3.5 μm, or Waters SunFire C8 4.6 × 50 mm<sup>2</sup>, 3.5 μm), using a multiwavelength photodiode array detector from 210 to 600 nm and Waters Micromass ZQ detector (electrospray ionization). All compounds tested had a purity of >95% as measured by LCMS unless otherwise noted. <sup>1</sup>H NMR spectra were obtained with Varian NMR systems, operating at either 400 or 500 MHz at room temperature, using solvents from Cambridge Isotope Laboratories. Chemical shifts (δ, ppm) are reported relative to the solvent peak (CDCl<sub>3</sub>: 7.26 [<sup>1</sup>H]; DMSO-<i>d</i><sub>6</sub>: 2.50 [<sup>1</sup>H]; acetone-<i>d</i><sub>6</sub>: 2.05; or CD<sub>3</sub>OD: 3.31 [<sup>1</sup>H]). Data for <sup>1</sup>H NMR spectra are reported as follows: chemical shift (ppm), multiplicity (s for singlet, d for doublet, t for triplet, dd for doublet of doublet, m for multiplet), coupling constant (Hz), and integration. Compounds obtained from GSK in-house library were not resynthesized unless otherwise noted.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> General Procedure A (For the Synthesis of 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-aryl-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridines)</h4><div class="NLM_p last">Intermediate <b>11</b> (1.0 equiv), desired boronic acid or ester (2.5 equiv), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (10 mol %) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (0.26 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (3.0 equiv) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave at 120 °C for 30 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure, and the title compound was purified by the stated method to afford the title compounds.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> General Procedure B (For the Synthesis of 3-(5-Aryl-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitriles)</h4><div class="NLM_p last">3-(5-Bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (1 equiv), the desired boronic acid or ester (1.1 equiv), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (0.1 equiv) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Dioxane (0.17 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (5 equiv) were added, and the reaction mixture was degassed. The reaction mixture was heated at 85 °C for ∼4–5 h, then diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by the stated method to afford the final compounds.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Procedure C (For the Synthesis of 3-(5-Amino-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitriles)</h4><div class="NLM_p last">3-(5-Bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (1 equiv), RuPhos (0.05 equiv), and RuPhos Pd G1 (0.05 equiv) were combined in a vial that was filled with nitrogen and evacuated three times. Then, 1.0 M LiHMDS in THF (2.5 equiv) was added, followed by the addition of the desired amine (1.8 equiv). The reaction mixture was heated at 65 °C for ∼5 h, then quenched by the addition of 1 M HCl, diluted with EtOAc, and poured over sat. aq. NaHCO<sub>3</sub>. The aqueous layer was extracted three times with EtOAc, and the combined organic layers were washed once with brine, dried with sodium sulfate, and concentrated under reduced pressure. The crude residue was purified by the stated method to afford the title compounds.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> General Procedure D (For the Synthesis of Detosylated 3,5-Disubstituted-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridines)</h4><div class="NLM_p last">The tosylated azaindole starting material (1.0 equiv) was suspended in dioxane (0.10 M), and 2 M NaOH (3.5–5.0 equiv) was added. The reaction was run in the microwave at 150 °C for the specified amount of time. The solvent was removed by rotovap, and the crude material was purified by the stated method to afford the title compounds.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Procedure E (For the Synthesis of Aryl 4,4,5,5-Tetramethyl-1,3,2-dioxaborolanes)</h4><div class="NLM_p">The desired aryl halide (1.0 equiv), bis(pinacolato)diboron (1.5 equiv), potassium acetate (3.5 equiv), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (0.05 equiv) were combined in a microwave vial that was filled with nitrogen and evacuated three times. Dry, degassed dioxane (0.13 M) was added and the reaction was run in the microwave (145 °C) for 30 min. The reaction mixture was diluted with MeOH, filtered through Celite, and concentrated. The crude material was purified by the stated method to afford the title compounds.</div><div id="sec4_3_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> 3-(1-Methyl-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>1</b>)</h5><div class="NLM_p last">3-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>NEU-1207</b> (58 mg, 0.194 mmol) was dissolved in dry dimethylformamide (DMF; 0.30 mL, 0.65 M). The reaction mixture was cooled to 0 °C, and sodium hydride (81 mg, 0.387 mmol) was added. The reaction mixture was stirred at 0 °C for ∼1 h before the addition of methyl iodide (25 μL, 0.401 mmol). The reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was diluted with EtOAc, poured over cold water, and extracted twice. The combined organic layers were washed once with brine, dried with sodium sulfate, and concentrated under reduced pressure. The crude residue was purified by flash chromatography (0–10% MeOH/EtOAc) to afford the title compound as an off-white solid (41 mg, 97%). LCMS [M + H]<sup>+</sup> 314.16 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.60 (d, <i>J</i> = 2.0 Hz, 1H), 8.46 (d, <i>J</i> = 2.0 Hz, 1H), 8.28 (s, 1H), 8.17 (s, 1H), 8.11–8.14 (m, 2H), 8.02 (s, 1H), 7.69 (s, 1H), 7.66 (d, <i>J</i> = 7.8 Hz, 1H), 3.89 (s, 3H), 3.88 (s, 3H).</div></div><div id="sec4_3_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 3-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>2</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 199 mg scale using (3-cyanophenyl)boronic acid. The crude material was purified by flash chromatography (20–80% EtOAc/hexanes) to afford the title compound as a light orange solid (135 mg, 71%). LCMS [M + H]<sup>+</sup> 454.16 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.70 (d, <i>J</i> = 2.0 Hz, 1H), 8.42 (d, <i>J</i> = 2.0 Hz, 1H), 8.40 (s, 1H), 8.34 (t, <i>J</i> = 1.5 Hz, 1H), 8.31 (s, 1H), 8.20 (dt, <i>J</i> = 7.8, 1.5 Hz, 1H), 8.06 (s, 1H), 8.04 (d, <i>J</i> = 3.4 Hz, 2H), 7.85 (dt, <i>J</i> = 7.8, 1.0 Hz, 1H), 7.70 (t, <i>J</i> = 7.8 Hz, 1H), 7.44 (d, <i>J</i> = 8.8 Hz, 2H), 3.88 (s, 3H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)furo[2,3-<i>b</i>]pyridine (<b>S2</b>)</h5><div class="NLM_p last">5-Bromofuro[2,3-<i>b</i>]pyridine <b>S1</b> (177 mg, 0.893 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (205 mg, 0.985 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (37 mg, 0.045 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Dioxane (5.2 mL, 0.17 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (1.3 mL, 2.60 mmol) were added, and the reaction mixture was degassed for 10 min. The reaction mixture was heated at 85 °C for ∼4.5 h. The reaction mixture was diluted with MeOH and filtered through Celite. The filtrate was purified by flash chromatography (20–50% EtOAc/Hex) to afford the title compound as an off-white solid (140 mg, 79%). LCMS [M + H]<sup>+</sup> 199.95 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 8.46 (s, 1H), 7.99 (d, <i>J</i> = 2.0 Hz, 1H), 7.79 (s, 1H), 7.72 (d, <i>J</i> = 2.0 Hz, 1H), 7.67 (s, 1H), 6.79 (d, <i>J</i> = 2.4 Hz, 1H), 3.99 (s, 3H).</div></div><div id="sec4_3_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 3-Bromo-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)furo[2,3-<i>b</i>]pyridine (<b>S3</b>)</h5><div class="NLM_p last">5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)furo[2,3-<i>b</i>]pyridine <b>S2</b> (70 mg, 0.351 mmol) was dissolved in DCM (4.2 mL, 0.09 M) and cooled to 0 °C. Bromine (0.4 M in DCM, 0.95 mL, 0.380 mmol) was added dropwise to the reaction mixture. The reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was concentrated, redissolved in THF (∼5 mL), and treated dropwise with 1 M KOH in MeOH (∼1 mL), upon which the reaction mixture turned cloudy. The reaction mixture was stirred at room temperature for ∼10 min, then poured over water, and extracted three times with EtOAc. The combined organic layers were washed once with brine, dried with sodium sulfate, and concentrated under reduced pressure. The crude material was purified by flash chromatography (20–40% EtOAc/Hex) to afford the title compound as an off-white solid (34 mg, 35%). 278.04 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 279.99 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 8.50 (d, <i>J</i> = 2.0 Hz, 1H), 7.93 (d, <i>J</i> = 2.0 Hz, 1H), 7.83 (s, 1H), 7.77 (s, 1H), 7.72 (s, 1H), 4.00 (s, 3H).</div></div><div id="sec4_3_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 3-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)furo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>3</b>)</h5><div class="NLM_p last">3-Bromo-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)furo[2,3-<i>b</i>]pyridine <b>S3</b> (34 mg, 0.122 mmol), (3-cyanophenyl)boronic acid (26 mg, 0.176 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (6 mg, 0.007 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (0.60 mL, 0.21 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.30 mL, 0.600 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (120 °C) for 5 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (1% MeOH/DCM) and then repurified by flash chromatography (30–50% EtOAc/hexanes) to afford the title compound as an off-white solid (59%). LCMS [M + H]<sup>+</sup> 301.15 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 8.53 (d, <i>J</i> = 2.0 Hz, 1H), 8.13 (d, <i>J</i> = 2.4 Hz, 1H), 7.95 (s, 1H), 7.91 (s, 1H), 7.86 (d, <i>J</i> = 7.8 Hz, 1H), 7.82 (s, 1H), 7.73 (s, 1H), 7.70 (d, <i>J</i> = 7.8 Hz, 1H), 7.63 (t, <i>J</i> = 8.3 Hz, 1H), 4.00 (s, 3H).</div></div><div id="sec4_3_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-indole (<b>S5</b>)</h5><div class="NLM_p last">5-Bromo-1<i>H</i>-indole <b>S4</b> (251 mg, 1.28 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (293 mg, 1.41 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (51 mg, 0.062 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Dioxane (8.0 mL, 0.16 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (2.0 mL, 4.00 mmol) were added, and the reaction mixture was degassed for 10 min. The reaction was run in the microwave (145 °C) for 30 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (10–40% EtOAc/Hex) to afford the title compound as an off-white solid (65 mg, 26%). LCMS [M + H]<sup>+</sup> 198.00 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.02 (br s, 1H), 8.01 (s, 1H), 7.78 (s, 1H), 7.68–7.71 (m, 1H), 7.36 (d, <i>J</i> = 8.3 Hz, 1H), 7.31 (t, <i>J</i> = 2.7 Hz, 1H), 7.26–7.29 (m, 1H), 6.38 (dd, <i>J</i> = 2.7, 1.7 Hz, 1H), 3.85 (s, 3H).</div></div><div id="sec4_3_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 3-Iodo-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-indole (<b>S6</b>)</h5><div class="NLM_p last">5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-indole <b>S5</b> (65 mg, 0.329 mmol) was dissolved in DCM (6.6 mL, 0.05 M), and KOH (10 mg, 0.178 mmol) was added. The reaction mixture was stirred at room temperature for 30 min, after which NIS (76 mg, 0.338 mmol) was added. The reaction mixture was stirred overnight at room temperature, quenched with Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, and extracted twice with DCM. The combined organic layers were dried with sodium sulfate and concentrated under reduced pressure to afford the title compound as a dark purple solid (97 mg, 91%). LCMS [M + H]<sup>+</sup> 324.02 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.46–11.51 (m, 1H), 8.11 (s, 1H), 7.82 (d, <i>J</i> = 1.0 Hz, 1H), 7.52 (d, <i>J</i> = 2.4 Hz, 1H), 7.35–7.40 (m, 3H), 3.86 (s, 3H).</div></div><div id="sec4_3_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 3-Iodo-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-indole (<b>S7</b>)</h5><div class="NLM_p last">3-Iodo-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-indole <b>S6</b> (97 mg, 0.300 mmol) was suspended in DCM (1.5 mL, 0.21 M), and TEA (0.15 mL, 1.08 mmol), DMAP (46 mg, 0.376 mmol), and 4-methylbenzenesulfonyl chloride (150 mg, 0.787 mmol) were added in that order. The reaction mixture was stirred overnight at room temperature. The reaction mixture was washed once with 1 M HCl, once with sat. aq. NaHCO<sub>3</sub>, and once with brine. The organic layer was dried with sodium sulfate and concentrated under reduced pressure. The crude material was purified by flash chromatography (50% EtOAc/Hex) to afford the title compound as a dark orange oil (102 mg, 71%). LCMS [M + H]<sup>+</sup> 477.98 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.21 (s, 1H), 8.04 (s, 1H), 7.89–7.93 (m, 3H), 7.89 (s, 1H), 7.62 (dd, <i>J</i> = 8.8, 1.5 Hz, 1H), 7.42 (d, <i>J</i> = 1.5 Hz, 1H), 7.40 (d, <i>J</i> = 7.8 Hz, 2H), 3.86 (s, 3H), 2.32 (s, 3H).</div></div><div id="sec4_3_5_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 3-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-indol-3-yl)benzonitrile (<b>S8</b>)</h5><div class="NLM_p last">3-Iodo-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-indole <b>S7</b> (100 mg, 0.210 mmol), (3-cyanophenyl)boronic acid (62 mg, 0.422 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (20 mg, 0.025 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (0.85 mL, 0.25 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.40 mL, 0.800 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (120 °C) for 30 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (20–50% EtOAc/Hex) to afford the title compound as an orange solid (81 mg, 86%). LCMS [M + H]<sup>+</sup> 453.14 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.25–8.28 (m, 2H), 8.19 (s, 1H), 8.13 (dt, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.98 (m, <i>J</i> = 8.8, 3.4 Hz, 3H), 7.93 (d, <i>J</i> = 1.0 Hz, 1H), 7.91 (d, <i>J</i> = 1.0 Hz, 1H), 7.85 (dt, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.70 (t, <i>J</i> = 7.8 Hz, 1H), 7.62 (dd, <i>J</i> = 8.8, 1.5 Hz, 1H), 7.41 (d, <i>J</i> = 7.8 Hz, 2H), 3.85 (s, 3H), 2.32 (s, 3H).</div></div><div id="sec4_3_5_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 3-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-indol-3-yl)benzonitrile (<b>4</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on an 81 mg scale using 3-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-indol-3-yl)benzonitrile <b>S8</b>. The reaction was run for 1 h, and the crude material was purified by flash chromatography (5% EtOAc/DCM) to afford the title compound as an off-white solid (20 mg, 38%). LCMS [M + H]<sup>+</sup> 299.13 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.53 (br s, 1H), 8.09–8.14 (m, 3H), 8.01 (s, 1H), 7.85–7.88 (m, 2H), 7.61–7.68 (m, 2H), 7.44 (d, <i>J</i> = 8.8 Hz, 1H), 7.39 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 3.87 (s, 3H).</div></div><div id="sec4_3_5_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 5-Bromo-3-iodo-4-methylpyridin-2-amine (<b>S10</b>)</h5><div class="NLM_p last">5-Bromo-4-methylpyridin-2-amine <b>S9</b> (500 mg, 2.67 mmol) was dissolved in acetic acid (3.3 mL, 0.82 M), and <i>N</i>-iodosuccinimide (666 mg, 2.96 mmol) was added, followed by the addition of TFA (41 μL, 0.535 mmol). The reaction mixture was stirred at 50 °C overnight. The reaction solution was poured over ice water and neutralized with 28% aqueous ammonia, upon which a light orange precipitate was observed and collected by vacuum filtration (washed with water) to afford the title compound as an orange solid (784 mg, 94%). LCMS [M + H]<sup>+</sup> 312.80 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 314.81 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 7.95 (s, 1H), 6.24 (br s, 2.48 (s, 3H)).</div></div><div id="sec4_3_5_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 5-Bromo-4-methyl-3-((trimethylsilyl)ethynyl)pyridin-2-amine (<b>S11</b>)</h5><div class="NLM_p last">5-Bromo-3-iodopyridin-2-amine <b>S10</b> (784 mg, 2.51 mmol), copper iodide (26 mg, 0.137 mmol), and PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (37 mg, 0.053 mmol) were combined in a round bottom flask that was filled with nitrogen and evacuated three times. Degassed THF (3.0 mL, 0.84 M) was added, followed by the addition of degassed triethylamine (16.0 mL, 114.79 mmol) and TMS-acetylene (0.450 mL, 3.25 mmol). The reaction was run at room temperature overnight under nitrogen. The reaction mixture was diluted with EtOAc and washed once with water and once with brine. The organic layer was dried with sodium sulfate and concentrated under reduced pressure. The crude material was purified by flash chromatography (20% EtOAc/Hex) to afford the title compound as a tan solid (602 mg, 85%). LCMS [M + H]<sup>+</sup> 282.95 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 284.96 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.00 (s, 1H), 6.26 (br s, 2H), 2.35 (s, 3H), 0.25 (s, 9H).</div></div><div id="sec4_3_5_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 5-Bromo-4-methyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S12</b>)</h5><div class="NLM_p last">Potassium <i>tert</i>-butoxide (525 mg, 4.68 mmol) was dissolved in NMP (16.0 mL, 0.30 M) and heated to 80 °C. 5-Bromo-4-methyl-3-((trimethylsilyl)ethynyl)pyridin-2-amine <b>S11</b> (602 mg, 2.13 mmol) was dissolved in NMP (10 mL, 0.23 M) and added dropwise to the KOtBu solution. The reaction mixture was stirred at 80 °C for 30 min. The reaction mixture was diluted with EtOAc and washed five times with water. The combined organic layers were washed once with brine, dried with sodium sulfate, and concentrated under reduced pressure. The crude material was purified by flash chromatography (20% EtOAc/hexanes) to afford the title compound as an off-white solid (236 mg, 53%). LCMS [M + H]<sup>+</sup> 210.84 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 212.86 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.79 (br s, 1H), 8.24 (s, 1H), 7.48 (d, <i>J</i> = 3.4 Hz, 1H), 6.57 (t, <i>J</i> = 2.7 Hz, 1H), 2.54 (d, <i>J</i> = 2.0 Hz, 3H).</div></div><div id="sec4_3_5_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 4-Methyl-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S13</b>)</h5><div class="NLM_p last">5-Bromo-4-methyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S12</b> (236 mg, 1.12 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (258 mg, 1.24 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (46 mg, 0.056 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Dioxane (6.6 mL, 0.17 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (1.7 mL, 3.40 mmol) were added, and the reaction mixture was degassed for 10 min. The reaction mixture was heated at 85 °C for ∼4 h. The reaction mixture was diluted with MeOH, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (1–10% MeOH/DCM), then repurified by flash chromatography (100% EtOAc) to afford the title compound as a tan solid (152 mg, 64%). LCMS [M + H]<sup>+</sup> 212.99 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.54 (br. s., 1H), 8.16 (s, 1H), 7.93 (s, 1H), 7.65 (s, 1H), 7.40 (t, <i>J</i> = 2.7 Hz, 1H), 6.52 (dd, <i>J</i> = 3.4, 2.0 Hz, 1H), 3.90 (s, 3H), 2.52 (s, 3H).</div></div><div id="sec4_3_5_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 3-Iodo-4-methyl-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S14</b>)</h5><div class="NLM_p last">4-Methyl-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S13</b> (152 mg, 0.716 mmol) was dissolved in acetonitrile (4.2 mL, 0.17 M), and <i>N</i>-iodosuccinimide (242 mg, 1.08 mmol) was added. The reaction mixture was stirred at 50 °C for 2 h. Upon cooling to room temperature, a dark brown precipitate was observed and collected by vacuum filtration to afford the title compound as a dark brown solid (101 mg, 42%). LCMS [M + H]<sup>+</sup> 338.93 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.02 (br s, 1H), 8.16 (s, 1H), 7.90 (s, 1H), 7.65 (d, <i>J</i> = 2.4 Hz, 1H), 7.61 (s, 1H), 3.90 (s, 3H), 2.79 (s, 3H).</div></div><div id="sec4_3_5_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 3-Iodo-4-methyl-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S15</b>)</h5><div class="NLM_p last">3-Iodo-4-methyl-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S14</b> (101 mg, 0.299 mmol) was suspended in DCM (1.6 mL, 0.19 M) and TEA (0.150 mL, 1.08 mmol), DMAP (46 mg, 0.377 mmol), and 4-methylbenzenesulfonyl chloride (142 mg, 0.745 mmol) were added in that order. The reaction mixture was stirred overnight at room temperature. The reaction mixture was washed once with 1 M HCl, once with sat. aq. NaHCO<sub>3</sub>, and once with brine. The organic layer was dried with sodium sulfate and concentrated under reduced pressure. The crude material was purified by flash chromatography (20–100% EtOAc/hexanes) to afford the title compound as an orange solid (37 mg, 25%). LCMS [M + H]<sup>+</sup> 492.90 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.30 (s, 1H), 8.09 (s, 1H), 8.00 (d, <i>J</i> = 8.8 Hz, 2H), 7.95 (s, 1H), 7.64 (s, 1H), 7.43 (d, <i>J</i> = 8.3 Hz, 2H), 3.89 (s, 3H), 2.76 (s, 3H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 3-(4-Methyl-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S16</b>)</h5><div class="NLM_p last">3-Iodo-4-methyl-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S15</b> (37 mg, 0.075 mmol), (3-cyanophenyl)boronic acid (15 mg, 0.102 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (7 mg, 0.009 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (0.40 mL, 0.21 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.15 mL, 0.300 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (120 °C) for 5 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as a light yellow solid (25 mg, 71%). LCMS [M + H]<sup>+</sup> 468.03 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.34 (s, 1H), 8.03–8.09 (m, 3H), 7.98 (s, 1H), 7.95 (s, 1H), 7.90 (d, <i>J</i> = 8.8 Hz, 2H), 7.64–7.69 (m, 2H), 7.45 (d, <i>J</i> = 7.8 Hz, 2H), 3.88 (s, 3H), 2.36 (s, 3H), 2.18 (s, 3H).</div></div><div id="sec4_3_5_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 3-(4-Methyl-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>5</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 25 mg scale using 3-(4-methyl-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>S16</b>. The reaction was run for 3 min, and the crude material was purified by flash chromatography (1–5% MeOH/DCM), then repurified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as a beige solid (9 mg, 55%). LCMS [M + H]<sup>+</sup> 314.05 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 10.40 (br s, 1H), 8.32 (br s, 1H), 7.77 (s, 1H), 7.72 (d, <i>J</i> = 7.8 Hz, 1H), 7.65 (d, <i>J</i> = 7.8 Hz, 1H), 7.61 (s, 1H), 7.54 (t, <i>J</i> = 7.8 Hz, 1H), 7.48 (s, 1H), 7.32 (s, 1H), 4.01 (s, 3H), 2.32 (s, 3H).</div></div><div id="sec4_3_5_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 5-Bromo-3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S17</b>)</h5><div class="NLM_p last">5-Bromo-3-iodo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>15</b> (1502 mg, 0.318 mmol), (1-methyl-1<i>H</i>-pyrazol-4-yl)boronic acid (43 mg, 0.341 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (27 mg, 0.033 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (1.3 mL, 0.24 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.50 mL, 1.00 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (120 °C) for 15 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (20–50% EtOAc/Hex) to afford the title compound as a tan solid (41 mg, 30%). LCMS [M + H]<sup>+</sup> 430.95 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 432.91 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.55 (d, <i>J</i> = 2.9 Hz, 1H), 8.48–8.53 (m, 1H), 8.41 (s, 1H), 8.24 (s, 1H), 8.05 (s, 1H), 7.94–8.01 (m, 2H), 7.38–7.46 (m, 2H), 3.88 (br s, 3H), 2.33 (br s, 3H).</div></div><div id="sec4_3_5_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 3-(3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzonitrile (<b>S18</b>)</h5><div class="NLM_p last">5-Bromo-3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S17</b> (41 mg, 0.095 mmol), (3-cyanophenyl)boronic acid (24 mg, 0.163 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (9 mg, 0.011 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Dioxane (0.6 mL, 0.17 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.20 mL, 0.400 mmol) were added, and the reaction mixture was degassed for 10 min. The reaction was run in the microwave (145 °C) for 5 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (50–100% EtOAc/Hex) to afford the title compound as a white solid (19 mg, 44%). LCMS [M + H]<sup>+</sup> 454.03 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.77 (d, <i>J</i> = 2.2 Hz, 1H), 8.54 (d, <i>J</i> = 2.2 Hz, 1H), 8.46 (s, 1H), 8.35 (s, 1H), 8.23 (s, 1H), 8.17 (d, <i>J</i> = 7.3 Hz, 1H), 8.12 (s, 1H), 8.02 (d, <i>J</i> = 8.1 Hz, 2H), 7.89 (d, <i>J</i> = 7.3 Hz, 1H), 7.71 (t, <i>J</i> = 8.1 Hz, 1H), 7.43 (d, <i>J</i> = 8.1 Hz, 2H), 3.91 (s, 3H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 3-(3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzonitrile (<b>6</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 19 mg scale using 3-(3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzonitrile <b>S18</b>. The reaction was run for 2 min, and the crude material was purified by flash chromatography (1–5% MeOH/DCM) to afford the title compound as a white solid (4 mg, 28%). LCMS [M + H]<sup>+</sup> 300.12 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.51 (d, <i>J</i> = 1.5 Hz, 1H), 8.42 (d, <i>J</i> = 2.2 Hz, 1H), 8.13 (d, <i>J</i> = 1.5 Hz, 1H), 8.09 (s, 1H), 8.04 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.86 (s, 1H), 7.71–7.75 (m, 1H), 7.68 (d, <i>J</i> = 7.3 Hz, 1H), 7.64 (s, 1H), 3.97 (s, 3H).</div></div><div id="sec4_3_5_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>7</b>)</h5><div class="NLM_p last">5-Bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>9</b> (686 mg, 3.48 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (800 mg, 3.84 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (147 mg, 0.180 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Dioxane (20 mL, 0.17 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (5.0 mL, 10.00 mmol) were added, and the reaction mixture was degassed for 10 min. The reaction mixture was heated at 85 °C for ∼4 h. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude mixture was purified by flash chromatography (1–10% MeOH/DCM) to afford the title compound as an orange solid (640 mg, 93%). LCMS [M + H]<sup>+</sup> 199.01 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.59 (br s, 1H), 8.45 (d, <i>J</i> = 1.95 Hz, 1H), 8.13 (s, 1H), 8.08 (d, <i>J</i> = 1.95 Hz, 1H), 7.88 (s, 1H), 7.44 (t, <i>J</i> = 2.93 Hz, 1H), 6.41 (dd, <i>J</i> = 3.42, 1.95 Hz, 1H), 3.87 (s, 3H).</div></div><div id="sec4_3_5_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 3-Iodo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S20</b>)</h5><div class="NLM_p last">3-Iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S19</b> (250 mg, 1.002 mmol) was suspended in DCM (10.0 mL, 0.10 M) and TEA (0.35 mL, 2.51 mmol), DMAP (67 mg, 0.548 mmol) and 4-methylbenzenesulfonyl chloride (403 mg, 2.11 mmol) were added in that order. Upon the addition of 4-methylbenzenesulfonyl chloride, the reaction mixture changed from a cloudy suspension to a clear solution. The reaction mixture was stirred overnight at room temperature. The reaction mixture was washed once with 1 M HCl, once with saturated aqueous NaHCO<sub>3</sub>, and once with brine. The organic layer was dried with sodium sulfate and concentrated under reduced pressure to afford the title compound as an orange solid (311 mg, 76%). LCMS [M + H]<sup>+</sup> 398.97 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.41 (dd, <i>J</i> = 4.9, 1.5 Hz, 1H), 8.15 (s, 1H), 8.02 (d, <i>J</i> = 8.3 Hz, 2H), 7.79 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.42 (d, <i>J</i> = 8.3 Hz, 2H), 7.39 (dd, <i>J</i> = 7.8, 4.9 Hz, 1H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 3-(1-Tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S21</b>)</h5><div class="NLM_p last">3-Iodo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S20</b> (150 mg, 0.377 mmol), (3-cyanophenyl)boronic acid (140 mg, 0.953 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (31 mg, 0.037 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (1.5 mL, 0.25 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.55 mL, 1.10 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (120 °C) for 30 min, then diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude residue was purified by flash chromatography (20–40% EtOAc/Hex) to afford the title compound as an off-white solid (67 mg, 48%). LCMS [M + H]<sup>+</sup> 374.13 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.43–8.47 (m, 2H), 8.40 (dd, <i>J</i> = 8.3, 1.5 Hz, 1H), 8.31 (s, 1H), 8.14 (d, <i>J</i> = 7.8 Hz, 1H), 8.06 (d, <i>J</i> = 8.8 Hz, 2H), 7.84 (d, <i>J</i> = 8.3 Hz, 1H), 7.69 (t, <i>J</i> = 7.8 Hz, 1H), 7.43 (d, <i>J</i> = 8.8 Hz, 2H), 7.38–7.42 (m, 1H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> 3-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>8</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 67 mg scale using 3-(1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>S21</b>. The reaction was run for 2 min, and the crude material was purified by flash chromatography (1–5% MeOH/DCM) to afford the title compound as a white solid (18 mg, 45%). LCMS [M + H]<sup>+</sup> 220.03 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.09 (br s, 1H), 8.38 (d, <i>J</i> = 8.3 Hz, 1H), 8.30 (dd, <i>J</i> = 4.6, 1.2 Hz, 1H), 8.16–8.20 (m, 1H), 8.06–8.13 (m, 2H), 7.67–7.72 (m, 1H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.19 (dd, <i>J</i> = 8.1, 4.6 Hz, 1H).</div></div><div id="sec4_3_5_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> 3-Iodo-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>10</b>)</h5><div class="NLM_p last">Intermediate <b>7</b> (640 mg, 3.23 mmol) was dissolved in acetonitrile (18 mL, 0.18 M), and <i>N</i>-iodosuccinimide (1.09 g, 4.84 mmol) was added. The reaction mixture was stirred at 50 °C for 2 h. Upon cooling to room temperature, a precipitate was observed and collected by vacuum filtration (washed with acetonitrile) to afford the title compound as a light brown solid (730 mg, 69%). LCMS [M + H]<sup>+</sup> 324.98 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.06 (br s, 1H), 8.51 (d, <i>J</i> = 1.95 Hz, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.76 (d, <i>J</i> = 2.44 Hz, 1H), 7.69 (d, <i>J</i> = 2.44 Hz, 1H), 3.88 (s, 3H).</div></div><div id="sec4_3_5_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 3-Iodo-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>11</b>)</h5><div class="NLM_p last">Intermediate <b>10</b> (730 mg, 2.25 mmol) was suspended in DCM (37 mL, 0.06 M) and TEA (1.5 mL, 10.76 mmol), DMAP (227 mg, 1.86 mmol) and 4-methylbenzenesulfonyl chloride (1.06 g, 5.56 mmol) were added in that order. The reaction mixture was stirred overnight at room temperature. The reaction mixture was washed once with 1 M HCl, once with sat. aq. NaHCO<sub>3</sub>, and once with brine. The organic layer was dried with sodium sulfate and concentrated under reduced pressure. The crude material was purified by flash chromatography (0–100% EtOAc/Hex—0–10% MeOH/DCM) to afford the title compound as a light orange solid (741 mg, 69%). LCMS [M + H]<sup>+</sup> 478.95 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.66 (d, <i>J</i> = 1.95 Hz, 1H), 8.33 (s, 1H), 8.12 (s, 1H), 7.98–8.04 (m, 3H), 7.85 (d, <i>J</i> = 2.44 Hz, 1H), 7.43 (d, <i>J</i> = 8.79 Hz, 2H), 3.87 (s, 3H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 2-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>12a</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 75 mg scale using 2-(cyanophenyl)boronic acid. The crude material was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as a light orange solid (48 mg, 68%). LCMS [M + H]<sup>+</sup> 454.03 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.72 (d, <i>J</i> = 1.95 Hz, 1H), 8.29 (s, 1H), 8.27 (s, 1H), 8.16 (d, <i>J</i> = 1.95 Hz, 1H), 8.01–8.07 (m, 3H), 7.98 (s, 1H), 7.85 (d, <i>J</i> = 3.91 Hz, 2H), 7.64 (m, <i>J</i> = 8.30, 4.20, 4.20 Hz, 1H), 7.45 (d, <i>J</i> = 7.81 Hz, 2H), 3.85 (s, 3H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> 3-(4-Fluorophenyl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>12b</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 65 mg scale using (4-fluorophenyl)boronic acid. The crude material was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as a light orange solid (42 mg, 69%). LCMS [M + H]<sup>+</sup> 447.02 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.68 (d, <i>J</i> = 1.95 Hz, 1H), 8.33 (d, <i>J</i> = 1.95 Hz, 1H), 8.30 (s, 1H), 8.19 (s, 1H), 8.04 (d, <i>J</i> = 8.30 Hz, 2H), 8.02 (s, 1H), 7.84–7.90 (m, 2H), 7.43 (d, <i>J</i> = 7.81 Hz, 2H), 7.30–7.36 (m, 2H), 3.87 (s, 3H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 3-(3,4-Difluorophenyl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>12c</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 69 mg scale using (3,4-difluorophenyl)boronic acid. The crude material was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as a light orange solid (42 mg, 62%). LCMS [M + H]<sup>+</sup> 465.05 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.69 (d, <i>J</i> = 1.95 Hz, 1H), 8.37 (d, <i>J</i> = 1.95 Hz, 1H), 8.32 (s, 1H), 8.30 (s, 1H), 8.02–8.07 (m, 3H), 7.96 (qd, <i>J</i> = 8.80, 2.00 Hz, 1H), 7.68–7.73 (m, 1H), 7.51–7.59 (m, 1H), 7.44 (d, <i>J</i> = 8.30 Hz, 2H), 3.88 (s, 3H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 3-(2-Fluorophenyl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>12d</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 75 mg scale using (2-fluorophenyl)boronic acid. The crude material was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as an off-white solid (55 mg, 78%). LCMS [M + H]<sup>+</sup> 447.08 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.70 (d, <i>J</i> = 1.95 Hz, 1H), 8.28 (s, 1H), 8.16 (t, <i>J</i> = 1.95 Hz, 1H), 8.11 (s, 1H), 8.06 (d, <i>J</i> = 8.30 Hz, 2H), 7.99 (s, 1H), 7.80 (td, <i>J</i> = 7.69, 1.71 Hz, 1H), 7.46–7.52 (m, 1H), 7.45 (d, <i>J</i> = 8.30 Hz, 2H), 7.34–7.43 (m, 2H), 3.86 (s, 3H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 3-Fluoro-5-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>12e</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 75 mg scale using (3-cyano-5-fluorophenyl)boronic acid. The crude material was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as an off-white solid (44 mg, 60%). LCMS [M + H]<sup>+</sup> 472.06 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.71 (d, <i>J</i> = 1.95 Hz, 1H), 8.49 (s, 1H), 8.45 (d, <i>J</i> = 2.44 Hz, 1H), 8.32 (s, 1H), 8.23 (s, 1H), 8.12 (d, <i>J</i> = 9.77 Hz, 1H), 8.04–8.08 (m, 3H), 7.87 (d, <i>J</i> = 8.30 Hz, 1H), 7.44 (d, <i>J</i> = 8.79 Hz, 2H), 3.88 (s, 3H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 2-Fluoro-5-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>12f</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 74 mg scale using 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile. The crude material was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as an off-white solid (48 mg, 66%). LCMS [M + H]<sup>+</sup> 472.07 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.69 (d, <i>J</i> = 1.95 Hz, 1H), 8.43 (dd, <i>J</i> = 6.35, 2.44 Hz, 1H), 8.41 (d, <i>J</i> = 1.95 Hz, 1H), 8.39 (s, 1H), 8.30 (s, 1H), 8.26 (m, <i>J</i> = 2.40, 2.40, 2.40, 2.40, 2.40, 2.40 Hz, 1H), 8.03–8.07 (m, 3H), 7.65 (t, <i>J</i> = 9.03 Hz, 1H), 7.44 (d, <i>J</i> = 8.30 Hz, 2H), 3.88 (s, 3H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 3-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)aniline (<b>12g</b>)</h5><div class="NLM_p last">Intermediate <b>11</b> (40 mg, 0.083 mmol), (3-aminophenyl)boronic acid (34 mg, 0.251 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (6 mg, 0.007 mmol) were combined in an 8 mL vial. The vial was purged with nitrogen and evacuated three times. Dioxane (0.8 mL, 0.1 M) and 2 M aqueous K<sub>2</sub>CO<sub>3</sub> (0.2 mL, 0.4 mmol) were added, and the reaction mixture was degassed for 10 min. The reaction was run at 100 °C for 4 h, then stopped, diluted with EtOAc, and filtered through Celite. The crude material was purified by flash chromatography (50–100% EtOAc/hexanes, step gradient) to afford the title compound as a solid (5 mg, 14%). LCMS [M + H]<sup>+</sup> 290.16 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.66 (d, <i>J</i> = 2.0 Hz, 1H), 8.29 (d, <i>J</i> = 2.0 Hz, 1H), 8.27 (s, 1H), 8.03 (d, <i>J</i> = 8.8 Hz, 2H), 8.00 (s, 2H), 7.43 (d, <i>J</i> = 8.3 Hz, 2H), 7.14 (t, <i>J</i> = 7.8 Hz, 1H), 6.96–6.98 (m, 1H), 6.89–6.93 (m, 1H), 6.59 (dd, <i>J</i> = 8.1, 2.2 Hz, 1H), 5.18–5.23 (m, 2H), 3.87 (s, 3H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> 1-(4-Bromophenyl)-<i>N</i>,<i>N</i>-dimethylmethanamine (<b>S23</b>)</h5><div class="NLM_p last">1-Bromo-4-(bromomethyl)benzene <b>S22</b> (499 mg 2.00 mmol) was suspended in hexane (2.0 mL, 1.0 M), and the reaction mixture was cooled to 0 °C. Then, 2 M dimethylamine in THF (4.00 mL, 8.00 mmol) was added dropwise. The reaction mixture was left stirring overnight and allowed to warm to room temperature. A precipitate was observed and removed by filtration; the filtrate was concentrated to afford the title compound as an orange oil (350 mg, 82%). LCMS [M + H]<sup>+</sup> 213.93 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 215.93 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 7.50 (d, <i>J</i> = 8.30 Hz, 2H), 7.24 (d, <i>J</i> = 8.30 Hz, 2H), 3.34 (s, 2H), 2.12 (s, 6H).</div></div><div id="sec4_3_5_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> <i>N</i>,<i>N</i>-Dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine (<b>S24</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure E on a 350 mg scale using 1-(4-bromophenyl)-<i>N</i>,<i>N</i>-dimethylmethanamine <b>S23</b>. The crude material was purified by flash chromatography (5–20% 5% NH<sub>4</sub>OH/MeOH:DCM) to afford the title compound as a brown oil (176 mg, 41%). LCMS [M + H]<sup>+</sup> 262.22 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 7.62 (d, <i>J</i> = 8.30 Hz, 2H), 7.30 (d, <i>J</i> = 8.30 Hz, 2H), 3.39 (s, 2H), 2.12 (s, 6H), 1.28 (s, 12H).</div></div><div id="sec4_3_5_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> <i>N</i>,<i>N</i>-Dimethyl-1-(4-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl) phenyl)methanamine (<b>12h</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 150 mg scale using <i>N</i>,<i>N</i>-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine <b>S24</b>. The crude material was purified by flash chromatography (50–100% EtOAc/Hex—0–20% MeOH/EtOAc—0–10% 5% NH<sub>4</sub>OH/MeOH:DCM) to afford the title compound as a glassy brown solid (36 mg, 24%). LCMS [M + H]<sup>+</sup> 486.23 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.59 (d, <i>J</i> = 1.95 Hz, 1H), 8.29 (d, <i>J</i> = 1.95 Hz, 1H), 8.07 (s, 1H), 8.05 (d, <i>J</i> = 8.30 Hz, 2H), 8.02 (s, 1H), 7.90 (s, 1H), 7.70 (d, <i>J</i> = 8.30 Hz, 2H), 7.48 (d, <i>J</i> = 8.30 Hz, 2H), 7.36 (d, <i>J</i> = 8.79 Hz, 2H), 3.94 (s, 3H), 3.58 (s, 2H), 2.37 (s, 3H), 2.32 (s, 6H).</div></div><div id="sec4_3_5_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-(3-nitrophenyl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>12i</b>)</h5><div class="NLM_p last">Intermediate <b>3–4</b> (38 mg, 0.08 mmol), (3-nitrophenyl)boronic acid (40 mg, 0.238 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (6 mg, 0.007 mmol) were combined in a 8 mL vial. The vial was purged with nitrogen and evacuated three times. Dioxane (0.8 mL, 0.1 M) and 2 M aqueous K<sub>2</sub>CO<sub>3</sub> (0.2 mL, 0.4 mmol) were added, and the reaction mixture was degassed for 10 min. The reaction was run at 100 °C for 4 h, then stopped, diluted with EtOAc, and filtered through Celite. The crude material was purified by flash chromatography (30–80% EtOAc/hexanes, step gradient) to afford the title compound as a solid (30 mg, 80%). LCMS [M + H]<sup>+</sup> 320.12 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.71 (d, <i>J</i> = 2.0 Hz, 1H), 8.60 (t, <i>J</i> = 2.4 Hz, 1H), 8.48 (s, 1H), 8.41 (d, <i>J</i> = 2.0 Hz, 1H), 8.28–8.32 (m, 2H), 8.24 (dd, <i>J</i> = 8.3, 1.5 Hz, 1H), 8.08 (d, <i>J</i> = 8.8 Hz, 2H), 8.02 (s, 1H), 7.80 (t, <i>J</i> = 7.8 Hz, 1H), 7.45 (d, <i>J</i> = 8.3 Hz, 2H), 3.87 (s, 3H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> 4-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenol (<b>12j</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 100 mg scale using (4-hydroxyphenyl)boronic acid. The crude material was purified by flash chromatography (50–100% EtOAc/Hex) to afford the title compound as a tan solid (49 mg, 52%). LCMS [M + H]<sup>+</sup> 445.13 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 9.62 (br s, 1H), 8.65 (d, <i>J</i> = 1.95 Hz, 1H), 8.30 (s, 1H), 8.28 (d, <i>J</i> = 1.46 Hz, 1H), 7.98–8.04 (m, 4H), 7.61 (d, <i>J</i> = 8.30 Hz, 2H), 7.42 (d, <i>J</i> = 8.30 Hz, 2H), 6.89 (d, <i>J</i> = 8.30 Hz, 2H), 3.87 (s, 3H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[<i>c</i>][1,2,5]oxadiazole (<b>S26</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure E on a 100 mg scale using 5-chlorobenzo[<i>c</i>][1,2,5]oxadiazole <b>S25</b>. The dark brown crude material was carried forward without further purification. *Does not ionize.</div></div><div id="sec4_3_5_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> 5-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole (<b>12k</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 151 mg scale using 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[<i>c</i>][1,2,5]oxadiazole <b>S26</b>. The crude material was purified by flash chromatography (20–60% EtOAc/hexanes) to afford the title compound as a white solid (109 mg, 73%). LCMS [M + H]<sup>+</sup> 471.02 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.74 (d, <i>J</i> = 2.20 Hz, 1H), 8.63 (s, 1H), 8.61 (d, <i>J</i> = 2.20 Hz, 1H), 8.53 (s, 1H), 8.38 (s, 1H), 8.21 (dd, <i>J</i> = 9.53, 1.47 Hz, 1H), 8.17 (d, <i>J</i> = 8.79 Hz, 1H), 8.06–8.12 (m, 3H), 7.45 (d, <i>J</i> = 8.79 Hz, 2H), 3.89 (s, 3H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 3-(1<i>H</i>-Indol-5-yl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>12l</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 76 mg scale using (1<i>H</i>-indol-5-yl)boronic acid. The crude material was purified by flash chromatography (20–100% EtOAc/hexanes) to afford the title compound as a glassy orange solid (41 mg, 55%). LCMS [M + H]<sup>+</sup> 468.007 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.21 (br s, 1H), 8.67 (d, <i>J</i> = 1.47 Hz, 1H), 8.34 (d, <i>J</i> = 2.20 Hz, 1H), 8.30 (s, 1H), 8.05 (d, <i>J</i> = 8.79 Hz, 2H), 8.02 (s, 1H), 8.01 (s, 1H), 7.95 (s, 1H), 7.46–7.56 (m, 2H), 7.39–7.45 (m, 3H), 6.52 (br s, 1H), 3.87 (s, 3H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-(pyridin-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>12m</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine. The crude material was carried forward without further purification. LCMS [M + H]<sup>+</sup> 430.11 <i>m</i>/<i>z</i>.</div></div><div id="sec4_3_5_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> 5-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)nicotinonitrile (<b>12n</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 75 mg scale using (5-cyanopyridin-3-yl)boronic acid. The crude material was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as a light orange solid (60 mg, 85%). LCMS [M + H]<sup>+</sup> 455.05 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 9.36 (t, <i>J</i> = 2.20 Hz, 1H), 9.03 (t, <i>J</i> = 1.95 Hz, 1H), 8.81 (q, <i>J</i> = 2.28 Hz, 1H), 8.72 (t, <i>J</i> = 1.95 Hz, 1H), 8.55 (d, <i>J</i> = 1.95 Hz, 1H), 8.50 (t, <i>J</i> = 1.95 Hz, 1H), 8.33 (d, <i>J</i> = 0.98 Hz, 1H), 8.04–8.08 (m, 3H), 7.44 (d, <i>J</i> = 8.30 Hz, 2H), 3.88 (s, 3H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 4-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)picolinonitrile (<b>12o</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 100 mg scale using crude (2-cyanopyridin-4-yl)boronic acid <b>5–26</b>. The crude material was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as a light yellow solid (34 mg, 36%). LCMS [M + H]<sup>+</sup> 455.12 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.80 (d, <i>J</i> = 5.37 Hz, 1H), 8.74 (s, 1H), 8.73 (d, <i>J</i> = 1.95 Hz, 1H), 8.61 (s, 1H), 8.57 (d, <i>J</i> = 1.95 Hz, 1H), 8.33 (s, 1H), 8.27 (dd, <i>J</i> = 5.86, 1.95 Hz, 1H), 8.08 (s, 1H), 8.06 (d, <i>J</i> = 8.30 Hz, 2H), 7.45 (d, <i>J</i> = 8.30 Hz, 2H), 3.89 (s, 3H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-(2-methylpyridin-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>12p</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 75 mg scale using (2-methylpyridin-4-yl)boronic acid. The crude material was purified by flash chromatography (3% MeOH/DCM) to afford the title compound as a dark orange solid (47 mg, 68%). LCMS [M + H]<sup>+</sup> 444.16 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.70 (d, <i>J</i> = 1.95 Hz, 1H), 8.52 (d, <i>J</i> = 5.37 Hz, 1H), 8.46 (s, 1H), 8.45 (d, <i>J</i> = 1.95 Hz, 1H), 8.33 (s, 1H), 8.03–8.08 (m, 3H), 7.74 (s, 1H), 7.68 (d, <i>J</i> = 5.86 Hz, 1H), 7.44 (d, <i>J</i> = 8.79 Hz, 2H), 3.88 (s, 3H), 2.56 (s, 3H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> 2,6-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (<b>S28</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure E on a 150 mg scale using 4-bromo-2,6-dimethylpyridine <b>S28</b>. The dark brown crude material was carried forward without further purification. LCMS [M + H]<sup>+</sup> 151.78 <i>m</i>/<i>z</i> (boronic acid).</div></div><div id="sec4_3_5_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> 3-(2,6-Dimethylpyridin-4-yl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>12q</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure A on a 75 mg scale using crude 2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine <b>S28</b>. The crude material was purified by flash chromatography (5% MeOH/DCM), then repurified by flash chromatography (10–100% EtOAc/DCM) to afford the title compound as a tan solid (43 mg, 60%). LCMS [M + H]<sup>+</sup> 458.14 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.69 (d, <i>J</i> = 1.95 Hz, 1H), 8.42 (d, <i>J</i> = 1.46 Hz, 1H), 8.41 (s, 1H), 8.32 (s, 1H), 8.05 (m, <i>J</i> = 3.90, 3.90 Hz, 3H), 7.52 (s, 2H), 7.44 (d, <i>J</i> = 8.30 Hz, 2H), 3.88 (s, 3H), 2.51 (s, 6H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> 2-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>13a</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 48 mg scale using <b>12a</b>. The reaction was run for 5 min, and the crude material was purified by flash chromatography (1–5% MeOH/DCM) and then by prep HPLC (70–5% water/ACN) to afford the title compound as a formate salt. The resulting solid was dissolved in MeOH, and MP-carbonate was added. The suspension was stirred overnight at room temperature, then the solids were removed by filtration, and the filtrate was concentrated to afford the title compound as a white solid (9 mg, 28%). LCMS [M + H]<sup>+</sup> 300.06 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.51 (d, <i>J</i> = 2.20 Hz, 1H), 8.22 (d, <i>J</i> = 2.20 Hz, 1H), 8.02 (s, 1H), 7.84–7.89 (m, 2H), 7.75–7.83 (m, 3H), 7.49 (td, <i>J</i> = 8.06, 1.47 Hz, 1H), 3.94 (s, 3H).</div></div><div id="sec4_3_5_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> 4-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>13b</b>)</h5><div class="NLM_p last">Intermediate <b>11</b> (90 mg, 0.188 mmol), (4-cyanophenyl)boronic acid (83 mg, 0.565 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> were combined in a microwave vial, which was then purged with nitrogen and evacuated three times. Dioxane (1.9 mL, 0.1 M) and K<sub>2</sub>CO<sub>3</sub> (0.565 mL, 1.1 mmol) were added, and the reaction mixture was then degassed for 10 min. The reaction was then run in the microwave for 30 min at 120 °C. Then, 2 M aqueous NaOH (0.3 mL, 0.6 mmol) was then added to the flask, and the solution was microwaved for 1.5 min at 150 °C. Additional 2 M NaOH (0.1 mL, 0.2 mmol) was then added, and the reaction mixture was microwaved for another 2.5 min at 150 °C. The crude product was then diluted with EtOAc and filtered through Celite using EtOAc to wash. The filtrate was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as a solid (36 mg, 64%). LCMS [M + H]<sup>+</sup> 300.12 <i>m</i>/<i>z</i>, <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.51 (d, <i>J</i> = 2.0 Hz, 1H), 8.46 (d, <i>J</i> = 2.0 Hz, 1H), 8.08 (s, 1H), 7.94 (d, <i>J</i> = 5.4 Hz, 2H), 7.93 (s, 1H), 7.87 (s, 1H), 7.80 (d, <i>J</i> = 8.3 Hz, 2H), 3.96 (s, 3H). *The −NH peak is too rapidly exchanging to be seen in the H NMR.</div></div><div id="sec4_3_5_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> 5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-3-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13c</b>)</h5><div class="NLM_p last">In a microwave tube, <b>10</b> (37.3 mg, 0.115 mmol) was added, followed by phenylboronic acid (41.5 mg, 0.340 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (12.70 mg, 0.016 mmol). The tube was sealed and purged with nitrogen three times. 1,4-Dioxane (0.115 mL, 1 M) and a 2 M solution of potassium carbonate (0.517 mL, 1.035 mmol) were then added, and the reaction mixture was degassed and run in the microwave for 30 min at 120 °C. The reaction mixture was then concentrated, and EtOAc was added. This solution was then washed with water, followed by brine, and the organic layer was dried over sodium sulfate and concentrated. The crude product was purified by reverse phase chromatography (30–70% ACN/water gradient) to afford the title compound as a white solid (5 mg, 16%). LCMS [M + H]<sup>+</sup> 275.1; <sup>1</sup>H NMR (399 MHz, chloroform-<i>d</i>): δ ppm 3.99 (s, 3H), 7.30–7.38 (m, 1H), 7.45–7.55 (m, 3H), 7.63–7.71 (m, 3H), 7.82 (s, 1H), 8.28 (s, 1H), 8.52 (s, 1H), 9.49 (br s, 1H).</div></div><div id="sec4_3_5_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> 3-(4-Chlorophenyl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13d</b>)</h5><div class="NLM_p last">In a microwave tube, <b>10</b> (25 mg, 0.077 mmol) was added, followed by (4-chlorophenyl)boronic acid (35.6 mg, 0.228 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (8.51 mg, 10.42 μmol). The tube was sealed and purged with nitrogen three times. 1,4-Dioxane (77 μL, 1 M) and a 2 M solution of potassium carbonate (0.347 mL, 0.695 mmol) were then added, and the reaction mixture was degassed and run in the microwave for 30 min at 120 °C. The reaction mixture was then concentrated, and EtOAc was added. This solution was then washed with water, followed by brine, and the organic layer was dried over sodium sulfate and concentrated. The crude product was purified by reverse phase chromatography (30–70% ACN/water gradient) to afford the title compound as a white solid (10 mg, 42%). LCMS [M + H]<sup>+</sup> 309.1; <sup>1</sup>H NMR (399 MHz, chloroform-<i>d</i>): δ ppm 4.00 (s, 3H), 7.43–7.48 (m, 2H), 7.50 (d, <i>J</i> = 1.5 Hz, 1H), 7.56–7.61 (m, 2H), 7.68 (s, 1H), 7.82 (s, 1H), 8.21 (d, <i>J</i> = 1.5 Hz, 1H), 8.52 (s, 1H), 9.17 (br s, 1H).</div></div><div id="sec4_3_5_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> 3-(3,4-Dichlorophenyl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13e</b>)</h5><div class="NLM_p last">In a microwave tube, <b>10</b> (25 mg, 0.090 mmol) was added, followed by (3,4-dichlorophenyl)boronic acid (19.7 mg, 0.103 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (7.51 mg, 9.2 μmol). The tube was sealed and purged with nitrogen three times. Tetrahydrofuran (0.626 mL, 0.144 M) and a 2 M solution of potassium carbonate (0.313 mL, 0.625 mmol, 6.93 equiv) were then added, and the reaction mixture was degassed and ran in the microwave for 30 min at 120 °C. The reaction mixture was then concentrated, and EtOAc was added. This solution was then washed with water, followed by brine, and the organic layer was dried over sodium sulfate and concentrated. The crude product was purified by reverse phase chromatography (20–95% ACN/water gradient) to afford the title compound as a white solid (3.2 mg, 10%). LCMS [M + H]<sup>+</sup> 343.0; <sup>1</sup>H NMR (399 MHz, chloroform-<i>d</i>): δ ppm 4.01 (d, <i>J</i> = 1.47 Hz, 3H), 7.45–7.50 (m, 1H), 7.53–7.59 (m, 2H), 7.71 (d, <i>J</i> = 5.86 Hz, 2H), 7.82 (s, 1H), 8.19 (s, 1H), 8.28 (s, 1H), 8.46 (br s, 1H).</div></div><div id="sec4_3_5_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-(<i>p</i>-tolyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13f</b>)</h5><div class="NLM_p last">In a microwave tube, <b>10</b> (70 mg, 0.253 mmol) was added followed by <i>p</i>-tolylboronic acid (37 mg, 0.275 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (21 mg, 0.026 mmol). The tube was sealed and purged with nitrogen three times. 1,4-Dioxane (1.754 mL, 0.144 M) and a 2 M solution of potassium carbonate (0.875 mL, 1.750 mmol) were then added, and the reaction mixture was degassed and ran in the microwave for 30 min at 120 °C. The reaction mixture was then concentrated, and EtOAc was added. This solution was then washed with water, followed by brine, and the organic layer was dried over sodium sulfate and concentrated. The crude product was purified by reverse phase chromatography (30–70% ACN/water gradient) to afford the title compound as a white solid (5.1 mg, 7%). LCMS [M + H]<sup>+</sup> 289.0; <sup>1</sup>H NMR (399 MHz, chloroform-<i>d</i>, D<sub>2</sub>O): δ ppm 2.36 (s, 3H), 3.93 (s, 3H), 7.24 (d, <i>J</i> = 8.1 Hz, 2H), 7.43 (s, 1H), 7.48 (d, <i>J</i> = 8.1 Hz, 2H), 7.61 (s, 1H), 7.74 (s, 1H), 8.23 (s, 1H), 8.41 (br s, 1H).</div></div><div id="sec4_3_5_55" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> 3-(4-Methoxyphenyl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13g</b>)</h5><div class="NLM_p last">In a microwave tube, <b>10</b> (21.30 mg, 0.066 mmol) was added, followed by (4-methoxyphenyl)boronic acid (28.5 mg, 0.188 mmol, 2.85 equiv) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (8 mg, 9.8 μmol, 0.149 equiv). The tube was sealed and purged with nitrogen three times. 1,4-Dioxane (65.7 μL, 1 M) and a 2 M solution of potassium carbonate (0.284 mL, 0.567 mmol) were then added, and the reaction mixture was degassed and ran in the microwave for 30 min at 120 °C. The reaction mixture was then concentrated, and EtOAc was added. This solution was then washed with water, followed by brine, and the organic layer was dried over sodium sulfate and concentrated. The crude product was purified by reverse phase chromatography (30–70% ACN/water gradient) to afford the title compound as a white solid (6.4 mg, 32%). LCMS [M + H]<sup>+</sup> 305.2; <sup>1</sup>H NMR (399 MHz, chloroform-<i>d</i>): δ ppm 3.89 (s, 3H), 3.99 (s, 3H), 7.05 (d, <i>J</i> = 8.8 Hz, 2H), 7.44 (s, 1H), 7.58 (d, <i>J</i> = 8.1 Hz, 2H), 7.68 (s, 1H), 7.81 (s, 1H), 8.25 (s, 1H), 8.49 (br s, 1H), 9. 17 (br s, 1H).</div></div><div id="sec4_3_5_56" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> 3-(3-Methoxyphenyl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13h</b>)</h5><div class="NLM_p last">In a microwave tube, <b>10</b> (30 mg, 0.108 mmol) was added, followed by (3-methoxyphenyl)boronic acid (28.1 mg, 0.185 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (9.02 mg, 0.011 mmol). The tube was sealed and purged with nitrogen three times. 1,4-Dioxane (0.752 mL, 0.144 M) and a 2 M solution of potassium carbonate (0.376 mL, 0.753 mmol) were then added, and the reaction mixture was degassed and ran in the microwave for 30 min at 120 °C. The reaction mixture was then concentrated, and EtOAc was added. This solution was then washed with water, followed by brine, and the organic layer was dried over sodium sulfate and concentrated. The crude product was purified by reverse phase chromatography (20–95% ACN/water gradient) to the title compound as a white solid (4.6 mg, 14%). LCMS [M + H]<sup>+</sup> 305.1; <sup>1</sup>H NMR (399 MHz, chloroform-<i>d</i>): δ ppm 3.87–3.95 (m, 3H), 3.96–4.03 (m, 3H), 6.90 (d, <i>J</i> = 8.8 Hz, 1H), 7.19 (d, <i>J</i> = 1.5 Hz, 1H), 7.25 (s, 1H), 7.42 (t, <i>J</i> = 8.1 Hz, 1H), 7.53 (s, 1H), 7.68 (s, 1H), 7.81 (s, 1H), 8.30 (s, 1H), 8.50 (s, 1H), 9.60 (br s, 1H).</div></div><div id="sec4_3_5_57" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-(4-(trifluoromethyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13i</b>)</h5><div class="NLM_p last">In a microwave tube, <b>10</b> (25.3 mg, 0.091 mmol) was added, followed by (3-trifluoromethylphenyl)boronic acid (20 mg, 0.105 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (8.9 mg, 10.9 μmol). The tube was sealed and purged with nitrogen three times. 1,4-Dioxane (0.634 mL, 0.144 M) and a 2 M solution of potassium carbonate (0.313 mL, 0.626 mmol) were then added, and the reaction mixture was degassed and ran in the microwave for 30 min at 120 °C. The reaction mixture was then concentrated, and EtOAc was added. This solution was then washed with water, followed by brine, and the organic layer was dried over sodium sulfate and concentrated. The crude product was purified by reverse phase chromatography (20–90% ACN/water gradient) to afford the title compound as a white solid (4.9 mg, 15.7% yield). LCMS [M + H]<sup>+</sup> 343.1; <sup>1</sup>H NMR (399 MHz, chloroform-<i>d</i>): δ ppm 4.01 (s, 3H), 7.56–7.64 (m, 3H), 7.69 (br s, 1H), 7.81–7.86 (m, 2H), 7.88 (s, 1H), 8.25 (s, 1H), 8.52–8.63 (m, 1H), 9.50–9.63 (m, 1H).</div></div><div id="sec4_3_5_58" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> 3-(3-Fluorophenyl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13j</b>)</h5><div class="NLM_p last">In a microwave tube, <b>10</b> (60 mg, 0.217 mmol) was added, followed by (3-fluoromethylphenyl)boronic acid (33 mg, 0.236 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (18 mg, 0.022 mmol). The tube was sealed and purged with nitrogen three times. 1,4-Dioxane (1.504 mL, 0.144 M) and a 2 M solution of potassium carbonate (0.750 mL, 1.5 mmol) were then added, and the reaction mixture was degassed and ran in the microwave for 30 min at 120 °C. The reaction mixture was then concentrated, and EtOAc was added. This solution was then washed with water, followed by brine, and the organic layer was dried over sodium sulfate and concentrated. The crude product was purified by reverse phase chromatography (30–70% ACN/water gradient) to afford the title compound as a white solid (5.4 mg, 8.5% yield). LCMS [M + H]<sup>+</sup> 293.0; <sup>1</sup>H NMR (399 MHz, chloroform-<i>d</i>): δ ppm 4.01 (s, 3H), 7.05 (t, <i>J</i> = 7.7 Hz, 1H), 7.34 (d, <i>J</i> = 10.3 Hz, 1H), 7.41–7.48 (m, 2H), 7.58 (s, 1H), 7.71 (br s, 1H), 7.83 (s, 1H), 8.33 (s, 1H), 8.62 (br s, 1H), 9.97–10.24 (m, 1H).</div></div><div id="sec4_3_5_59" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> 3-(4-Fluorophenyl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13k</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 42 mg scale using <b>12b</b>. The reaction was run for 1.75 h, and the crude material was purified by flash chromatography (1–5% MeOH/DCM) to afford the title compound as a tan solid (11 mg, 39%). LCMS [M + H]<sup>+</sup> 293.17 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, METHANOL-<i>d</i><sub>4</sub>): δ ppm 8.45 (d, <i>J</i> = 1.46 Hz, 1H), 8.33 (d, <i>J</i> = 1.95 Hz, 1H), 8.03 (s, 1H), 7.89 (d, <i>J</i> = 0.98 Hz, 1H), 7.67–7.72 (m, 2H), 7.61 (s, 1H), 7.15–7.21 (m, 2H), 3.95 (s, 3H).</div></div><div id="sec4_3_5_60" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> 3-(3,4-Difluorophenyl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13l</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 42 mg scale using <b>12c</b>. The reaction was run for 1.75 h, and the crude material was purified by flash chromatography (1–5% MeOH/DCM) to afford the title compound as a tan solid (17 mg, 59%). LCMS [M + H]<sup>+</sup> 311.14 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.47 (d, <i>J</i> = 1.95 Hz, 1H), 8.35 (d, <i>J</i> = 1.95 Hz, 1H), 8.06 (s, 1H), 7.91 (s, 1H), 7.68 (s, 1H), 7.59 (ddd, <i>J</i> = 11.96, 7.81, 2.20 Hz, 1H), 7.48–7.54 (m, 1H), 7.34 (m, <i>J</i> = 10.50, 8.40, 8.40 Hz, 1H), 3.94–3.99 (m, 3H).</div></div><div id="sec4_3_5_61" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> 3-(2-Fluorophenyl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13m</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 55 mg scale using <b>12d</b>. The reaction was run for 6 min, and the crude material was purified by flash chromatography (1–5% MeOH/DCM) to afford the title compound as an off-white solid (23 mg, 64%). LCMS [M + H]<sup>+</sup> 293.11 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.02 (br s, 1H), 8.54 (d, <i>J</i> = 1.47 Hz, 1H), 8.22 (s, 1H), 8.18 (s, 1H), 7.93 (s, 1H), 7.74–7.81 (m, 2H), 7.28–7.37 (m, 3H), 3.87 (s, 3H).</div></div><div id="sec4_3_5_62" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> 3-Fluoro-5-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>13n</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 44 mg scale using <b>12e</b>. The reaction was run for 2 min, and the crude material was purified by flash chromatography (5% MeOH/DCM) to afford the title compound as a white solid (22 mg, 73%). LCMS [M + H]<sup>+</sup> 318.09 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.17 (s, 1H), 8.56 (d, <i>J</i> = 1.95 Hz, 1H), 8.48 (d, <i>J</i> = 1.46 Hz, 1H), 8.29 (s, 1H), 8.16 (s, 1H), 8.11 (s, 1H), 8.03 (s, 1H), 8.01 (d, <i>J</i> = 10.25 Hz, 1H), 7.68 (d, <i>J</i> = 8.30 Hz, 1H), 3.90 (s, 3H).</div></div><div id="sec4_3_5_63" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> 2-Fluoro-5-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>13o</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 48 mg scale using <b>12f</b>. The reaction was run for 1 min, and the crude material was purified by flash chromatography (1–10% MeOH/DCM, then 1–10% MeOH/EtOAc) to afford the title compound as a white solid (11 mg, 34%). LCMS [M + H]<sup>+</sup> 318.09 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.07 (br s, 1H), 8.55 (d, <i>J</i> = 2.20 Hz, 1H), 8.43 (d, <i>J</i> = 1.47 Hz, 1H), 8.28 (dd, <i>J</i> = 5.13, 2.20 Hz, 1H), 8.26 (s, 1H), 8.16–8.23 (m, 1H), 8.02 (d, <i>J</i> = 2.20 Hz, 1H), 8.01 (s, 1H), 7.58 (t, <i>J</i> = 9.53 Hz, 1H), 3.89 (s, 3H).</div></div><div id="sec4_3_5_64" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> 4-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzamide (<b>13p</b>)</h5><div class="NLM_p last">4-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>13b</b> (15 mg, 0.05 mmol) was put in a microwave vial and dissolved in dioxane (0.1 M, 0.5 mL). Then, 2 M aqueous NaOH was added (0.25 mL, 0.5 mmol) and the reaction was run in the microwave at 150 °C for 40 min. The crude material was purified by flash chromatography (4–15% 5%NH<sub>4</sub>OH/MeOH:DCM) to afford the title compound as a solid (11 mg, 72%). LCMS [M + H]<sup>+</sup> 318.15 <i>m</i>/<i>z</i>, <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.54 (s, 1H), 8.42 (s, 1H), 8.26 (s, 1H), 7.97–8.03 (m, 3H), 7.96 (d, <i>J</i> = 8.8 Hz, 2H), 7.86 (d, <i>J</i> = 7.8 Hz, 2H), 7.32 (s, 1H), 6.63 (s, 1H), 3.89 (s, 3H).</div></div><div id="sec4_3_5_65" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> 4-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzoic acid (<b>13q</b>)</h5><div class="NLM_p last">4-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>13b</b> (15 mg, 0.05 mmol) was put in a microwave vial and dissolved in dioxane (0.1 M, 0.5 mL). Then, 2 M aqueous NaOH was added (1 mL, 2 mmol). The reaction was run in the microwave at 150 °C for 30 min. The crude material was purified by flash chromatography (4–15% 5% NH<sub>4</sub>OH/MeOH:DCM) to afford the title compound as a solid (16 mg, 100%). LCMS [M + H]<sup>+</sup> 319.13 <i>m</i>/<i>z</i>, <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.48–8.50 (m, 1H), 8.47 (d, <i>J</i> = 2.0 Hz, 1H), 8.12 (d, <i>J</i> = 8.3 Hz, 2H), 8.08 (s, 1H), 7.93 (s, 1H), 7.85 (d, <i>J</i> = 8.8 Hz, 2H), 7.82 (s, 1H), 3.96 (s, 3H). *The −NH and −OH peaks are too rapidly exchanging to be seen in the H NMR.</div></div><div id="sec4_3_5_66" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> 3-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)aniline (<b>13r</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 24 mg scale for 10 min using <b>12g</b>. The crude material was purified by flash chromatography (10% MeOH/DCM) to afford the title compound as a solid (5 mg, 32%). LCMS [M + H]<sup>+</sup> 290.19 <i>m</i>/<i>z</i>, <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.07 (d, <i>J</i> = 2.4 Hz, 1H), 8.04 (d, <i>J</i> = 2.0 Hz, 1H), 7.96–7.97 (m, 1H), 7.76 (s, 1H), 7.72 (s, 1H), 7.47–7.49 (m, 1H), 7.46 (s, 1H), 7.11 (d, <i>J</i> = 7.8 Hz, 2H), 6.91 (t, <i>J</i> = 7.6 Hz, 1H), 6.83 (d, <i>J</i> = 7.8 Hz, 1H), 6.14–6.20 (m, 1H), 3.86 (s, 3H).</div></div><div id="sec4_3_5_67" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> <i>N</i>,<i>N</i>-Dimethyl-1-(4-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenyl)methanamine (<b>13s</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 36 mg scale using <b>12h</b>. The reaction was run for 5 min, and the crude material was purified by flash chromatography (1–10% 10% NH<sub>4</sub>OH/MeOH:DCM), then repurified by preparative HPLC (99–5% water/ACN) to afford the title compound as a colorless oil (6 mg, 25%). LCMS [M + H]<sup>+</sup> 332.12 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.46 (d, <i>J</i> = 1.95 Hz, 1H), 8.39 (d, <i>J</i> = 1.95 Hz, 1H), 8.04 (s, 1H), 7.89 (d, <i>J</i> = 0.98 Hz, 1H), 7.74 (d, <i>J</i> = 8.30 Hz, 2H), 7.69 (s, 1H), 7.46 (d, <i>J</i> = 8.30 Hz, 2H), 3.95 (s, 3H), 3.78 (s, 2H), 2.48 (s, 6H).</div></div><div id="sec4_3_5_68" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-(3-nitrophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13t</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 30 mg scale for 10 min using <b>12i</b>. The crude material was purified by flash chromatography (3% MeOH/DCM) to afford the title compound as a solid (15 mg, 74%). LCMS [M + H]<sup>+</sup> 320.12 <i>m</i>/<i>z</i>, <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.13 (br s, 1H), 8.57 (d, <i>J</i> = 2.0 Hz, 1H), 8.49 (s, 1H), 8.42 (d, <i>J</i> = 2.0 Hz, 1H), 8.27 (d, <i>J</i> = 8.3 Hz, 1H), 8.25 (s, 1H), 8.14 (d, <i>J</i> = 2.4 Hz, 1H), 8.09 (dd, <i>J</i> = 7.8, 2.0 Hz, 1H), 7.98–7.99 (m, 1H), 7.74 (t, <i>J</i> = 8.1 Hz, 1H), 3.89 (s, 3H).</div></div><div id="sec4_3_5_69" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> 4-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)phenol (<b>13u</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 50 mg scale using <b>12j</b>. The reaction was run for 15 min, and the crude material was purified by flash chromatography (1–10% MeOH/DCM) to afford the title compound as a white solid (11 mg, 33%). LCMS [M + H]<sup>+</sup> 291.15 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.69 (br. s, 1H), 9.34 (br. s, 1H), 8.49 (d, <i>J</i> = 1.95 Hz, 1H), 8.28 (d, <i>J</i> = 1.95 Hz, 1H), 8.22 (s, 1H), 7.94 (d, <i>J</i> = 0.98 Hz, 1H), 7.66 (d, <i>J</i> = 2.44 Hz, 1H), 7.55 (d, <i>J</i> = 8.79 Hz, 2H), 6.85 (d, <i>J</i> = 8.30 Hz, 2H), 3.88 (s, 3H).</div></div><div id="sec4_3_5_70" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> 5-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzo[<i>c</i>][1,2,5]oxadiazole (<b>13v</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 109 mg scale using <b>12k</b>. The reaction was run for 5 min, and the crude reaction mixture was neutralized with acetic acid. A precipitate was observed and collected by vacuum filtration to afford the title compound as a yellow-green solid (37 mg, 50%). LCMS [M + H]<sup>+</sup> 317.11 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.32 (br s, 1H), 8.65 (s, 1H), 8.61 (d, <i>J</i> = 1.47 Hz, 1H), 8.35 (m, <i>J</i> = 5.10 Hz, 3H), 8.16 (d, <i>J</i> = 9.53 Hz, 1H), 8.06–8.10 (m, 2H), 3.91 (s, 3H).</div></div><div id="sec4_3_5_71" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> 3-(1<i>H</i>-Indol-5-yl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13w</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 41 mg scale using <b>12l</b>. The reaction was run for 1 h, and the crude material was purified by flash chromatography (1–10% MeOH/DCM) to afford the title compound as a white solid (12 mg, 43%). LCMS [M + H]<sup>+</sup> 314.09 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.42 (br s, 1H), 8.37 (s, 1H), 7.98 (s, 1H), 7.85 (s, 1H), 7.83 (s, 1H), 7.53 (s, 1H), 7.48 (d, <i>J</i> = 8.79 Hz, 1H), 7.42 (d, <i>J</i> = 9.53 Hz, 1H), 7.26 (d, <i>J</i> = 2.93 Hz, 1H), 6.51 (d, <i>J</i> = 2.93 Hz, 1H), 3.93 (s, 3H).</div></div><div id="sec4_3_5_72" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-(pyridin-3-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13x</b>)</h5><div class="NLM_p last">Intermediate <b>11</b> (30 mg, 0.0627 mmol) was combined with pyridin-3-ylboronic acid and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (23 mg, 0.188 mmol) in a microwave vial, which was purged with nitrogen and evacuated three times. Dioxane (0.6 mL, 0.1 M) and K<sub>2</sub>CO<sub>3</sub> (0.25 mL, 0.5 mmol) were added and the mixture was degassed for 10 min. The reaction was run in the microwave for 40 min at 120 °C. Aqueous NaOH (2 M, 0.3 mL, 0.6 mmol) was added, and the solution was then microwaved for 10 min at 150 °C. The crude product was then diluted with EtOAc and filtered through Celite using EtOAc to wash. The filtrate was purified by flash chromatography (5% MeOH/DCM) to afford the title compound as a solid (13 mg, 73%). LCMS [M + H]<sup>+</sup> 276.14 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.91 (s, 1H), 8.51 (d, <i>J</i> = 2.0 Hz, 1H), 8.45 (d, <i>J</i> = 4.4 Hz, 1H), 8.40 (d, <i>J</i> = 2.4 Hz, 1H), 8.21 (dt, <i>J</i> = 8.3, 3.4 Hz, 1H), 8.07 (s, 1H), 7.92 (s, 1H), 7.82 (s, 1H), 7.54 (dd, <i>J</i> = 7.8, 4.9 Hz, 1H), 3.96 (s, 3H). *The −NH peak is too rapidly exchanging to be seen in the H NMR.</div></div><div id="sec4_3_5_73" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-(pyridin-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13y</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 40 mg scale for 20 min using crude <b>12m</b>. The crude material was purified by flash chromatography (1–10% MeOH/DCM) to afford the title compound as a solid (23 mg, 92%) LCMS [M + H]<sup>+</sup> 276.15 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.20 (s, 1H), 8.57 (d, <i>J</i> = 2.0 Hz, 1H), 8.55 (d, <i>J</i> = 6.3 Hz, 2H), 8.51 (d, <i>J</i> = 2.0 Hz, 1H), 8.30 (s, 1H), 8.21 (d, <i>J</i> = 2.9 Hz, 1H), 8.03 (d, <i>J</i> = 1.0 Hz, 1H), 7.83 (d, <i>J</i> = 6.3 Hz, 2H), 3.89 (s, 3H).</div></div><div id="sec4_3_5_74" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> 5-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)nicotinonitrile (<b>13z</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 60 mg scale using <b>12n</b>. The reaction was run for 2 min, and the crude material was purified by flash chromatography (1–10% MeOH/DCM) to afford the title compound as a light pink solid (13 mg, 33%). LCMS [M + H]<sup>+</sup> 301.05 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.22 (br s, 1H), 9.33 (d, <i>J</i> = 1.95 Hz, 1H), 8.87 (d, <i>J</i> = 1.95 Hz, 1H), 8.68 (t, <i>J</i> = 2.20 Hz, 1H), 8.58 (d, <i>J</i> = 1.46 Hz, 1H), 8.53 (d, <i>J</i> = 1.95 Hz, 1H), 8.30 (s, 1H), 8.19 (s, 1H), 8.05 (s, 1H), 3.89 (s, 3H).</div></div><div id="sec4_3_5_75" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> 4-(5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)picolinonitrile (<b>13aa</b>)</h5><div class="NLM_p last">Intermediate <b>12o</b> (34 mg, 0.075 mmol) was dissolved in dioxane (1.5 mL, 0.05 M), and 2 M aq NaOH (0.10 mL, 0.200 mmol) was added. The reaction mixture was stirred at 85 °C for 1 h. The reaction mixture was purified directly by flash chromatography (0–10% MeOH/EtOAc) to afford the title compound as an off-white solid (8 mg, 34%). LCMS [M + H]<sup>+</sup> 301.08 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.41 (br s, 1H), 8.68 (d, <i>J</i> = 5.37 Hz, 1H), 8.60 (s, 2H), 8.46 (d, <i>J</i> = 1.46 Hz, 1H), 8.42 (s, 1H), 8.31 (s, 1H), 8.19 (dd, <i>J</i> = 4.39, 1.95 Hz, 1H), 8.06 (s, 1H), 3.90 (s, 3H).</div></div><div id="sec4_3_5_76" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-(2-methylpyridin-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13ab</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 47 mg scale using <b>12p</b>. The reaction was run for 5 min, and the crude material was purified by flash chromatography (1–10% 5% NH<sub>4</sub>OH/MeOH:DCM) to afford the title compound as a brown solid (19 mg, 60%). LCMS [M + H]<sup>+</sup> 290.16 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.45 (d, <i>J</i> = 1.95 Hz, 1H), 8.41 (d, <i>J</i> = 1.95 Hz, 1H), 8.36 (d, <i>J</i> = 5.37 Hz, 1H), 8.03 (s, 1H), 7.91 (s, 1H), 7.90 (s, 1H), 7.60 (s, 1H), 7.56 (dd, <i>J</i> = 5.37, 1.46 Hz, 1H), 3.94 (s, 3H), 2.57 (s, 3H).</div></div><div id="sec4_3_5_77" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> 3-(2,6-Dimethylpyridin-4-yl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13ac</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 43 mg scale using <b>12q</b>. The reaction was run for 5 min, and the crude material was purified by flash chromatography (1–10% MeOH/DCM) to afford the title compound as a tan solid (24 mg, 83%). LCMS [M + H]<sup>+</sup> 304.21 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.11 (br s, 1H), 8.55 (d, <i>J</i> = 1.95 Hz, 1H), 8.44 (d, <i>J</i> = 1.95 Hz, 1H), 8.27 (s, 1H), 8.11 (s, 1H), 8.02 (s, 1H), 7.45 (s, 2H), 3.90 (s, 3H), 2.49 (s, 6H).</div></div><div id="sec4_3_5_78" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> 5-Bromo-3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>14</b>)</h5><div class="NLM_p last">5-Bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>9</b> (1.01 g, 5.13 mmol) was dissolved in acetonitrile (30 mL, 0.17 M), and <i>N</i>-iodosuccinimide (1.71 g, 7.60 mmol) was added. The reaction mixture was stirred at 50 °C for 2 h. Upon cooling to room temperature, a tan precipitate was observed and collected by vacuum filtration (washed with hexanes) to afford the title compound as a pale orange solid (1.38 g, 83%). LCMS [M + H]<sup>+</sup> 322.87 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 324.89 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.35 (br s, 1H), 8.32 (d, <i>J</i> = 1.95 Hz, 1H), 7.87 (d, <i>J</i> = 2.93 Hz, 1H), 7.80 (d, <i>J</i> = 2.44 Hz, 1H).</div></div><div id="sec4_3_5_79" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> 5-Bromo-3-iodo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>15</b>)</h5><div class="NLM_p last">Intermediate <b>14</b> (1.38 g, 4.27 mmol) was suspended in DCM (20 mL, 0.21 M), and TEA (1.80 mL, 12.91 mmol), DMAP (646 mg, 5.29 mmol), and 4-methylbenzenesulfonyl chloride (2.05 g, 10.75 mmol) were added in that order. The reaction mixture was stirred overnight at room temperature, then washed once with 1 M HCl, once with sat. aq. NaHCO<sub>3</sub>, and once with brine. The organic layer was dried with sodium sulfate and concentrated under reduced pressure. The crude material was purified by flash chromatography (0–50% EtOAc/Hex) to afford the title compound as a light orange solid (1.58 g, 78%). LCMS [M + H]<sup>+</sup> 476.90 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 478.92 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.51 (d, <i>J</i> = 1.95 Hz, 1H), 8.22 (s, 1H), 7.97–8.04 (m, 3H), 7.43 (d, <i>J</i> = 8.79 Hz, 2H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_80" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> <i>tert</i>-Butyl 4-(5-bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>16a</b>)</h5><div class="NLM_p last">Intermediate <b>15</b> (323 mg, 0.678 mmol), <i>tert</i>-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (272 mg, 0.880 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (28 mg, 0.034 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (3.2 mL, 0.21 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (1.0 mL, 2.00 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (80 °C) for 10 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (0–20% EtOAc/Hex) to afford the title compound as an off-white solid (200 mg, 56%). LCMS [M + H]<sup>+</sup> 532.07 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 533.96 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 8.46 (d, <i>J</i> = 2.0 Hz, 1H), 8.18 (d, <i>J</i> = 2.0 Hz, 1H), 8.05 (d, <i>J</i> = 8.3 Hz, 2H), 7.67 (s, 1H), 7.29 (d, <i>J</i> = 8.3 Hz, 2H), 6.11 (br s, 1H), 4.13 (br s, 2H), 3.67 (t, <i>J</i> = 5.4 Hz, 2H), 2.52 (br s, 2H), 2.39 (s, 3H), 1.51 (s, 9H).</div></div><div id="sec4_3_5_81" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> <i>tert</i>-Butyl 3-(5-bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxylate (<b>16b</b>)</h5><div class="NLM_p last">Intermediate <b>15</b> (200 mg, 0.419 mmol), <i>tert</i>-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxylate (160 mg, 0.232 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (19 mg, 0.023 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (2.1 mL, 0.21 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.65 mL, 1.30 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (80 °C) for 15 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (0–20% EtOAc/Hex) to afford the title compound as a yellow solid (159 mg, 73%). LCMS [M + H]<sup>+</sup> 518.09 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 520.10 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.62 (d, <i>J</i> = 8.8 Hz, 1H), 8.52 (s, 1H), 8.03 (s, 1H), 8.00 (d, <i>J</i> = 6.8 Hz, 2H), 7.42 (d, <i>J</i> = 7.3 Hz, 2H), 6.58 (d, <i>J</i> = 18.1 Hz, 1H), 4.48 (br s, 2H), 4.22 (br s, 2H), 2.34 (s, 3H), 1.47 (d, <i>J</i> = 14.2 Hz, 9H).</div></div><div id="sec4_3_5_82" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> <i>tert</i>-Butyl 5-(5-bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>16c</b>)</h5><div class="NLM_p last">Intermediate <b>15</b> (200 mg, 0.419 mmol), <i>tert</i>-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (169 mg, 0.546 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (17 mg, 0.021 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (2.1 mL, 0.20 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.65 mL, 1.30 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (80 °C) for 15 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (0–20% EtOAc/Hex) to afford the title compound as an off-white solid (158 mg, 71%). LCMS [M + H]<sup>+</sup> 532.13 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 534.09 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.51 (s, 1H), 8.50 (s, 1H), 8.00 (d, <i>J</i> = 8.8 Hz, 2H), 7.94 (br s, 1H), 7.42 (d, <i>J</i> = 8.3 Hz, 2H), 6.46 (s, 1H), 4.22 (br s, 2H), 3.49 (br s, 2H), 2.34 (s, 3H), 2.28 (br s, 2H), 1.45 (s, 9H).</div></div><div id="sec4_3_5_83" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> <i>tert</i>-Butyl 4-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>17a</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-(5-bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate <b>16a</b> (200 mg, 0.376 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (95 mg, 0.456 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (15 mg, 0.018 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Dioxane (2.2 mL, 0.17 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.55 mL, 1.10 mmol) were added and the reaction mixture was degassed for 10 min. The reaction mixture was heated at 85 °C for ∼4 h, then the reaction mixture was diluted with EtOAc and filtered through Celite. The filtrate was purified by flash chromatography (50% EtOAc/Hex) to afford the title compound as a light orange solid (169 mg, 85%). LCMS [M + H]<sup>+</sup> 534.27 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.64 (d, <i>J</i> = 1.5 Hz, 1H), 8.38 (d, <i>J</i> = 2.0 Hz, 1H), 8.31 (s, 1H), 8.04 (s, 1H), 7.98 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (s, 1H), 7.41 (d, <i>J</i> = 7.8 Hz, 2H), 6.45 (s, 1H), 4.08 (br s, 2H), 3.87 (s, 3H), 3.52–3.61 (m, 2H), 2.55 (br s, 2H), 2.33 (s, 3H), 1.44 (s, 9H).</div></div><div id="sec4_3_5_84" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> <i>Tert</i>-Butyl 3-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (<b>17b</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 3-(5-bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxylate <b>16b</b> (159 mg, 0.306 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (77 mg, 0.370 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (14 mg, 0.017 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Dioxane (1.8 mL, 0.17 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.45 mL, 0.900 mmol) were added, and the reaction mixture was degassed for 10 min. The reaction mixture was heated at 85 °C for ∼4 h. The reaction mixture was diluted with EtOAc and filtered through Celite. The filtrate was purified by flash chromatography (20–50% EtOAc/Hex) to afford the title compound as an off-white solid (132 mg, 83%). LCMS [M + H]<sup>+</sup> 520.17 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.67 (d, <i>J</i> = 2.0 Hz, 1H), 8.41 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 8.34 (d, <i>J</i> = 3.4 Hz, 1H), 8.06 (d, <i>J</i> = 2.4 Hz, 1H), 8.01 (d, <i>J</i> = 6.8 Hz, 2H), 7.93 (s, 1H), 7.42 (d, <i>J</i> = 7.3 Hz, 2H), 6.66 (d, <i>J</i> = 24.9 Hz, 1H), 4.50 (br s, 2H), 4.27 (br s, 2H), 3.88 (s, 3H) 2.34 (s, 3H), 1.48 (d, <i>J</i> = 14.2 Hz, 9H).</div></div><div id="sec4_3_5_85" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> <i>tert</i>-Butyl 5-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>17c</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 5-(5-bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate <b>16c</b> (158 mg, 0.297 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (75 mg, 0.360 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (12 mg, 0.015 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Dioxane (1.7 mL, 0.17 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.50 mL, 1.00 mmol) were added and the reaction mixture was degassed for 10 min. The reaction mixture was heated at 85 °C for ∼4 h. The reaction mixture was diluted with EtOAc and filtered through Celite. The filtrate was purified by flash chromatography (20–50% EtOAc/hexanes) to afford the title compound as an off-white solid (93%). LCMS [M + H]<sup>+</sup> 534.21 <i>m</i>/<i>z</i>, <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.63 (d, <i>J</i> = 2.0 Hz, 1H), 8.32 (s, 1H), 8.28 (s, 1H), 7.96–8.03 (m, 3H), 7.82 (s, 1H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 6.54 (br s, 1H), 4.23 (br s, 2H), 3.85 (s, 3H), 3.50 (br s, 2H), 2.28–2.34 (m, 5H), 1.44 (s, 9H).</div></div><div id="sec4_3_5_86" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> <i>tert</i>-Butyl 4-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)piperidine-1-carboxylate (<b>18a</b>)</h5><div class="NLM_p last">t<i>ert</i>-Butyl 4-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate <b>17a</b> (169 mg, 0.317 mmol) was dissolved in EtOH (6.3 mL, 0.05 M), and 10 wt % Pd/C (35 mg, 0.033 mmol) was added. Ammonium formate (160 mg, 2.54 mmol) was added, and the reaction mixture was refluxed at 85 °C for 1.5 h. The reaction mixture was diluted with EtOAc and filtered through Celite. Solids were removed from the filtrate by gravity filtration and the filtrate was concentrated under reduced pressure to afford the title compound as a tan solid (100 mg, 59%). LCMS [M + H]<sup>+</sup> 536.16 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 8.54 (s, 1H), 8.07 (d, <i>J</i> = 8.3 Hz, 2H), 7.83 (s, 1H), 7.75 (s, 1H), 7.64 (s, 1H), 7.46 (s, 1H), 7.29 (s, 2H), 4.19–4.33 (m, 2H), 3.98 (s, 3H), 2.88 (t, <i>J</i> = 11.2 Hz, 2H), 2.38 (s, 3H), 1.99 (d, <i>J</i> = 12.7 Hz, 2H), 1.66 (qd, <i>J</i> = 12.7, 4.4 Hz, 2H), 1.50 (s, 9H).</div></div><div id="sec4_3_5_87" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> <i>tert</i>-Butyl 3-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrrolidine-1-carboxylate (<b>18b</b>)</h5><div class="NLM_p last">Intermediate <b>17b</b> (132 mg, 0.254 mmol) was dissolved in EtOH (5.0 mL, 0.05 M), and 10 wt % Pd/C (27 mg, 0.025 mmol) was added. Ammonium formate (126 mg, 2.00 mmol) was added, and the reaction mixture was refluxed at 85 °C for 1.5 h. The reaction mixture was diluted with EtOAc and filtered through Celite. Solids were removed from the filtrate by gravity filtration and the filtrate was purified by flash chromatography (2% MeOH/DCM). However, separation was not achieved. Impure fractions containing the title compound were combined to afford a yellow oil (109 mg) which was taken forward without further purification. LCMS [M + H]<sup>+</sup> 522.18 <i>m</i>/<i>z</i>.</div></div><div id="sec4_3_5_88" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> <i>tert</i>-Butyl 3-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)piperidine-1-carboxylate (<b>18c</b>)</h5><div class="NLM_p last">Intermediate <b>17c</b> (147 mg, 0.275 mmol) was dissolved in EtOH (5.0 mL, 0.05 M) and 10 wt % Pd/C (27 mg, 0.025 mmol) was added. Ammonium formate (119 mg, 1.89 mmol) was added, and the reaction mixture was refluxed at 85 °C for 1 h. The reaction mixture was diluted with EtOAc and filtered through Celite. Solids were removed from the filtrate by gravity filtration and the filtrate was purified by flash chromatography (2% MeOH/DCM) to afford the title compound as a white solid (68%). LCMS [M + H]<sup>+</sup> 536.23 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 8.54 (s, 1H), 8.06 (d, <i>J</i> = 7.3 Hz, 2H), 7.88 (br s, 1H), 7.75 (s, 1H), 7.64 (s, 1H), 7.51 (s, 1H), 7.29 (s, 2H), 4.04–4.14 (m, 1H), 3.98 (s, 3H), 2.91 (m, <i>J</i> = 11.7 Hz, 3H), 2.38 (s, 3H), 2.16 (d, <i>J</i> = 13.2 Hz, 1H), 1.79 (d, <i>J</i> = 12.2 Hz, 1H), 1.60–1.73 (m, 3H), 1.49 (s, 9H).</div></div><div id="sec4_3_5_89" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> <i>tert</i>-Butyl 4-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)piperidine-1-carboxylate (<b>19a</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 100 mg scale using <b>18a</b>. The reaction was run for 15 min, and the crude material was purified by flash chromatography (70–80% EtOAc/hexanes) to afford the title compound as a white solid (53 mg, 75%). LCMS [M + H]<sup>+</sup> 382.19 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.30 (s, 1H), 8.42 (d, <i>J</i> = 2.0 Hz, 1H), 8.16 (s, 1H), 8.11 (d, <i>J</i> = 2.0 Hz, 1H), 7.89 (s, 1H), 7.22 (d, <i>J</i> = 2.0 Hz, 1H), 3.98–4.16 (m, 2H), 3.87 (s, 3H), 2.80–3.00 (m, 3H), 1.97 (d, <i>J</i> = 13.7 Hz, 2H), 1.47–1.58 (m, 2H), 1.42 (s, 9H).</div></div><div id="sec4_3_5_90" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> <i>tert</i>-Butyl 3-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrrolidine-1-carboxylate (<b>19b</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 109 mg scale using <b>18b</b>. The reaction was run for 15 min, and the crude material was purified by flash chromatography (2–5% MeOH/DCM, step gradient) to afford the title compound as a white solid (34 mg, 44%). LCMS [M + H]<sup>+</sup> 368.16 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.39 (br s, 1H), 8.45 (d, <i>J</i> = 2.0 Hz, 1H), 8.13–8.20 (m, 2H), 7.92 (s, 1H), 7.30 (br s, 1H), 3.87 (s, 3H), 3.72–3.84 (m, 1H), 3.43–3.63 (m, 2H), 3.33–3.36 (m, 1H), 3.16–3.28 (m, 1H), 2.21–2.35 (m, 1H), 1.99–2.14 (m, 1H), 1.41 (d, <i>J</i> = 11.7 Hz, 9H).</div></div><div id="sec4_3_5_91" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> <i>tert</i>-Butyl 3-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)piperidine-1-carboxylate (<b>19c</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 109 mg scale using <b>5–28c</b>. The reaction was run for 15 min, and the crude material was purified by flash chromatography (2–5% MeOH/DCM, step gradient) to afford the title compound as a white solid (38 mg, 54%). LCMS [M + H]<sup>+</sup> 382.19 <i>m</i>/<i>z</i>, <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 8.70–8.82 (m, 1H), 8.43 (s, 1H), 8.00–8.09 (m, 1H), 7.80 (s, 1H), 7.67 (s, 1H), 7.13 (s, 1H), 4.27–4.45 (m, 1H), 3.99 (s, 3H), 2.97–3.08 (m, 1H), 2.88 (br s, 2H), 2.16–2.22 (m, 1H), 1.69–1.85 (m, 4H), 1.50 (s, 9H).</div></div><div id="sec4_3_5_92" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-(piperidin-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>20a</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)piperidine-1-carboxylate <b>19a</b> (48 mg, 0.125 mmol) was taken up in 4 M HCl in dioxane (0.5 mL, 2.00 mmol). The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated under reduced pressure and the resulting white residue was dissolved in MeOH and stirred at room temperature with Si-carbonate overnight. The Si-carbonate was removed by filtration and the filtrate was concentrated to afford the title compound as a light yellow solid (34 mg, 97%). LCMS [M + H]<sup>+</sup> 282.19 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.25 (br s, 1H), 8.42 (d, <i>J</i> = 2.0 Hz, 1H), 8.17 (s, 1H), 8.11 (s, 1H), 7.90 (s, 1H), 7.17 (s, 1H), 3.87 (s, 3H), 3.05 (d, <i>J</i> = 10.2 Hz, 2H), 2.86 (t, <i>J</i> = 13.2 Hz, 1H), 2.67 (t, <i>J</i> = 11.7 Hz, 2H), 1.89 (d, <i>J</i> = 13.7 Hz, 2H), 1.52–1.66 (m, 2H).</div></div><div id="sec4_3_5_93" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-(pyrrolidin-3-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine hydrochloride (<b>20b</b>)</h5><div class="NLM_p"><i>tert</i>-Butyl 3-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)pyrrolidine-1-carboxylate <b>19b</b> (22 mg, 0.060 mmol) was taken up in 4 M HCl in dioxane (0.1 mL, 0.400 mmol). The reaction mixture was stirred at room temperature for 1 h, then stopped and concentrated under reduced pressure to afford the title compound as a tan solid (14 mg, 78%). LCMS [M + H]<sup>+</sup> 268.19 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.95 (d, <i>J</i> = 1.5 Hz, 1H), 8.68 (d, <i>J</i> = 1.5 Hz, 1H), 8.27 (s, 1H), 8.06 (s, 1H), 7.71 (s, 1H), 3.99 (s, 3H), 3.94 (q, <i>J</i> = 8.8 Hz, 1H), 3.87 (dd, <i>J</i> = 11.2, 7.8 Hz, 1H), 3.59–3.67 (m, 1H), 3.47 (ddd, <i>J</i> = 10.7, 9.3, 7.8 Hz, 1H), 3.41 (t, <i>J</i> = 10.2 Hz, 1H), 2.64 (m, <i>J</i> = 3.9 Hz, 1H), 2.23–2.33 (m, 1H).</div><div class="NLM_p last">*The -NH peaks are too rapidly exchanging to be seen in the H NMR in CD<sub>3</sub>OD. 1.0 equiv HCl salt confirmed by H NMR in DMSO-<i>d</i><sub>6</sub>.</div></div><div id="sec4_3_5_94" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-3-(piperidin-3-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>20c</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 3-(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)piperidine-1-carboxylate <b>19c</b> (34 mg, 0.089 mmol) was taken up in 4 M HCl in dioxane (0.25 mL, 1.00 mmol). The reaction mixture was stirred at room temperature for 3 h, after which the solvent was removed under reduced pressure. The resulting yellow solid was dissolved in MeOH and Si-carbonate was added. The mixture was stirred overnight at room temperature. The Si-carbonate was removed by filtration and the filtrate was concentrated to afford the title compound as an off-white solid (20 mg, 78%). LCMS [M + H]<sup>+</sup> 282.19 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 8.19 (d, <i>J</i> = 2.0 Hz, 1H), 8.02 (s, 1H), 7.88 (s, 1H), 7.25 (s, 1H), 3.96 (s, 3H), 3.44 (d, <i>J</i> = 12.7 Hz, 1H), 3.27 (d, <i>J</i> = 9.8 Hz, 1H), 3.10–3.22 (m, 1H), 2.87 (t, <i>J</i> = 12.2 Hz, 2H), 2.15–2.22 (m, 1H), 1.93–1.99 (m, 1H), 1.76–1.88 (m, 2H).</div></div><div id="sec4_3_5_95" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> 3-(5-Bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>21</b>)</h5><div class="NLM_p last">Intermediate <b>15</b> (575 mg, 1.21 mmol), (3-cyanophenyl)boronic acid (176 mg, 1.20 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (88 mg, 0.108 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (8 mL, 0.15 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (2.0 mL, 4.00 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (120 °C) for 5 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (0–20% EtOAc/Hex) to afford the title compound as a light yellow solid (322 mg, 59%). LCMS [M + H]<sup>+</sup> 452.03 (<sup>79</sup>Br), 454.04 (<sup>81</sup>Br) <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.65 (d, <i>J</i> = 1.95 Hz, 1H), 8.55 (d, <i>J</i> = 1.95 Hz, 1H), 8.50 (s, 1H), 8.33 (d, <i>J</i> = 1.46 Hz, 1H), 8.16 (dd, <i>J</i> = 8.06, 1.22 Hz, 1H), 8.04 (d, <i>J</i> = 8.30 Hz, 2H), 7.84 (dd, <i>J</i> = 7.81, 0.98 Hz, 1H), 7.68 (t, <i>J</i> = 7.32 Hz, 1H), 7.44 (d, <i>J</i> = 7.81 Hz, 2H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_96" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120"> 3-(5-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>22a</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure B on a 76 mg scale using 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. The crude material was purified by flash chromatography (20–100% EtOAc/hexanes) to afford the title compound as a light orange solid (57 mg, 72%). LCMS [M + H]<sup>+</sup> 468.06 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.50 (d, <i>J</i> = 1.6 Hz, 1H), 8.43 (s, 1H), 8.33 (s, 1H), 8.26 (d, <i>J</i> = 1.8 Hz, 1H), 8.17 (d, <i>J</i> = 6.6 Hz, 1H), 8.07 (d, <i>J</i> = 8.4 Hz, 2H), 8.02 (s, 1H), 7.84 (d, <i>J</i> = 7.7 Hz, 1H), 7.69 (t, <i>J</i> = 8.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.2 Hz, 2H), 3.79 (s, 3H), 2.35 (s, 3H), 2.29 (s, 3H).</div></div><div id="sec4_3_5_97" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> 3-(1-Tosyl-5-(1,3,5-trimethyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>22b</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure B on a 101 mg scale using 1,3,5-trimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole. The crude material was purified by flash chromatography (20–70% EtOAc/Hex) to afford the title compound as a yellow solid (67 mg, 62%). LCMS [M + H]<sup>+</sup> 482.07 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.46 (s, 1H), 8.34 (d, <i>J</i> = 2.0 Hz, 1H), 8.31 (s, 1H), 8.18 (d, <i>J</i> = 2.0 Hz, 1H), 8.14 (d, <i>J</i> = 7.8 Hz, 1H), 8.10 (d, <i>J</i> = 8.3 Hz, 2H), 7.82 (d, <i>J</i> = 7.8 Hz, 1H), 7.67 (t, <i>J</i> = 7.8 Hz, 1H), 7.46 (d, <i>J</i> = 8.3 Hz, 2H), 3.71 (s, 3H), 2.36 (s, 3H), 2.19 (s, 3H), 2.10 (s, 3H).</div></div><div id="sec4_3_5_98" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> 3-(5-(4-(Methylsulfonyl)phenyl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>22c</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure B on a 30 mg scale using (4-(methylsulfonyl)phenyl)boronic acid. The crude material was purified by flash chromatography (20–70% EtOAc/hexanes) to afford the title compound as a white solid (11 mg, 31%). LCMS [M + H]<sup>+</sup> 528.07 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.81 (d, <i>J</i> = 1.5 Hz, 1H), 8.63 (d, <i>J</i> = 1.5 Hz, 1H), 8.52 (s, 1H), 8.41 (s, 1H), 8.26 (d, <i>J</i> = 6.8 Hz, 1H), 8.07–8.13 (m, 4H), 8.00–8.07 (m, 2H), 7.86 (d, <i>J</i> = 7.3 Hz, 1H), 7.71 (t, <i>J</i> = 7.8 Hz, 1H), 7.46 (d, <i>J</i> = 8.8 Hz, 2H), 3.27 (s, 3H), 2.36 (s, 3H).</div></div><div id="sec4_3_5_99" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> 3-(5-(Pyrimidin-5-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>22d</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure B on a 74 mg scale using 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine. The crude material was purified by flash chromatography (20–100% EtOAc/Hex) to afford the title compound as an off-white solid (53 mg, 72%). LCMS [M + H]<sup>+</sup> 452.06 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 9.29 (s, 2H), 9.24 (s, 1H), 8.85 (d, <i>J</i> = 2.2 Hz, 1H), 8.77 (d, <i>J</i> = 2.2 Hz, 1H), 8.55 (s, 1H), 8.42 (s, 1H), 8.28 (d, <i>J</i> = 8.1 Hz, 1H), 8.09 (d, <i>J</i> = 8.8 Hz, 2H), 7.86 (d, <i>J</i> = 8.1 Hz, 1H), 7.70 (t, <i>J</i> = 8.1 Hz, 1H), 7.46 (d, <i>J</i> = 8.1 Hz, 2H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_100" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> 3-(5-(Pyridin-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>22e</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure B on a 74 mg scale using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine. The crude material was purified by flash chromatography to afford the title compound as an off-white solid (62 mg, 84%). LCMS [M + H]<sup>+</sup> 451.08 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.86 (s, 1H), 8.67 (m, <i>J</i> = 5.9 Hz, 3H), 8.52 (s, 1H), 8.41 (s, 1H), 8.26 (d, <i>J</i> = 7.3 Hz, 1H), 8.09 (d, <i>J</i> = 8.1 Hz, 2H), 7.84–7.91 (m, 3H), 7.71 (t, <i>J</i> = 8.1 Hz, 1H), 7.46 (d, <i>J</i> = 8.1 Hz, 2H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_101" class="NLM_sec NLM_sec_level_4"><div id="ac_i125" class="anchor-spacer"></div><h5 class="article-section__title" id="_i125"> 3-(5-(1<i>H</i>-Pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>23a</b>)</h5><div class="NLM_p last">3-(5-Bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (18 mg, 0.060 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (49 mg, 0.252 mmol), potassium carbonate (25 mg, 0.181 mmol), and palladium tetrakis (3 mg, 3 μmol) were combined in a microwave vial that was filled with nitrogen and evacuated three times. A 4:2:1 mixture of DME/EtOH/H<sub>2</sub>O (1.5 mL, 0.04 M) was added and the reaction mixture was degassed and run in the microwave (175 °C) for 15 min. The reaction mixture was diluted with MeOH, filtered through Celite, and concentrated under reduced pressure. The filtrate was purified by flash chromatography (1–10% 5% NH<sub>4</sub>OH/MeOH:DCM) to afford the title compound as a white solid (13 mg, 76%). LCMS [M + H]<sup>+</sup> 286.09 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.98 (br s, 1H), 12.06 (br s, 1H), 8.60 (d, <i>J</i> = 1.5 Hz, 1H), 8.48 (d, <i>J</i> = 1.5 Hz, 1H), 8.33 (br s, 1H), 8.22 (s, 1H), 8.16 (dt, <i>J</i> = 7.5, 1.7 Hz, 1H), 8.02–8.12 (m, 2H), 7.67–7.71 (m, 1H), 7.64 (t, <i>J</i> = 8.1 Hz, 1H).</div></div><div id="sec4_3_5_102" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> 3-(5-(1,3-Dimethyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>23b</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 57 mg scale using 3-(5-(1,3-dimethyl-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile. The reaction was run for 2 min, and the crude material was purified by flash chromatography (1–10% MeOH/DCM) to afford the title compound as an off-white solid (31 mg, 81%). LCMS [M + H]<sup>+</sup> 314.09 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.11 (br s, 1H), 8.35 (br s, 1H), 8.27 (br s, 1H), 8.19 (br s, 1H), 8.12 (d, <i>J</i> = 8.06 Hz, 1H), 8.08 (br s, 1H), 7.97 (s, 1H), 7.68 (d, <i>J</i> = 7.33 Hz, 1H), 7.64 (t, <i>J</i> = 5.86 Hz, 1H), 3.81 (s, 3H), 2.31 (s, 3H).</div></div><div id="sec4_3_5_103" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127"> 3-(5-(1,3,5-Trimethyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>23c</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 67 mg scale using 3-(1-tosyl-5-(1,3,5-trimethyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile. The reaction was run for 2 min, and the crude material was purified by flash chromatography (5–10% MeOH/DCM) to afford the title compound as an off-white solid (17 mg, 36%). LCMS [M + H]<sup>+</sup> 328.10 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.14 (s, 1H), 8.14–8.19 (m, 3H), 8.07–8.12 (m, 2H), 7.67 (d, <i>J</i> = 7.8 Hz, 1H), 7.61 (t, <i>J</i> = 8.3 Hz, 1H), 3.73 (s, 3H), 2.22 (s, 3H), 2.13 (s, 3H).</div></div><div id="sec4_3_5_104" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> 3-(5-(4-(Methylsulfonyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>23d</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on an 11 mg scale using 3-(5-(4-(methylsulfonyl)phenyl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile. The reaction was run for 2 min, and the crude material was purified by flash chromatography (2–10% MeOH/DCM) to afford the title compound as an off-white solid (7 mg, 89%). LCMS [M + H]<sup>+</sup> 374.03 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.30 (br s, 1H), 8.69 (d, <i>J</i> = 12.5 Hz, 1H), 8.63–8.66 (m, 1H), 8.28 (s, 1H), 8.20 (d, <i>J</i> = 7.3 Hz, 1H), 8.16 (s, 1H), 8.11 (d, <i>J</i> = 8.8 Hz, 2H), 8.03 (d, <i>J</i> = 8.1 Hz, 2H), 7.72 (d, <i>J</i> = 8.1 Hz, 1H), 7.65 (t, <i>J</i> = 7.3 Hz, 1H), 3.27 (s, 3H).</div></div><div id="sec4_3_5_105" class="NLM_sec NLM_sec_level_4"><div id="ac_i129" class="anchor-spacer"></div><h5 class="article-section__title" id="_i129"> 3-(5-(Pyrimidin-5-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>23e</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 53 mg scale using 3-(5-(pyrimidin-5-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile. The reaction was run for two minutes, then diluted with MeOH, upon which a precipitate was observed and removed by gravity filtration. The filtrate was purified by flash chromatography (5% MeOH/DCM) to afford the title compound as an off-white solid (17 mg, 47%). LCMS [M + H]<sup>+</sup> 298.03 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.34 (br s, 1H), 9.31 (s, 2H), 9.21 (s, 1H), 8.77 (s, 1H), 8.71 (s, 1H), 8.30 (s, 1H), 8.23 (d, <i>J</i> = 8.1 Hz, 1H), 8.19 (br s, 1H), 7.71 (d, <i>J</i> = 7.3 Hz, 1H), 7.65 (t, <i>J</i> = 8.1 Hz, 1H).</div></div><div id="sec4_3_5_106" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> 3-(5-(Pyridin-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>23f</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 62 mg scale using 3-(5-(pyridin-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile. The reaction was run for two minutes, and the crude material was purified by flash chromatography (5% MeOH/DCM) to afford the title compound as an off-white solid (36 mg, 88%). LCMS [M + H]<sup>+</sup> 297.04 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.34 (br s, 1H), 8.74 (s, 1H), 8.69 (s, 1H), 8.66 (d, <i>J</i> = 5.1 Hz, 2H), 8.29 (s, 1H), 8.21 (d, <i>J</i> = 8.1 Hz, 1H), 8.17 (s, 1H), 7.90 (d, <i>J</i> = 5.9 Hz, 2H), 7.72 (d, <i>J</i> = 8.1 Hz, 1H), 7.65 (t, <i>J</i> = 7.3 Hz, 1H).</div></div><div id="sec4_3_5_107" class="NLM_sec NLM_sec_level_4"><div id="ac_i131" class="anchor-spacer"></div><h5 class="article-section__title" id="_i131"> 3-(5-(Pyrrolidin-1-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>24a</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure C on a 153 mg scale using pyrrolidine. The crude material was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as a yellow solid (12 mg, 12%). LCMS [M + H]<sup>+</sup> 289.12 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.68 (br s, 1H), 8.11 (s, 1H), 8.06 (d, <i>J</i> = 6.8 Hz, 1H), 7.91 (d, <i>J</i> = 2.4 Hz, 1H), 7.83 (d, <i>J</i> = 2.4 Hz, 1H), 7.59–7.66 (m, 2H), 7.32 (s, 1H) 3.29–3.32 (m, 4H), 1.97–2.02 (m, 4H).</div></div><div id="sec4_3_5_108" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> 3-(5-(Piperidin-1-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>24b</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure C on a 152 mg scale using piperidine. The crude material was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as a light orange solid (20 mg, 19%). LCMS [M + H]<sup>+</sup> 303.10 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.84 (br s, 1H), 8.13 (d, <i>J</i> = 2.0 Hz, 2H), 8.06 (d, <i>J</i> = 7.3 Hz, 1H), 7.96 (d, <i>J</i> = 2.4 Hz, 1H), 7.76 (d, <i>J</i> = 2.4 Hz, 1H), 7.60–7.67 (m, 2H), 3.11 (t, <i>J</i> = 5.9 Hz, 4H), 1.70 (quin, <i>J</i> = 5.4 Hz, 4H), 1.54 (quin, <i>J</i> = 5.9 Hz, 2H).</div></div><div id="sec4_3_5_109" class="NLM_sec NLM_sec_level_4"><div id="ac_i133" class="anchor-spacer"></div><h5 class="article-section__title" id="_i133"> 3-(5-(Piperidin-1-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>24c</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure C on a 95 mg scale using <i>N</i>-methylpiperazine. The crude material was purified by flash chromatography (5–10% MeOH/DCM) to afford the title compound as a light orange solid (12 mg, 18%). LCMS [M + H]<sup>+</sup> 318.15 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, METHANOL-<i>d</i><sub>4</sub>): δ ppm 8.13 (d, <i>J</i> = 2.4 Hz, 1H), 7.95–8.00 (m, 2H), 7.85 (d, <i>J</i> = 2.4 Hz, 1H), 7.73 (s, 1H), 7.57–7.63 (m, 2H), 3.24 (br t, <i>J</i> = 4.9, 4.9 Hz, 4H), 2.71 (br t, <i>J</i> = 4.9, 4.9 Hz, 4H), 2.39 (s, 3H).</div></div><div id="sec4_3_5_110" class="NLM_sec NLM_sec_level_4"><div id="ac_i134" class="anchor-spacer"></div><h5 class="article-section__title" id="_i134"> <i>tert</i>-Butyl 4-(3-(3-cyanophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)piperazine-1-carboxylate (<b>24d</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure C on a 150 mg scale using <i>tert</i>-butyl piperazine-1-carboxylate; the reaction was run overnight. The crude material was purified by flash chromatography (20–100% EtOAc/hexanes) to afford the title compound as a yellow solid (40 mg, 30%). LCMS [M + H]<sup>+</sup> 404.21 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.89 (br s, 1H), 8.16 (d, <i>J</i> = 2.4 Hz, 1H), 8.14 (t, <i>J</i> = 1.7 Hz, 1H), 8.08 (dt, <i>J</i> = 8.1, 1.6 Hz, 1H), 7.99 (d, <i>J</i> = 2.9 Hz, 1H), 7.83 (d, <i>J</i> = 2.4 Hz, 1H), 7.64–7.68 (m, 1H), 7.62 (t, <i>J</i> = 7.8 Hz, 1H), 3.52 (m, <i>J</i> = 4.9, 3.4 Hz, 4H), 3.11 (br t, <i>J</i> = 4.9, 4.9 Hz, 4H), 1.43 (s, 9H).</div></div><div id="sec4_3_5_111" class="NLM_sec NLM_sec_level_4"><div id="ac_i135" class="anchor-spacer"></div><h5 class="article-section__title" id="_i135"> 3-(5-(4-Methyl-1,4-diazepan-1-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>24e</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure C on a 70 mg scale using 1-methyl-1,4-diazepane. The crude material was purified by flash chromatography (5–25% MeOH/DCM) to afford the title compound as a yellow solid (9 mg, 12%). LCMS [M + H]<sup>+</sup> 332.16 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 7.93–8.01 (m, 3H), 7.67 (s, 1H), 7.54–7.63 (m, 3H), 3.69 (br t, <i>J</i> = 4.4, 4.4 Hz, 2H), 3.55 (t, <i>J</i> = 6.3 Hz, 2H), 3.04 (br t, <i>J</i> = 4.4, 4.4 Hz, 2H), 2.90 (br t, <i>J</i> = 4.9, 4.9 Hz, 1H), 2.57 (s, 3H), 2.15 (quint, <i>J</i> = 11.1, 11.1, 11.1, 11.1, 5.9, 5.9 Hz, 2H).</div></div><div id="sec4_3_5_112" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136"> <i>tert</i>-Butyl 4-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)piperazine-1-carboxylate (<b>S29</b>)</h5><div class="NLM_p last">5-Bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>9</b> (250 mg, 1.27 mmol), 1-boc piperazine (286 mg, 1.54 mmol) RuPhos (30 mg, 0.064 mmol), and RuPhos Pd G1 (51 mg, 0.062 mmol) were combined in a vial that was filled with nitrogen and evacuated three times. Then, 1.0 M LiHMDS in THF (3.2 mL, 3.2 mmol) was added, and the reaction mixture was heated at 65 °C for ∼5 h. The reaction mixture was cooled to room temperature and quenched by the addition of 1 M HCl, then diluted with EtOAc, and poured over sat. aq. NaHCO<sub>3</sub>. The aqueous layer was extracted three times with EtOAc, and the combined organic layers were washed once with brine, dried with sodium sulfate, and concentrated under reduced pressure. The crude residue was purified by flash chromatography (50–80% EtOAc/hexanes) to afford the title compound as a light yellow solid (350 mg, 91%). LCMS [M + H]<sup>+</sup> 303.16 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.34–11.42 (m, 1H), 8.06 (d, <i>J</i> = 2.4 Hz, 1H), 7.51 (d, <i>J</i> = 2.4 Hz, 1H), 7.37 (t, <i>J</i> = 2.9 Hz, 1H), 6.32 (dd, <i>J</i> = 3.2, 1.7 Hz, 1H), 3.49 (br t, <i>J</i> = 4.9, 4.9 Hz, 4H), 3.01 (br t, <i>J</i> = 4.9, 4.9 Hz, 4H), 1.43 (s, 9H).</div></div><div id="sec4_3_5_113" class="NLM_sec NLM_sec_level_4"><div id="ac_i137" class="anchor-spacer"></div><h5 class="article-section__title" id="_i137"> <i>tert</i>-Butyl 4-(3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)piperazine-1-carboxylate (<b>S30</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)piperazine-1-carboxylate <b>S29</b> (350 mg, 1.16 mmol) was dissolved in acetonitrile (6.5 mL, 0.18 M), and <i>N</i>-iodosuccinimide (314 mg, 1.40 mmol) was added. The reaction mixture was stirred at 50 °C for 2 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, and washed three times with water and once with brine. The organic layer was dried with sodium sulfate and concentrated under reduced pressure. The crude residue was purified by flash chromatography (50% EtOAc/hexanes) to afford the title compound as a yellow solid (230 mg, 46%). LCMS [M + H]<sup>+</sup> 429.11 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.83–11.93 (m, 1H), 8.12 (d, <i>J</i> = 2.9 Hz, 1H), 7.61 (d, <i>J</i> = 2.9 Hz, 1H), 7.13 (d, <i>J</i> = 2.4 Hz, 1H), 3.51 (br s, 1H), 3.07 (t, <i>J</i> = 4.9 Hz, 4H), 1.43 (s, 9H).</div></div><div id="sec4_3_5_114" class="NLM_sec NLM_sec_level_4"><div id="ac_i138" class="anchor-spacer"></div><h5 class="article-section__title" id="_i138"> <i>tert</i>-Butyl 4-(3-iodo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)piperazine-1-carboxylate (<b>S31</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-(3-iodo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)piperazine-1-carboxylate <b>S30</b> (230 mg, 0.537 mmol) was suspended in DCM (2.7 mL, 0.21 M) and TEA (0.30 mL, 2.15 mmol), DMAP (84 mg, 0.688 mmol) and 4-methylbenzenesulfonyl chloride (240 mg, 1.26 mmol) were added in that order. The reaction mixture was stirred overnight at room temperature and washed once with 1 M HCl, once with sat. aq. NaHCO<sub>3</sub>, and once with brine; the organic layer was dried with sodium sulfate and concentrated under reduced pressure. The crude residue was purified by flash chromatography (20% EtOAc/Hex) to afford the title compound as an orange oil (138 mg, 44%). LCMS [M + H]<sup>+</sup> 583.04 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.22 (t, <i>J</i> = 2.4 Hz, 1H), 8.03 (d, <i>J</i> = 2.4 Hz, 1H), 7.95 (dd, <i>J</i> = 8.5, 2.2 Hz, 2H), 7.41 (d, <i>J</i> = 6.8 Hz, 2H), 7.13 (t, <i>J</i> = 2.4 Hz, 1H), 3.47 (br s, 4H), 3.14 (br s, 4H), 2.33 (s, 3H), 1.42 (s, 9H).</div></div><div id="sec4_3_5_115" class="NLM_sec NLM_sec_level_4"><div id="ac_i139" class="anchor-spacer"></div><h5 class="article-section__title" id="_i139"> 3-Iodo-5-(piperazin-1-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S32</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-(3-iodo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)piperazine-1-carboxylate <b>S31</b> (138 mg, 0.237 mmol) was taken up in 4 M HCl in dioxane (0.60 mL, 2.40 mmol), and the reaction mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure, and the yellow residue (HCl salt) was dissolved in water and poured over 1 M NaOH. The aqueous layer (pH ∼ 13–14) was extracted three times with DCM. The combined organic layers were dried with sodium sulfate and concentrated under reduced pressure to afford the title compound as a yellow oil (73 mg, 64%). LCMS [M + H]<sup>+</sup> 483.01 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.20 (d, <i>J</i> = 2.9 Hz, 1H), 8.01 (s, 1H), 7.95 (d, <i>J</i> = 8.3 Hz, 2H), 7.41 (d, <i>J</i> = 8.8 Hz, 2H), 7.05 (d, <i>J</i> = 2.9 Hz, 1H), 3.08 (t, <i>J</i> = 4.9 Hz, 4H), 2.84 (t, <i>J</i> = 5.4 Hz, 4H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_116" class="NLM_sec NLM_sec_level_4"><div id="ac_i140" class="anchor-spacer"></div><h5 class="article-section__title" id="_i140"> 3-Iodo-5-(4-(methylsulfonyl)piperazin-1-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S33</b>)</h5><div class="NLM_p last">3-Iodo-5-(piperazin-1-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S32</b> (73 mg, 0.151) was dissolved in DCM (0.5 mL, 0.32 M) and TEA (42 μL, 0.301 mmol) was added. The reaction mixture was stirred for 10 min at room temperature before the addition of methanesulfonyl chloride (14 μL, 0.181 mmol). The reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched with water and extracted four times with DCM. The combined organic layers were washed once with brine, dried with sodium sulfate, and concentrated under reduced pressure. The crude material was purified by flash chromatography (20–50% EtOAc/hexanes) to afford the title compound as an orange solid (68 mg, 80%). LCMS [M + H]<sup>+</sup> 560.98 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.25 (d, <i>J</i> = 2.4 Hz, 1H), 8.04 (s, 1H), 7.96 (d, <i>J</i> = 8.3 Hz, 2H), 7.41 (d, <i>J</i> = 8.3 Hz, 2H), 7.17 (d, <i>J</i> = 2.9 Hz, 1H), 3.28–3.32 (m, 4H), 3.24–3.28 (m, 4H), 2.93 (s, 3H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_117" class="NLM_sec NLM_sec_level_4"><div id="ac_i141" class="anchor-spacer"></div><h5 class="article-section__title" id="_i141"> 3-(5-(4-(Methylsulfonyl)piperazin-1-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S34</b>)</h5><div class="NLM_p last">3-Iodo-5-(4-(methylsulfonyl)piperazin-1-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S33</b> (68 mg, 0.121 mmol), (3-cyanophenyl)boronic acid (36 mg, 0.245 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (10 mg, 0.012 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (0.50 mL, 0.25 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.20 mL, 0.400 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (120 °C) for 5 min, then diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude residue was purified by flash chromatography (50% EtOAc/Hex) to afford the title compound as a dull red glassy solid (41 mg, 63%). LCMS [M + H]<sup>+</sup> 536.10 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.31 (s, 1H), 8.28 (s, 1H), 8.28 (s, 1H), 8.10–8.15 (m, 1H), 8.01 (d, <i>J</i> = 8.3 Hz, 2H), 7.83 (d, <i>J</i> = 7.8 Hz, 1H), 7.76 (d, <i>J</i> = 2.4 Hz, 1H), 7.68 (t, <i>J</i> = 7.8 Hz, 1H), 7.42 (d, <i>J</i> = 8.8 Hz, 2H), 3.29–3.31 (m, 4H), 3.26 (m, <i>J</i> = 5.9 Hz, 4H), 2.93 (s, 3H), 2.34 (s, 3H).</div></div><div id="sec4_3_5_118" class="NLM_sec NLM_sec_level_4"><div id="ac_i142" class="anchor-spacer"></div><h5 class="article-section__title" id="_i142"> 3-(5-(4-(Methylsulfonyl)piperazin-1-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>25</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 45 mg scale using 3-(5-(4-(methylsulfonyl)piperazin-1-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>S34</b>. The reaction was run for 45 min, and the crude material was purified by flash chromatography (50–100% EtOAc/hexanes) to afford the title compound as a white solid (15 mg, 53%). LCMS [M + H]<sup>+</sup> 382.13 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.92 (s, 1H), 8.18 (d, <i>J</i> = 2.4 Hz, 1H), 8.15 (s, 1H), 8.09 (d, <i>J</i> = 7.8 Hz, 1H), 8.00 (s, 1H), 7.86 (d, <i>J</i> = 2.0 Hz, 1H), 7.66 (d, <i>J</i> = 7.3 Hz, 1H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 3.29–3.32 (m, 4H), 3.27 (m, <i>J</i> = 5.9 Hz, 4H), 2.95 (s, 3H).</div></div><div id="sec4_3_5_119" class="NLM_sec NLM_sec_level_4"><div id="ac_i143" class="anchor-spacer"></div><h5 class="article-section__title" id="_i143"> 3-(5-(Piperazin-1-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>26</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-(3-(3-cyanophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)piperazine-1-carboxylate <b>24d</b> (40 mg, 0.099 mmol) was taken up in 4 M HCl in dioxane (0.25 mL, 1.00 mmol), and the reaction mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure, and the yellow residue (HCl salt) was dissolved in water and poured over sat. aq. NaHCO<sub>3</sub>. The aqueous layer (pH ∼ 8) was extracted three times with DCM. The pH of the aqueous layer was increased to ∼13–14 by the addition of 1 M NaOH, and the aqueous layer was extracted once more with DCM. The combined organic layers were dried with sodium sulfate and concentrated under reduced pressure to afford the title compound as a yellow solid (19 mg, 62%). LCMS [M + H]<sup>+</sup> 304.17 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.84 (br s, 1H), 8.13 (d, <i>J</i> = 2.0 Hz, 2H), 8.05–8.09 (m, 1H), 7.96 (d, <i>J</i> = 2.4 Hz, 1H), 7.74 (d, <i>J</i> = 2.4 Hz, 1H), 7.60–7.68 (m, 2H), 3.30 (br s, 1H), 3.07 (br t, <i>J</i> = 4.4, 4.4 Hz, 4H), 2.90 (m, <i>J</i> = 4.9 Hz, 4H).</div></div><div id="sec4_3_5_120" class="NLM_sec NLM_sec_level_4"><div id="ac_i144" class="anchor-spacer"></div><h5 class="article-section__title" id="_i144"> 3-(5-((1-Methyl-1<i>H</i>-pyrazol-4-yl)amino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>27</b>)</h5><div class="NLM_p last">3-(5-Bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>21</b> (151 mg, 0.334 mmol), BrettPhos (19 mg, 0.035 mmol), BrettPhos Pd G1 (32 mg, 0.040 mmol), and 4-amino-1-methylpyrazole (69 mg, 0.710 mmol) were combined in a vial that was filled with nitrogen and evacuated three times. Then, 1.0 M LiHMDS in THF (0.800 mL, 0.800 mmol) was added and the reaction mixture was heated at 65 °C overnight. The reaction was quenched by the addition of 1 M HCl, then diluted with EtOAc, and poured over sat. aq. NaHCO<sub>3</sub>. The aqueous layer was extracted three times with EtOAc, and the combined organic layers were washed once with brine, dried with sodium sulfate, and concentrated under reduced pressure. The crude material was purified by flash chromatography (20–100% EtOAc/Hex—1–5% MeOH/EtOAc) and then repurified by preparative HPLC (95–5% water/ACN) to afford the title compound (0.5 equiv formate salt) as a dark orange residue (5 mg, 8%). LCMS [M + H]<sup>+</sup> 315.19 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ ppm 8.46–8.65 (m, 0 H), 7.95–7.98 (m, 1H), 7.93–7.95 (m, 1H), 7.91 (dt, <i>J</i> = 6.8, 2.0 Hz, 1H), 7.71 (d, <i>J</i> = 2.4 Hz, 1H), 7.69 (s, 1H), 7.54–7.61 (m, 3H), 7.41 (d, <i>J</i> = 1.0 Hz, 1H), 3.88 (s, 3H).</div></div><div id="sec4_3_5_121" class="NLM_sec NLM_sec_level_4"><div id="ac_i145" class="anchor-spacer"></div><h5 class="article-section__title" id="_i145"> <i>N</i>-(4-(Methylsulfonyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-amine (<b>S35</b>)</h5><div class="NLM_p last">5-Bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>9</b> (250 mg, 1.27 mmol), 4-(methylsulfonyl)aniline (264 mg, 1.54 mmol), BrettPhos (34 mg, 0.063 mmol), and BrettPhos Pd G1 (51 mg, 0.064 mmol) were combined in a vial that was filled with nitrogen and evacuated three times. Then, 1.0 M LiHMDS in THF (3.2 mL, 3.2 mmol) was added and the reaction mixture was heated at 65 °C for ∼5 h. The reaction was quenched by the addition of 1 M HCl, then diluted with EtOAc, and poured over sat. aq. NaHCO<sub>3</sub>. The aqueous layer was extracted three times with EtOAc, and the combined organic layers were washed once with brine, dried with sodium sulfate, and concentrated under reduced pressure. The crude material was purified by flash chromatography (50–100% EtOAc/Hex) to afford the title compound as a light yellow solid (146 mg, 40%). LCMS [M + H]<sup>+</sup> 288.08 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.65 (br s, 1H), 8.69 (s, 1H), 8.09 (d, <i>J</i> = 2.4 Hz, 1H), 7.82 (d, <i>J</i> = 2.0 Hz, 1H), 7.63 (d, <i>J</i> = 8.8 Hz, 2H), 7.49 (t, <i>J</i> = 2.9 Hz, 1H), 6.91 (d, <i>J</i> = 8.8 Hz, 2H), 6.43 (dd, <i>J</i> = 3.2, 1.7 Hz, 1H), 3.07 (s, 3H).</div></div><div id="sec4_3_5_122" class="NLM_sec NLM_sec_level_4"><div id="ac_i146" class="anchor-spacer"></div><h5 class="article-section__title" id="_i146"> 3-Iodo-<i>N</i>-(4-(methylsulfonyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-amine (<b>S36</b>)</h5><div class="NLM_p last"><i>N</i>-(4-(methylsulfonyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-amine <b>S35</b> (146 mg, 0.508 mmol) was dissolved in acetonitrile (2.8 mL 0.18 M) and <i>N</i>-iodosuccinimide (138 mg, 0.613 mmol) was added. The reaction mixture was stirred at 50 °C for 5 h. Upon cooling, a dark brown precipitate was observed and collected by vacuum filtration to afford the title compound as a red-brown solid (110 mg, 52%). LCMS [M + H]<sup>+</sup> 413.99 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.13 (br s, 1H), 8.80 (s, 1H), 8.15 (d, <i>J</i> = 2.4 Hz, 1H), 7.74 (d, <i>J</i> = 2.4 Hz, 1H), 7.67 (d, <i>J</i> = 8.8 Hz, 2H), 7.47 (d, <i>J</i> = 2.0 Hz, 1H), 6.97 (d, <i>J</i> = 8.8 Hz, 2H), 3.08 (s, 3H).</div></div><div id="sec4_3_5_123" class="NLM_sec NLM_sec_level_4"><div id="ac_i147" class="anchor-spacer"></div><h5 class="article-section__title" id="_i147"> 3-Iodo-<i>N</i>-(4-(methylsulfonyl)phenyl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-amine (<b>S37</b>)</h5><div class="NLM_p last">3-Iodo-<i>N</i>-(4-(methylsulfonyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-amine <b>S36</b> (110 mg, 0.266 mmol) was suspended in DCM (1.3 mL, 0.21 M) and TEA (0.15 mL, 1.08 mmol), DMAP (43 mg, 0.352 mmol) and 4-methylbenzenesulfonyl chloride (129 mg, 0.677 mmol) were added in that order. The reaction mixture was stirred overnight at room temperature and washed once with 1 M HCl, once with sat. aq. NaHCO<sub>3</sub>, and once with brine; the organic layer was dried with sodium sulfate and concentrated under reduced pressure. The crude material was purified by flash chromatography (20–50% EtOAc/Hex) to afford the title compound as an off-white solid (66 mg, 44%). LCMS [M + H]<sup>+</sup> 567.90 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 9.03 (s, 1H), 8.27 (d, <i>J</i> = 2.4 Hz, 1H), 8.13 (s, 1H), 8.01 (d, <i>J</i> = 8.3 Hz, 2H), 7.71 (d, <i>J</i> = 8.8 Hz, 2H), 7.50 (d, <i>J</i> = 2.4 Hz, 1H), 7.44 (d, <i>J</i> = 8.8 Hz, 2H), 7.10 (d, <i>J</i> = 8.8 Hz, 2H), 3.11 (s, 3H), 2.35 (s, 3H).</div></div><div id="sec4_3_5_124" class="NLM_sec NLM_sec_level_4"><div id="ac_i148" class="anchor-spacer"></div><h5 class="article-section__title" id="_i148"> 3-(5-((4-(Methylsulfonyl)phenyl)amino)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S38</b>)</h5><div class="NLM_p last">3-Iodo-<i>N</i>-(4-(methylsulfonyl)phenyl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-amine <b>S37</b> (65 mg, 0.114 mmol), (3-cyanophenyl)boronic acid (35 mg, 0.238 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (9 mg, 0.011 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (0.50 mL, 0.25 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.20 mL, 0.400 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (120 °C) for 5 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude residue was purified by flash chromatography (20–75% EtOAc/Hex) to afford the title compound as a dark orange solid (46 mg, 74%). LCMS [M + H]<sup>+</sup> 543.03 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.99 (s, 1H), 8.42 (s, 1H), 8.33 (d, <i>J</i> = 2.4 Hz, 1H), 8.29 (t, <i>J</i> = 1.5 Hz, 1H), 8.13 (d, <i>J</i> = 2.4 Hz, 1H), 8.11 (dt, <i>J</i> = 8.3, 1.5 Hz, 1H), 8.06 (d, <i>J</i> = 8.3 Hz, 2H), 7.82 (dt, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.65–7.70 (m, 3H), 7.45 (d, <i>J</i> = 8.3 Hz, 2H), 7.09 (d, <i>J</i> = 8.8 Hz, 2H), 3.09 (s, 3H), 2.36 (s, 3H).</div></div><div id="sec4_3_5_125" class="NLM_sec NLM_sec_level_4"><div id="ac_i149" class="anchor-spacer"></div><h5 class="article-section__title" id="_i149"> 3-(5-((4-(Methylsulfonyl)phenyl)amino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>28</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 46 mg scale using 3-(5-((4-(methylsulfonyl)phenyl)amino)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>S38</b>. The reaction was run for 80 min, and the crude material was purified by flash chromatography (50% EtOAc/hexanes) to afford the title compound as a white solid (15 mg, 46%). LCMS [M + H]<sup>+</sup> 389.12 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.13–12.20 (m, 1H), 8.79 (s, 1H), 8.20 (dd, <i>J</i> = 11.5, 2.2 Hz, 2H), 8.16 (s, 1H), 8.11 (s, 1H), 8.06 (d, <i>J</i> = 7.8 Hz, 1H), 7.60–7.69 (m, 4H), 6.97 (d, <i>J</i> = 9.3 Hz, 2H), 3.08 (s, 3H).</div></div><div id="sec4_3_5_126" class="NLM_sec NLM_sec_level_4"><div id="ac_i150" class="anchor-spacer"></div><h5 class="article-section__title" id="_i150"> Tetrahydro-2<i>H</i>-pyran-4-yl methanesulfonate (<b>S40a</b>)</h5><div class="NLM_p last">Tetrahydro-2<i>H</i>-pyran-4-ol <b>S39a</b> (0.500 mL, 5.24 mmol) was dissolved in DCM (9.0 mL, 0.60 M) and TEA (0.750 mL, 5.38 mmol) was added, followed by the addition of DMAP (128 mg, 1.05 mmol). The solution was cooled to 0 °C, and MsCl (0.410 mL, 5.30 mmol) was added dropwise, upon which the reaction mixture turned opaque. The reaction was run at 0 °C for 4 h, after which water was added and the reaction mixture was transferred to a separatory funnel. The organic layer was washed once with brine, dried with sodium sulfate, and concentrated under reduced pressure to afford the title compound as an off-white solid (770 mg, 82%). <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 4.92 (spt, <i>J</i> = 4.2 Hz, 1H), 3.92–4.00 (m, 2H), 3.56 (td, <i>J</i> = 10.2, 8.8 Hz, 2H), 3.05 (s, 3H), 2.02–2.10 (m, 2H), 1.84–1.95 (m, 2H). *Does not ionize.</div></div><div id="sec4_3_5_127" class="NLM_sec NLM_sec_level_4"><div id="ac_i151" class="anchor-spacer"></div><h5 class="article-section__title" id="_i151"> <i>tert</i>-Butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate (<b>S40b</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-hydroxypiperidine-1-carboxylate <b>S39b</b> (2.00 g, 9.94 mmol) was dissolved in DCM (20 mL, 0.5 M), and the reaction mixture was cooled to 0–5. TEA (3.0 mL, 21.52 mmol) was slowly added, followed by the slow addition of methanesulfonyl chloride (1.0 mL, 12.92 mmol). The reaction mixture was stirred for 1 h at room temperature. The reaction mixture was purified by flash chromatography (10% EtOAc/hexanes) to afford the title compound as a white solid (1.7 g, 61%). LCMS [M + H]<sup>+</sup> 223.95 <i>m</i>/<i>z</i> (loss of <i>t</i>-Bu group); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 4.82 (tt, <i>J</i> = 8.1, 3.8 Hz, 1H), 3.60 (tt, <i>J</i> = 5.9, 4.4 Hz, 2H), 3.20 (s, 3H), 3.12–3.19 (m, 2H), 1.86–1.94 (m, 2H), 1.60 (dtd, <i>J</i> = 13.0, 8.8, 8.8, 4.1 Hz, 2H), 1.40 (s, 9H).</div></div><div id="sec4_3_5_128" class="NLM_sec NLM_sec_level_4"><div id="ac_i152" class="anchor-spacer"></div><h5 class="article-section__title" id="_i152"> 1-Methylpiperidin-4-yl methanesulfonate (<b>S40c</b>)</h5><div class="NLM_p last">1-Methylpiperidin-4-ol <b>S39c</b> (0.500 mL, 4.25 mmol) was dissolved in DCM (7.0 mL, 0.60 M), and TEA (0.600 mL, 4.30 mmol) was added, followed by the addition of DMAP (103 mg, 0.843 mmol). The solution was cooled to 0 °C, and MsCl (0.330 mL, 4.26 mmol) was added dropwise, upon which the reaction mixture turned opaque. The reaction was run at 0 °C for 5 h. Water was added, and the reaction mixture was transferred to a separatory funnel. The organic layer was washed once more with water, once with brine, dried with sodium sulfate, and concentrated under reduced pressure to afford the title compound as a yellow oil (444 mg, 54%). LCMS [M + H]<sup>+</sup> 193.97 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 4.75 (br s, 1H), 3.03 (s, 3H), 2.67 (br s, 2H), 2.21–2.35 (m, 5H), 1.99–2.07 (m, 2H), 1.88–1.97 (m, 2H).</div></div><div id="sec4_3_5_129" class="NLM_sec NLM_sec_level_4"><div id="ac_i153" class="anchor-spacer"></div><h5 class="article-section__title" id="_i153"> 4-Bromo-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazole (<b>S41a</b>)</h5><div class="NLM_p last">4-Bromo-1<i>H</i>-pyrazole (200 mg, 1.36 mmol) was dissolved in DMF (1.7 mL, 0.81 M) and cooled to 0 °C. NaH (165 mg, 4.13 mmol) was added portionwise, and the reaction mixture was stirred for 1 h at 0 °C. Tetrahydro-2<i>H</i>-pyran-4-yl methanesulfonate <b>S40a</b> (317 mg, 1.76 mmol) was added. The reaction was mixture was gradually heated to 100 °C and stirred overnight. The reaction mixture was quenched with water and extracted twice with EtOAc. The combined organic layers were washed with brine, dried with sodium sulfate, and concentrated under reduced pressure. The product was purified by flash chromatography (2% 5% NH<sub>4</sub>OH/MeOH:DCM) to afford the title compound as an off-white solid (191 mg, 61%). LCMS [M + H]<sup>+</sup> 230.93 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 232.92 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.06 (s, 1H), 7.55 (s, 1H), 4.39 (tt, <i>J</i> = 10.6, 5.2 Hz, 1H), 3.94 (d, <i>J</i> = 12.7 Hz, 2H), 3.44 (td, <i>J</i> = 11.5, 2.9 Hz, 2H), 1.85–1.98 (m, 4H).</div></div><div id="sec4_3_5_130" class="NLM_sec NLM_sec_level_4"><div id="ac_i154" class="anchor-spacer"></div><h5 class="article-section__title" id="_i154"> <i>tert</i>-Butyl 4-(4-bromo-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate (<b>S41b</b>)</h5><div class="NLM_p last">4-Bromo-1<i>H</i>-pyrazole (200 mg, 1.36 mmol) was dissolved in DMF (1.7 mL, 0.81 M) and cooled to 0 °C. NaH (166 mg, 4.15 mmol) was added portionwise, and the reaction mixture was stirred for 1 h at 0 °C. <i>tert</i>-Butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate <b>S40b</b> (497 mg, 1.78 mmol) was added, and the reaction mixture was gradually heated to 100 °C and stirred overnight. The reaction mixture was quenched with water and extracted twice with EtOAc. The combined organic layers were washed with brine, dried with sodium sulfate, and concentrated under reduced pressure. The product was purified by flash chromatography (0–50% EtOAc/Hex) to afford the title compound as a colorless oil (282 mg, 36%). LCMS [M + H]<sup>+</sup> 273.94 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 275.96 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 7.47 (s, 1H), 7.44 (s, 1H), 4.16–4.41 (m, 3H), 2.76–2.97 (m, 2H), 2.10 (d, <i>J</i> = 12.2 Hz, 2H), 1.87 (qd, <i>J</i> = 12.2, 3.9 Hz, 2H), 1.47 (s, 9H).</div></div><div id="sec4_3_5_131" class="NLM_sec NLM_sec_level_4"><div id="ac_i155" class="anchor-spacer"></div><h5 class="article-section__title" id="_i155"> 4-(4-Bromo-1<i>H</i>-pyrazol-1-yl)-1-methylpiperidine (<b>S41c</b>)</h5><div class="NLM_p last">4-Bromo-1<i>H</i>-pyrazole (200 mg, 1.36 mmol) was dissolved in dry DMF (1.7 mL, 0.81 M) and cooled to 0 °C. NaH (168 mg, 4.20 mmol) was added portionwise, and the reaction mixture was stirred for 1 h at 0 °C, after which 1-methylpiperidin-4-yl methanesulfonate <b>406c</b> (444 mg, 2.30 mmol) was dissolved in dry DMF (1.4 mL, 1.7 M) added. The reaction mixture was gradually heated to 100 °C and stirred for 2 days. The reaction mixture was quenched with water and extracted twice with EtOAc. The combined organic layers were washed with brine, dried with sodium sulfate, and concentrated under reduced pressure. The crude material was purified by flash chromatography (3% 5% NH<sub>4</sub>OH/MeOH:DCM) to afford the title compound as an off-white solid (80 mg, 24%). LCMS [M + H]<sup>+</sup> 243.97 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 245.98 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.04 (s, 1H), 7.53 (s, 1H), 4.09 (dt, <i>J</i> = 10.5, 5.0 Hz, 1H), 2.82 (d, <i>J</i> = 11.7 Hz, 2H), 2.18 (s, 3H), 1.96–2.07 (m, 2H), 1.85–1.95 (m, 4H).</div></div><div id="sec4_3_5_132" class="NLM_sec NLM_sec_level_4"><div id="ac_i156" class="anchor-spacer"></div><h5 class="article-section__title" id="_i156"> 3-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S42</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure E on a 600 mg scale using 3-(5-bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>21</b>. The crude material was purified by flash chromatography (0–20% EtOAc/Hex) and then repurified by flash chromatography (1% MeOH/DCM) to afford the title compound as a white solid (148 mg, 22%). LCMS [M + H]<sup>+</sup> 500.08 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 8.86 (s, 1H), 8.40 (s, 1H), 8.15 (d, <i>J</i> = 8.3 Hz, 2H), 7.92 (s, 1H), 7.89 (s, 1H), 7.85 (d, <i>J</i> = 7.8 Hz, 1H), 7.67 (d, <i>J</i> = 7.8 Hz, 1H), 7.61 (t, <i>J</i> = 7.8 Hz, 1H), 7.29 (d, <i>J</i> = 8.3 Hz, 2H), 2.39 (s, 3H), 1.36 (s, 12H).</div></div><div id="sec4_3_5_133" class="NLM_sec NLM_sec_level_4"><div id="ac_i157" class="anchor-spacer"></div><h5 class="article-section__title" id="_i157"> 3-(5-(1-(Tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S43a</b>)</h5><div class="NLM_p last">4-Bromo-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazole <b>S41a</b> (44 mg, 0.190 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (14 mg, 0.017 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Crude 3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>S42</b> (84 mg, 0.168 mmol) was dissolved in dioxane (1.0 mL, 0.17 M) and added to the reaction mixture, followed by the addition of 2 M K<sub>2</sub>CO<sub>3</sub> (0.40 mL, 0.800 mmol). The reaction mixture was degassed and run in the microwave (145 °C) for 5 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (20–75% EtOAc/Hex) to afford the title compound as a pale yellow solid (37 mg, 43%). LCMS [M + H]<sup>+</sup> 524.07 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.72 (s, 1H), 8.44 (m, <i>J</i> = 6.3 Hz, 2H), 8.40 (s, 1H), 8.34 (s, 1H), 8.19 (d, <i>J</i> = 8.3 Hz, 1H), 8.03–8.10 (m, 3H), 7.86 (d, <i>J</i> = 7.3 Hz, 1H), 7.71 (t, <i>J</i> = 8.3 Hz, 1H), 7.44 (d, <i>J</i> = 7.8 Hz, 2H), 4.37–4.46 (m, 1H), 3.97 (d, <i>J</i> = 12.7 Hz, 2H), 3.48 (t, <i>J</i> = 10.7 Hz, 2H), 2.35 (s, 3H), 1.88–2.06 (m, 4H).</div></div><div id="sec4_3_5_134" class="NLM_sec NLM_sec_level_4"><div id="ac_i158" class="anchor-spacer"></div><h5 class="article-section__title" id="_i158"> <i>tert</i>-Butyl 4-(4-(3-(3-cyanophenyl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate (<b>S43b</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-(4-bromo-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate <b>S41b</b> (282 mg, 0.854 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (54 mg, 0.066 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Crude 3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>S42</b> (332 mg, 0.665 mmol) was dissolved in dioxane (3.5 mL, 0.17 M) and added to the reaction mixture, followed by the addition of 2 M K<sub>2</sub>CO<sub>3</sub> (1.3 mL, 2.60 mmol). The reaction mixture was degassed and run in the microwave (145 °C) for 25 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (20–40–60% EtOAc/Hex, step gradient) to afford the title compound as a pale yellow solid (180 mg, 43%). LCMS [M + H]<sup>+</sup> 623.07 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.71 (d, <i>J</i> = 1.5 Hz, 1H), 8.44 (s, 1H), 8.43 (d, <i>J</i> = 1.5 Hz, 1H), 8.40 (s, 1H), 8.34 (s, 1H), 8.18 (d, <i>J</i> = 7.8 Hz, 1H), 8.03–8.09 (m, 3H), 7.85 (d, <i>J</i> = 7.8 Hz, 1H), 7.71 (t, <i>J</i> = 8.3 Hz, 1H), 7.43 (d, <i>J</i> = 7.8 Hz, 2H), 4.34–4.42 (m, 1H), 4.02 (br s, 2H), 2.93 (br s, 2H), 2.34 (s, 3H), 2.04 (d, <i>J</i> = 10.7 Hz, 2H), 1.79 (dd, <i>J</i> = 12.2, 3.9 Hz, 2H), 1.42 (s, 9H).</div></div><div id="sec4_3_5_135" class="NLM_sec NLM_sec_level_4"><div id="ac_i159" class="anchor-spacer"></div><h5 class="article-section__title" id="_i159"> 3-(5-(1-(1-Methylpiperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S43c</b>)</h5><div class="NLM_p last">3-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>S42</b> (64 mg, 0.128 mmol), 4-(4-bromo-1<i>H</i>-pyrazol-1-yl)-1-methylpiperidine <b>S41c</b> (40 mg, 0.164 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (11 mg, 0.013 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Dioxane (1.0 mL, 0.17 M) was added to the reaction mixture, followed by the addition of 2 M K<sub>2</sub>CO<sub>3</sub> (0.30 mL, 0.600 mmol). The reaction mixture was degassed and run in the microwave (145 °C) for 5 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The product was purified by flash chromatography (1–10% MeOH/DCM) to afford the title compound as an orange residue (45 mg, 65%). LCMS [M + H]<sup>+</sup> 537.11 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.71 (s, 1H), 8.43 (s, 2H), 8.40 (s, 1H), 8.34 (s, 1H), 8.19 (d, <i>J</i> = 7.3 Hz, 1H), 8.02–8.09 (m, 3H), 7.86 (d, <i>J</i> = 7.8 Hz, 1H), 7.71 (t, <i>J</i> = 7.8 Hz, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 4.05–4.17 (m, 1H), 2.83–2.91 (m, 2H), 2.35 (s, 3H), 2.20 (s, 3H), 1.96–2.07 (m, 6H).</div></div><div id="sec4_3_5_136" class="NLM_sec NLM_sec_level_4"><div id="ac_i160" class="anchor-spacer"></div><h5 class="article-section__title" id="_i160"> 3-(5-(1-(Tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>29a</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 37 mg scale using 3-(5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>S43a</b>. The reaction was run for 6 min, and the crude material was purified by flash chromatography (1–10% MeOH/DCM) to afford the title compound as an off-white solid (13 mg, 49%). LCMS [M + H]<sup>+</sup> 370.10 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.07 (br s, 1H), 8.58 (d, <i>J</i> = 1.5 Hz, 1H), 8.46 (s, 1H), 8.40 (s, 1H), 8.21 (s, 1H), 8.16 (d, <i>J</i> = 7.8 Hz, 1H), 8.06 (d, <i>J</i> = 2.4 Hz, 1H), 8.04 (s, 1H), 7.70 (d, <i>J</i> = 7.8 Hz, 1H), 7.65 (t, <i>J</i> = 7.8 Hz, 1H), 4.43 (tquin, <i>J</i> = 6.3, 6.3, 4.9, 4.9, 4.9, 4.9 Hz, 1H), 3.99 (d, <i>J</i> = 11.7 Hz, 2H), 3.49 (td, <i>J</i> = 10.7, 2.4 Hz, 2H), 1.94–2.08 (m, 4H).</div></div><div id="sec4_3_5_137" class="NLM_sec NLM_sec_level_4"><div id="ac_i161" class="anchor-spacer"></div><h5 class="article-section__title" id="_i161"> <i>tert</i>-Butyl 4-(4-(3-(3-cyanophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate (<b>29b</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 50 mg scale using <i>tert</i>-butyl 4-(4-(3-(3-cyanophenyl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate <b>S43b</b>. The reaction was run for 10 min, and the crude material was purified by flash chromatography (3% 5% NH<sub>4</sub>OH/MeOH:DCM) to afford the title compound as a light yellow solid (21 mg, 55%). LCMS [M + H]<sup>+</sup> 469.10 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.07 (br s, 1H), 8.57 (d, <i>J</i> = 1.5 Hz, 1H), 8.46 (s, 1H), 8.41 (s, 1H), 8.21 (s, 1H), 8.16 (d, <i>J</i> = 7.3 Hz, 1H), 8.06 (d, <i>J</i> = 2.4 Hz, 1H), 8.04 (s, 1H), 7.69 (d, <i>J</i> = 8.3 Hz, 1H), 7.66 (t, <i>J</i> = 7.8 Hz, 1H), 4.34–4.44 (m, 1H), 4.01–4.16 (m, 2H), 2.81–3.06 (m, 2H), 2.05 (d, <i>J</i> = 10.7 Hz, 2H), 1.83 (qd, <i>J</i> = 14.2, 12.2 Hz, 2H), 1.43 (s, 9H).</div></div><div id="sec4_3_5_138" class="NLM_sec NLM_sec_level_4"><div id="ac_i162" class="anchor-spacer"></div><h5 class="article-section__title" id="_i162"> 3-(5-(1-(1-Methylpiperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>29c</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 45 mg scale using 3-(5-(1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>S43c</b>. The reaction was run for 5 min, and the crude material was purified by flash chromatography (5–10% 5% NH<sub>4</sub>OH/MeOH:DCM) to afford the title compound as an off-white solid (19 mg, 59%). LCMS [M + H]<sup>+</sup> 383.12 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.06 (br s, 1H), 8.57 (d, <i>J</i> = 1.5 Hz, 1H), 8.45 (d, <i>J</i> = 1.5 Hz, 1H), 8.38 (s, 1H), 8.21 (s, 1H), 8.16 (d, <i>J</i> = 7.8 Hz, 1H), 8.06 (d, <i>J</i> = 2.4 Hz, 1H), 8.02 (s, 1H), 7.69 (d, <i>J</i> = 7.8 Hz, 1H), 7.65 (t, <i>J</i> = 7.8 Hz, 1H), 4.13 (s, 1H), 2.88 (d, <i>J</i> = 10.7 Hz, 2H), 2.22 (s, 3H), 1.95–2.11 (m, 6H).</div></div><div id="sec4_3_5_139" class="NLM_sec NLM_sec_level_4"><div id="ac_i163" class="anchor-spacer"></div><h5 class="article-section__title" id="_i163"> 5-Bromo-1-(4-(methylsulfonyl)phenyl)-3-(pyridin-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S44</b>)</h5><div class="NLM_p last">Intermediate <b>15</b> (200 mg, 0.419 mmol), pyridin-4-ylboronic acid (52 mg, 0.423 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (36 mg, 0.044 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (2.8 mL, 0.15 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (0.70 mL, 1.40 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (120 °C) for 5 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (20–60% EtOAc/Hex) to afford the title compound as a light yellow solid (116 mg, 65%). LCMS [M + H]<sup>+</sup> 427.85 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 429.86 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.67 (d, <i>J</i> = 2.0 Hz, 1H), 8.65 (d, <i>J</i> = 5.9 Hz, 2H), 8.61 (s, 1H), 8.57 (d, <i>J</i> = 2.0 Hz, 1H), 8.06 (d, <i>J</i> = 8.3 Hz, 2H), 7.86 (d, <i>J</i> = 5.9 Hz, 2H), 7.45 (d, <i>J</i> = 7.8 Hz, 2H), 2.36 (s, 3H).</div></div><div id="sec4_3_5_140" class="NLM_sec NLM_sec_level_4"><div id="ac_i164" class="anchor-spacer"></div><h5 class="article-section__title" id="_i164"> 1-(4-(Methylsulfonyl)phenyl)-3-(pyridin-4-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S45</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure E on a 115 mg scale using 5-bromo-3-(pyridin-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S44</b>. The resulting crude dark brown solid was used in the next reaction without further purification. LCMS [M + H]<sup>+</sup> 476.09 <i>m</i>/<i>z</i>.</div></div><div id="sec4_3_5_141" class="NLM_sec NLM_sec_level_4"><div id="ac_i165" class="anchor-spacer"></div><h5 class="article-section__title" id="_i165"> 1-(4-(Methylsulfonyl)phenyl)-3-(pyridin-4-yl)-5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S46</b>)</h5><div class="NLM_p last">4-Bromo-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazole <b>S41a</b> (50 mg, 0.216 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (23 mg, 0.028 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Crude 3-(pyridin-4-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S45</b> (129 mg, 0.271 mmol) was dissolved in dioxane (1.6 mL, 0.17 M) and added to the reaction mixture, followed by the addition of 2 M K<sub>2</sub>CO<sub>3</sub> (0.60 mL, 1.20 mmol). The reaction mixture was degassed and run in the microwave (145 °C) for 10 min. The reaction mixture was diluted with EtOAc/MeOH, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (1–10% MeOH/EtOAc) to afford the title compound as a dark red residue (31 mg, 23%). LCMS [M + H]<sup>+</sup> 500.02 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.74 (d, <i>J</i> = 2.0 Hz, 1H), 8.67 (d, <i>J</i> = 6.3 Hz, 2H), 8.51 (s, 1H), 8.50 (d, <i>J</i> = 2.0 Hz, 1H), 8.48 (s, 1H), 8.09 (s, 1H), 8.07 (d, <i>J</i> = 8.3 Hz, 2H), 7.90 (d, <i>J</i> = 5.9 Hz, 2H), 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 4.38–4.47 (m, 1H), 3.98 (d, <i>J</i> = 10.2 Hz, 2H), 3.93 (s, 3H), 3.49 (td, <i>J</i> = 11.7, 2.0 Hz, 2H), 1.93–2.07 (m, 4H).</div></div><div id="sec4_3_5_142" class="NLM_sec NLM_sec_level_4"><div id="ac_i166" class="anchor-spacer"></div><h5 class="article-section__title" id="_i166"> 3-(Pyridin-4-yl)-5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>30</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 31 mg scale using 3-(pyridin-4-yl)-5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S46</b>. The reaction was run for 5 min, and the crude material was purified by flash chromatography (5–10% 5% NH<sub>4</sub>OH/MeOH:DCM) to afford the title compound as an orange solid (12 mg, 57%). LCMS [M + H]<sup>+</sup> 346.11 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 12.20 (br s, 1H), 8.60 (d, <i>J</i> = 2.0 Hz, 1H), 8.56 (d, <i>J</i> = 5.9 Hz, 2H), 8.53 (d, <i>J</i> = 2.0 Hz, 1H), 8.44 (s, 1H), 8.21 (s, 1H), 8.06 (s, 1H), 7.83 (d, <i>J</i> = 5.9 Hz, 2H), 4.43 (spt, <i>J</i> = 6.3 Hz, 1H), 3.99 (d, <i>J</i> = 11.2 Hz, 2H), 3.50 (td, <i>J</i> = 10.7, 2.4 Hz, 2H), 1.96–2.08 (m, 4H).</div></div><div id="sec4_3_5_143" class="NLM_sec NLM_sec_level_4"><div id="ac_i167" class="anchor-spacer"></div><h5 class="article-section__title" id="_i167"> <i>tert</i>-Butyl 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>S47</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure E on a 320 mg scale using <i>tert</i>-butyl 5-(5-bromo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate <b>16c</b>. The product was purified by flash chromatography (10–20% EtOAc/Hex) to afford the title compound as an off-white solid (156 mg, 45%). LCMS [M + H]<sup>+</sup> 580.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 1.30 (s, 12H), 1.45 (s, 9H), 2.28–2.32 (m, 2H), 2.33 (s, 3H), 3.49 (t, <i>J</i> = 4.9 Hz, 2H), 4.24 (br s, 2H), 6.37 (br s, 1H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.89–7.93 (m, 1H), 8.02 (d, <i>J</i> = 8.3 Hz, 2H), 8.32–8.36 (m, 1H), 8.57 (s, 1H)</div></div><div id="sec4_3_5_144" class="NLM_sec NLM_sec_level_4"><div id="ac_i168" class="anchor-spacer"></div><h5 class="article-section__title" id="_i168"> tert-Butyl 5-(5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>S48</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate <b>S47</b> (156 mg, 0.269 mmol), 4-bromo-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazole <b>S41a</b> (93 mg, 0.402 mmol), and PdCl2(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (22 mg, 0.027 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Dioxane (1.6 mL, 0.17 M) was added to the reaction mixture, followed by the addition of 2 M K<sub>2</sub>CO<sub>3</sub> (0.4 mL, 0.800 mmol). The reaction mixture was degassed and run in the microwave (145 °C, H abs) for 10 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated. The crude material was purified by flash chromatography (0–70% EtOAc/Hex) to afford the title compound as a dull orange solid (48 mg, 30%). LCMS [M + H]<sup>+</sup> 604.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 1.45 (s, 9H), 1.91–2.07 (m, 4H), 2.30–2.39 (m, 5H), 3.44–3.57 (m, 4H), 3.94–4.00 (m, 2H), 4.25 (br s, 2H), 4.37–4.46 (m, 1H), 6.56 (br s, 1H), 7.42 (d, <i>J</i> = 7.8 Hz, 2H), 7.84 (s, 1H), 8.01 (d, <i>J</i> = 8.3 Hz, 2H), 8.05 (s, 1H), 8.36 (s, 1H), 8.44 (s, 1H), 8.67 (d, <i>J</i> = 2.0 Hz, 1H).</div></div><div id="sec4_3_5_145" class="NLM_sec NLM_sec_level_4"><div id="ac_i169" class="anchor-spacer"></div><h5 class="article-section__title" id="_i169"> <i>tert</i>-Butyl 3-(5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)piperidine-1-carboxylate (<b>S49</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 5-(5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate <b>S48</b> (48 mg, 0.080 mmol) was dissolved in EtOH (1.6 mL, 0.05 M) and 10 wt % Pd/C (8 mg, 0.008 mmol) was added. Ammonium formate (34 mg, 0.539 mmol) was added, and the reaction mixture was refluxed at 85 °C overnight. An additional catalyst (16 mg 5 wt % Pd/C, 0.008 mmol) was added and the reaction was monitored by LCMS. Upon completion, the reaction was stopped and cooled to room temperature. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated to afford the title compound as a yellow solid (46 mg, 95%). LCMS [M + H]<sup>+</sup> 606.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 1.40 (br s, 9H), 1.57–1.79 (m, 2H), 1.88–2.09 (m, 6H), 2.33 (s, 3H), 2.88–3.08 (m, 2H), 3.10–3.22 (m, 1H), 3.48 (t, <i>J</i> = 11.0 Hz, 2H), 3.76–3.88 (m, 1H), 3.97 (m, <i>J</i> = 7.3 Hz, 3H), 4.35–4.46 (m, 1H), 7.41 (d, <i>J</i> = 7.8 Hz, 2H), 7.67 (s, 1H), 7.96 (d, <i>J</i> = 7.8 Hz, 2H), 8.00 (s, 1H), 8.21–8.26 (m, 1H), 8.38 (s, 1H), 8.63 (s, 1H).</div></div><div id="sec4_3_5_146" class="NLM_sec NLM_sec_level_4"><div id="ac_i170" class="anchor-spacer"></div><h5 class="article-section__title" id="_i170"> <i>tert</i>-Butyl 3-(5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)piperidine-1-carboxylate (<b>S50</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 46 mg scale using <i>tert</i>-butyl 3-(5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)piperidine-1-carboxylate <b>S49</b>. The reaction was run for 2 mins and the crude material was purified by flash chromatography (2–5% MeOH/DCM) to afford the title compound as a pale yellow solid (17 mg, 51%). LCMS [M + H]<sup>+</sup> 452.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 1.50 (s, 9H), 1.72 (m, <i>J</i> = 10.7 Hz, 4H), 2.06–2.26 (m, 6H), 2.88 (t, <i>J</i> = 12.0 Hz, 2H), 2.96–3.09 (m, 1H), 3.59 (td, <i>J</i> = 11.5, 2.9 Hz, 2H), 4.16 (d, <i>J</i> = 11.7 Hz, 2H), 4.42 (spt, <i>J</i> = 5.4 Hz, 1H), 7.13 (d, <i>J</i> = 1.5 Hz, 1H), 7.74 (s, 1H), 7.83 (s, 1H), 8.02 (br s, 1H), 8.46 (br s, 1H), 8.81 (br s, 1H).</div></div><div id="sec4_3_5_147" class="NLM_sec NLM_sec_level_4"><div id="ac_i171" class="anchor-spacer"></div><h5 class="article-section__title" id="_i171"> 3-(Piperidin-3-yl)-5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>31</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 3-(5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)piperidine-1-carboxylate <b>S50</b> (17 mg, 0.028 mmol) was dissolved in dioxane (0.300 mL, 0.10 M), and 4 M HCl in dioxane (0.05 mL, 0.200 mmol) was added. The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated under reduced pressure and the resulting light yellow residue was dissolved in MeOH. Si-carbonate was added and the reaction mixture was stirred at room temperature overnight. The Si-carbonate was filtered off and the filtrate was purified by flash chromatography (10–25% 5% NH<sub>4</sub>OH/MeOH:DCM, stepwise gradient) to afford the title compound as a white solid (9 mg, 72%). LCMS [M + H]<sup>+</sup> 352.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 1.77 (qd, <i>J</i> = 7.8, 3.9 Hz, 1H), 1.82–1.94 (m, 2H), 1.94–2.10 (m, 5H), 2.95 (td, <i>J</i> = 12.1, 3.7 Hz, 1H), 3.03 (t, <i>J</i> = 12.2 Hz, 1H), 3.23–3.32 (m, 3H), 3.42–3.54 (m, 3H), 3.98 (d, <i>J</i> = 11.2 Hz, 2H), 4.42 (spt, <i>J</i> = 4.9 Hz, 1H), 7.33 (s, 1H), 7.95 (s, 1H), 8.19 (s, 1H), 8.31 (s, 1H), 8.49 (d, <i>J</i> = 1.5 Hz, 1H), 11.51 (br s, 1H).</div></div><div id="sec4_3_5_148" class="NLM_sec NLM_sec_level_4"><div id="ac_i172" class="anchor-spacer"></div><h5 class="article-section__title" id="_i172"> 5-Bromo-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine (<b>S52a</b>)</h5><div class="NLM_p last">5-Bromo-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine <b>S51a</b> (300 mg, 1.51 mmol) was suspended in DCE (6.6 mL, 0.23 M) and NIS (511 mg, 2.27 mmol) was added. The reaction mixture was refluxed at 80 °C overnight. An off-white precipitate was observed and collected by vacuum filtration (washed with DCE) to afford the title compound as an ivory solid (465 mg, 95%). LCMS [M + H]<sup>+</sup> 323.7 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 325.8 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.21 (d, <i>J</i> = 1.1 Hz, 1H), 8.65 (d, <i>J</i> = 2.2 Hz, 1H), 14.31 (s, 1H).</div></div><div id="sec4_3_5_149" class="NLM_sec NLM_sec_level_4"><div id="ac_i173" class="anchor-spacer"></div><h5 class="article-section__title" id="_i173"> 5-Bromo-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine (<b>S53a</b>)</h5><div class="NLM_p last">5-Bromo-3-iodo-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine <b>S52a</b> (465 mg, 1.44 mmol) was dissolved in DMF (3.7 mL, 0.039 M), and the reaction mixture was cooled to 0 °C. NaH (178 mg, 4.45 mmol) was added, and the reaction mixture was stirred at 0 °C. After stirring for a few minutes, the reaction mixture changed from a cloudy off-white suspension to a bright orange solution. After 30 min, 2-(trimethylsilyl)ethoxymethyl chloride (0.300 mL, 1.70 mmol) was added and the reaction turned bright yellow. The reaction mixture was left stirring at 0 °C for another 2 h. The reaction was quenched with water and extracted three times with EtOAc. The combined organic layers were washed once with brine, dried with sodium sulfate, and concentrated. The crude material was dried under high vacuum overnight to afford the title compound as a beige solid (564 mg, 87%). LCMS [M + H]<sup>+</sup> 453.8 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 455.8 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm −0.13 to −0.10 (m, 9H), 0.80 (t, <i>J</i> = 7.8 Hz, 2H), 3.58 (t, <i>J</i> = 8.1 Hz, 2H), 5.74 (s, 2H), 8.28 (d, <i>J</i> = 2.4 Hz, 1H), 8.74 (d, <i>J</i> = 2.4 Hz, 1H).</div></div><div id="sec4_3_5_150" class="NLM_sec NLM_sec_level_4"><div id="ac_i174" class="anchor-spacer"></div><h5 class="article-section__title" id="_i174"> 3-(5-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S54a</b>)</h5><div class="NLM_p last">5-Bromo-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine <b>S53a</b> (564 mg, 1.24 mmol), (3-cyanophenyl)boronic acid (184 mg, 1.25 mmol), and PdCl2(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (101 mg, 0.124 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (7.0 mL, 0.18 M) was added, followed by the addition of 2 M K<sub>2</sub>CO<sub>3</sub> (1.5 mL, 3.00 mmol). The reaction mixture was degassed for ∼10 min and the reaction was run in the microwave (80 °C, 15 min). The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated. The crude material was purified by flash chromatography (0–20% EtOAc/Hex) to afford the title compound as a light yellow solid (259 mg, 49%). LCMS [M + H]<sup>+</sup> 428.98 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 431.0 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm −0.11 (s, 9H), 0.84 (t, <i>J</i> = 7.8 Hz, 2H), 3.66 (t, <i>J</i> = 8.1 Hz, 2H), 5.85 (s, 2H), 7.75 (t, <i>J</i> = 7.8 Hz, 1H), 7.94 (d, <i>J</i> = 7.8 Hz, 1H), 8.39 (d, <i>J</i> = 8.3 Hz, 1H), 8.48 (s, 1H), 8.77 (d, <i>J</i> = 2.0 Hz, 1H), 9.11 (d, <i>J</i> = 2.0 Hz, 1H).</div></div><div id="sec4_3_5_151" class="NLM_sec NLM_sec_level_4"><div id="ac_i175" class="anchor-spacer"></div><h5 class="article-section__title" id="_i175"> 3-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S55a</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure E on a 140 mg scale using 3-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)benzonitrile <b>S54a</b>. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated under reduced pressure. The crude material was purified by flash chromatography (10% EtOAc/Hex) to afford the title compound as a light yellow oil (96 mg, 61%). LCMS [M + H]<sup>+</sup> 477.0 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm −0.05 (s, 9H), 0.97 (t, <i>J</i> = 8.3 Hz, 2H), 1.41 (s, 12H), 3.71 (t, <i>J</i> = 8.3 Hz, 2H), 5.95 (s, 2H), 7.66 (t, <i>J</i> = 7.8 Hz), 7.72 (d, <i>J</i> = 7.8 Hz, 1H), 8.29 (d, <i>J</i> = 7.8 Hz, 1H), 8.34 (s, 1H), 8.73 (s, 1H), 8.97 (s, 1H).</div></div><div id="sec4_3_5_152" class="NLM_sec NLM_sec_level_4"><div id="ac_i176" class="anchor-spacer"></div><h5 class="article-section__title" id="_i176"> 3-(5-(1-(Tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S56a</b>)</h5><div class="NLM_p last">3-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)benzonitrile <b>S55a</b> (96 mg, 0.201 mmol), 4-bromo-1-(tetrahydro-2H-pyran-4-yl)-1<i>H</i>-pyrazole <b>S41a</b> (58 mg, 0.251 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (19 mg, 0.023 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. Dioxane (2.0 mL, 0.10 M) was added to the reaction mixture, followed by the addition of 2 M K<sub>2</sub>CO<sub>3</sub> (0.3 mL, 0.600 mmol). The reaction mixture was degassed and run in the microwave (145 °C, H abs) for 10 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated. The crude material was purified by flash chromatography (20–60% EtOAc/Hex) to afford the title compound as an orange oil (37 mg, 36%). LCMS [M + H]<sup>+</sup> 501.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm −0.04 (s, 9H), 0.98 (t, <i>J</i> = 8.3 Hz, 2H), 2.16–2.25 (m, 4H), 3.60 (td, <i>J</i> = 8.3, 3.9 Hz, 2H), 3.74 (t, <i>J</i> = 8.8 Hz, 2H), 4.17 (d, <i>J</i> = 11.2 Hz, 2H), 4.39–4.50 (m, 1H), 5.95 (s, 2H), 7.66 (t, <i>J</i> = 7.8 Hz, 1H), 7.73 (d, <i>J</i> = 7.8 Hz, 1H), 7.82 (s, 1H), 7.89 (s, 1H), 8.27 (d, <i>J</i> = 7.8 Hz, 1H), 8.30 (s, 1H), 8.30 (s, 1H), 8.79 (d, <i>J</i> = 2.0 Hz, 1H).</div></div><div id="sec4_3_5_153" class="NLM_sec NLM_sec_level_4"><div id="ac_i177" class="anchor-spacer"></div><h5 class="article-section__title" id="_i177"> 3-(5-(1-(Tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)benzonitrile (<b>32</b>)</h5><div class="NLM_p last">To 3-(5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl)benzonitrile <b>S56a</b> (37 mg, 0.074 mmol) was added 4 M HCl in dioxane (0.600 mL, 2.40 mmol). The reaction mixture was stirred at room temperature for 3 days, then at 50 °C overnight. The reaction was stopped and cooled to room temperature. The solvent was evaporated and the resulting yellow residue was redissolved in MeOH. Si-carbonate was added and the mixture was stirred overnight at room temperature. The Si-carbonate was filtered off and the filtrate was purified by flash chromatography (2–5% MeOH/DCM) to afford the title compound as a white solid (10 mg, 38%). LCMS [M + H]<sup>+</sup> 371.06 <i>m</i>/<i>z</i> 64; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 14.02 (br s, 1H), 8.91 (d, <i>J</i> = 1.6 Hz, 1H), 8.75 (d, <i>J</i> = 1.6 Hz, 1H), 8.50 (s, 1H), 8.46 (s, 1H), 8.44 (d, <i>J</i> = 8.2 Hz), 8.15 (s, 1H), 7.90 (d, <i>J</i> = 7.7 Hz, 1H), 7.76 (t, <i>J</i> = 7.7 Hz, 1H), 4.45 (tquin, <i>J</i> = 6.6, 6.6, 4.9, 4.9, 4.9, 4.9 Hz, 1H), 4.00 (d, <i>J</i> = 13.7 Hz, 2H), 3.51 (td, <i>J</i> = 11.7, 1.9 Hz, 2H), 1.94–2.09 (m, 4H).</div></div><div id="sec4_3_5_154" class="NLM_sec NLM_sec_level_4"><div id="ac_i178" class="anchor-spacer"></div><h5 class="article-section__title" id="_i178"> 5-Bromo-3-iodo-4-methyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S52b</b>)</h5><div class="NLM_p last">5-Bromo-4-methyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S51b</b> (412 mg, 1.95 mmol) was dissolved in acetonitrile (12 mL, 0.17 M) and <i>N</i>-iodosuccinimide (690 mg, 3.07 mmol) was added. The reaction mixture was stirred at 50 °C for 2 h. The reaction was stopped and cooled to room temperature. Upon cooling, a tan precipitate was observed and collected by vacuum filtration (washed with hexanes) to afford the title compound as a dull orange solid (495 mg, 75%). LCMS [M + H]<sup>+</sup> 336.85 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 338.86 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 9.09 (br s, 1H), 8.38 (s, 1H), 7.41 (d, <i>J</i> = 2.0 Hz, 1H), 2.95 (s, 3H).</div></div><div id="sec4_3_5_155" class="NLM_sec NLM_sec_level_4"><div id="ac_i179" class="anchor-spacer"></div><h5 class="article-section__title" id="_i179"> 5-Bromo-3-iodo-4-methyl-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>S53b</b>)</h5><div class="NLM_p last">5-Bromo-3-iodo-4-methyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>52b</b> (495 mg,1.47 mmol) was suspended in DCM (7.4 mL, 0.19 M), and TEA (0.60 mL, 4.30 mmol), DMAP (215 mg, 1.76 mmol), and 4-methylbenzenesulfonyl chloride (700 mg, 3.67 mmol) were added in that order. The reaction mixture was stirred overnight at room temperature. The reaction mixture was washed once with 1 M HCl, once with sat. aq. NaHCO<sub>3</sub>, and once with brine. The organic layer was dried with sodium sulfate and concentrated under reduced pressure. The product was purified by flash chromatography (0–20% EtOAc/Hex) to afford the title compound as a light orange solid (573 mg, 79%). LCMS [M + H]<sup>+</sup> 490.85 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 492.86 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, CHLOROFORM-d): δ ppm 8.47 (s, 1H), 8.05 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 (s, 1H), 7.30 (d, <i>J</i> = 7.8 Hz, 2H), 2.86 (s, 3H), 2.39 (s, 3H).</div></div><div id="sec4_3_5_156" class="NLM_sec NLM_sec_level_4"><div id="ac_i180" class="anchor-spacer"></div><h5 class="article-section__title" id="_i180"> 3-(5-Bromo-4-methyl-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S54b</b>)</h5><div class="NLM_p last">5-Bromo-3-iodo-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>S53b</b> (573 mg, 1.20 mmol), (3-cyanophenyl)boronic acid (206 mg, 1.40 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (95 mg, 0116 mmol) were combined in a microwave vial that was purged with nitrogen and evacuated three times. Dioxane (6.0 mL, 0.20 M) and 2 M K<sub>2</sub>CO<sub>3</sub> (1.8 mL, 3.60 mmol) were added, and the reaction mixture was degassed for ∼10 min. The reaction was run in the microwave (120 °C) for 5 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated. The product was purified by flash chromatography (0–50% EtOAc/Hex) to afford the title compound as a dull yellow solid (335 mg, 62%). LCMS [M + H]<sup>+</sup> 465.96 <i>m</i>/<i>z</i> (<sup>79</sup>Br), 467.96 <i>m</i>/<i>z</i> (<sup>81</sup>Br); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>): δ ppm 8.52 (s, 1H), 8.12 (d, <i>J</i> = 8.3 Hz, 2H), 7.72 (d, <i>J</i> = 7.8 Hz, 1H), 7.68 (s, 2H), 7.63 (d, <i>J</i> = 7.8 Hz, 1H), 7.57 (t, <i>J</i> = 8.3 Hz, 1H), 7.33 (d, <i>J</i> = 8.3 Hz, 2H), 2.41 (s, 3H), 2.23 (s, 3H).</div></div><div id="sec4_3_5_157" class="NLM_sec NLM_sec_level_4"><div id="ac_i181" class="anchor-spacer"></div><h5 class="article-section__title" id="_i181"> 3-(4-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S55b</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure E on a 335 mg scale using 3-(5-bromo-4-methyl-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>54b</b>. The crude material was purified by flash chromatography (20% EtOAc/Hex) to afford the title compound as a white solid (175 mg, 47%). LCMS [M + H]<sup>+</sup> 514.12 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, chloroform-d): δ ppm 8.76 (s, 1H), 8.14 (d, <i>J</i> = 8.3 Hz, 2H), 7.69 (m, <i>J</i> = 3.9, 2.0 Hz, 2H), 7.61–7.66 (m, 2H), 7.53 (t, <i>J</i> = 7.8 Hz, 1H), 7.29 (d, <i>J</i> = 8.3 Hz, 2H), 2.39 (s, 3H), 2.37 (s, 3H), 1.33 (s, 12H).</div></div><div id="sec4_3_5_158" class="NLM_sec NLM_sec_level_4"><div id="ac_i182" class="anchor-spacer"></div><h5 class="article-section__title" id="_i182"> 3-(4-Methyl-5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>S56b</b>)</h5><div class="NLM_p last">4-Bromo-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazole <b>S41a</b> (87 mg, 0.376 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (28 mg, 0.034 mmol) were combined in a reaction vial that was filled with nitrogen and evacuated three times. 3-(4-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>S55b</b> (175 mg, 0.341 mmol) was dissolved in dioxane (2.0 mL, 0.17 M) and added to the reaction mixture, followed by the addition of 2 M K<sub>2</sub>CO<sub>3</sub> (0.70 mL, 01.40 mmol). The reaction mixture was degassed and run in the microwave (145 °C) for 5 min. The reaction mixture was diluted with EtOAc, filtered through Celite, and concentrated. The crude material was purified by flash chromatography (50–70% EtOAc/Hex, step gradient) to afford the title compound as a tan solid (69 mg, 38%). LCMS [M + H]<sup>+</sup> 538.05 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 8.38 (s, 1H), 8.03–8.11 (m, 4H), 7.98 (s, 1H), 7.89 (d, <i>J</i> = 7.3 Hz, 2H), 7.70 (s, 1H), 7.68 (t, <i>J</i> = 7.8 Hz, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 4.43 (spt, <i>J</i> = 5.9 Hz, 1H), 3.96 (d, J = 10.2 Hz, 2H), 3.43–3.51 (m, 2H), 2.36 (s, 3H), 2.19 (s, 3H), 1.91–2.04 (m, 4H).</div></div><div id="sec4_3_5_159" class="NLM_sec NLM_sec_level_4"><div id="ac_i183" class="anchor-spacer"></div><h5 class="article-section__title" id="_i183"> 3-(4-Methyl-5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile (<b>33</b>)</h5><div class="NLM_p last">The title compound was prepared according to General Procedure D on a 69 mg scale using 3-(4-methyl-5-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)-1-tosyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)benzonitrile <b>S56b</b>. The reaction was run for 5 min and the crude material was purified directly by flash chromatography (5% MeOH/DCM) to afford the title compound as an off-white solid (29 mg, 60%). LCMS [M + H]<sup>+</sup> 384.14 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 11.94 (br s, 1H), 8.24 (s, 1H), 8.04 (s, 1H), 7.92 (s, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.78 (d, <i>J</i> = 7.8 Hz), 7.68 (s, 1H), 7.62 (t, <i>J</i> = 7.8 Hz, 1H), 7.58 (s, 1H), 4.44 (spt, <i>J</i> = 6.3 Hz, 1H), 3.98 (d, <i>J</i> = 11.7 Hz, 2H), 3.48 (t, <i>J</i> = 11.0 Hz, 2H), 2.31 (s, 3H), 1.95–2.07 (m, 4H).</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i184"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00674" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63103" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63103" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00674?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00674</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional biological and ADME data, experimental procedures, and characterization (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf">jm1c00674_si_001.pdf (477.52 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_002.csv">jm1c00674_si_002.csv (4.17 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00674" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55356" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55356" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lori Ferrins</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry & Chemical Biology, Northeastern
University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-8992-0919" title="Orcid link">https://orcid.org/0000-0001-8992-0919</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#acc082cac9dedec5c2dfecc2c3ded8c4c9cddfd8c9dec282c9c8d9"><span class="__cf_email__" data-cfemail="a8c486cecddadac1c6dbe8c6c7dadcc0cdc9dbdccddac686cdccdd">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dana M. Klug</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry & Chemical Biology, Northeastern
University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8982-0640" title="Orcid link">https://orcid.org/0000-0002-8982-0640</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eftychia M. Mavrogiannaki</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry & Chemical Biology, Northeastern
University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine C. Forbes</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry & Chemical Biology, Northeastern
University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisseth Silva</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry & Chemical Biology, Northeastern
University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rosario Diaz-Gonzalez</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”
Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guiomar Pérez-Moreno</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”
Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gloria Ceballos-Pérez</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”
Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raquel Garcia-Hernández</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”
Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cristina Bosch-Navarrete</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”
Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlos Cordón-Obras</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”
Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudia Gómez-Liñán</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”
Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreu Saura</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”
Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeremiah D. Momper</span> - <span class="hlFld-Affiliation affiliation">Center
for Discovery and Innovation in Parasitic Diseases, Skaggs School
of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, La Jolla, San Diego, California 92093, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Santos Martinez-Martinez</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos 28760, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pilar Manzano</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos 28760, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ali Syed</span> - <span class="hlFld-Affiliation affiliation">Center
for Discovery and Innovation in Parasitic Diseases, Skaggs School
of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, La Jolla, San Diego, California 92093, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nelly El-Sakkary</span> - <span class="hlFld-Affiliation affiliation">Center
for Discovery and Innovation in Parasitic Diseases, Skaggs School
of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, La Jolla, San Diego, California 92093, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Conor R. Caffrey</span> - <span class="hlFld-Affiliation affiliation">Center
for Discovery and Innovation in Parasitic Diseases, Skaggs School
of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, La Jolla, San Diego, California 92093, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francisco Gamarro</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”
Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luis Miguel Ruiz-Perez</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”
Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dolores Gonzalez Pacanowska</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”
Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4303-5209" title="Orcid link">https://orcid.org/0000-0002-4303-5209</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Miguel Navarro</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Parasitología y Biomedicina “López-Neyra”
Consejo Superior de Investigaciones Científicas (CSIC), Granada 18016, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael P. Pollastri</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry & Chemical Biology, Northeastern
University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9943-7197" title="Orcid link">https://orcid.org/0000-0001-9943-7197</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e11408-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i185">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74375" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74375" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors acknowledge funding from the National Institute of Allergy and Infectious Diseases (M.P.P. and M.N., R01AI114685; M.P.P., 1R21AI127594, R01AI124046; C.R.C., R21AI126296; <a href="https://www.niaid.nih.gov/" class="extLink">https://www.niaid.nih.gov/</a>), the Spanish Ministerio de Economí a, Industria y Competitividad (M.N., SAF2015-71444-P; D.G.-P., SAF2016-79957-R; <a href="http://www.mineco.gob.es" class="extLink">http://www.mineco.gob.es</a>), Subdireccion General de Redes ́ y Centros de Investigacion Cooperativa (RICET, <a href="https://www.ricet.es/" class="extLink">https://www.ricet.es/</a>) (M.N., RD16/0027/0019; D.G.P., RD16/ 0027/0014), and RTI2018-097210-B-I00 (MINCIU-FEDER) to F.G. An ACS MEDI Predoctoral Fellowship for D.M.K. is gratefully acknowledged, as is support from the National Science Foundation for K.F. (CHE-1262734). We thank AstraZeneca, Charles River Laboratories, and GlaxoSmithKline for the provision of the <i>in vitro</i> ADME and physicochemical properties data. The use of JChem/ChemAxon software is acknowledged.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption distribution metabolism excretion</p></td></tr><tr><td class="NLM_term">Clint</td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">Cmax</td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">CNS-MPO</td><td class="NLM_def"><p class="first last">central nervous system-multiparameter optimization</p></td></tr><tr><td class="NLM_term">GSK</td><td class="NLM_def"><p class="first last">GlaxoSmithKline</p></td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">human African trypanosomiasis</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screen</p></td></tr><tr><td class="NLM_term">ip</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">NECT</td><td class="NLM_def"><p class="first last">nifurtimox–eflornithine combination therapy</p></td></tr><tr><td class="NLM_term">NTD</td><td class="NLM_def"><p class="first last">neglected tropical disease</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term"><i>T.b.b.</i></td><td class="NLM_def"><p class="first last"><i>Trypanosoma brucei brucei</i></p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time at which maximum concentration is achieved</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i187">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14262" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14262" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 23 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">World Health Organization</span>. <span> </span><span class="NLM_article-title">Neglected Tropical
Diseases</span>. <a href="http://www.who.int/neglected_diseases/diseases/en/" class="extLink">http://www.who.int/neglected_diseases/diseases/en/</a> (accessed Sept 13, <span class="NLM_year">2016</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=World+Health+Organization&title=Neglected+Tropical%0ADiseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DNeglected%2520Tropical%250ADiseases%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Büscher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamonneau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priotto, G.</span></span> <span> </span><span class="NLM_article-title">Human African Trypanosomiasis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">2397</span>– <span class="NLM_lpage">2409</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)31510-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1016%2FS0140-6736%2817%2931510-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=28673422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A280%3ADC%252BC1cjktFCrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=2397-2409&author=P.+B%C3%BCscherauthor=G.+Cecchiauthor=V.+Jamonneauauthor=G.+Priotto&title=Human+African+Trypanosomiasis&doi=10.1016%2FS0140-6736%2817%2931510-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Human African trypanosomiasis</span></div><div class="casAuthors">Buscher Philippe; Cecchi Giuliano; Jamonneau Vincent; Priotto Gerardo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">10110</span>),
    <span class="NLM_cas:pages">2397-2409</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human African trypanosomiasis (sleeping sickness) is a parasitic infection that almost invariably progresses to death unless treated.  Human African trypanosomiasis caused devastating epidemics during the 20th century.  Thanks to sustained and coordinated efforts over the past 15 years, the number of reported cases has fallen to an historically low level.  Fewer than 3000 cases were reported in 2015, and the disease is targeted for elimination by WHO.  Despite these recent successes, the disease is still endemic in parts of sub-Saharan Africa, where it is a considerable burden on rural communities, most notably in central Africa.  Since patients are also reported from non-endemic countries, human African trypanosomiasis should be considered in differential diagnosis for travellers, tourists, migrants, and expatriates who have visited or lived in endemic areas.  In the absence of a vaccine, disease control relies on case detection and treatment, and vector control.  Available drugs are suboptimal, but ongoing clinical trials provide hope for safer and simpler treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBg2yQ4XqfsRgd2Wuil24tfW6udTcc2ebOoLTSxfXFl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjktFCrsw%253D%253D&md5=521e7f5c04b32c04763c6b7a65af6439</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2931510-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252931510-6%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25BCscher%26aufirst%3DP.%26aulast%3DCecchi%26aufirst%3DG.%26aulast%3DJamonneau%26aufirst%3DV.%26aulast%3DPriotto%26aufirst%3DG.%26atitle%3DHuman%2520African%2520Trypanosomiasis%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26spage%3D2397%26epage%3D2409%26doi%3D10.1016%2FS0140-6736%2817%2931510-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehlhorn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, J.</span></span> <span> </span><span class="NLM_article-title">Light and electron microscopic studies on the effect of praziquantel on <i>Schistosoma mansoni</i>, <i>Dicrocoelium dendriticum</i>, and <i>Fasciola hepatica</i> (Trematoda) in vitro</span>. <i>Z Parasitenkd.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1007/BF00927527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1007%2FBF00927527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=7456640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADyaL3MXhsl0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1980&pages=113-128&author=B.+Beckerauthor=H.+Mehlhornauthor=P.+Andrewsauthor=H.+Thomasauthor=J.+Eckert&title=Light+and+electron+microscopic+studies+on+the+effect+of+praziquantel+on+Schistosoma+mansoni%2C+Dicrocoelium+dendriticum%2C+and+Fasciola+hepatica+%28Trematoda%29+in+vitro&doi=10.1007%2FBF00927527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro</span></div><div class="casAuthors">Becker, B.; Mehlhorn, H.; Andrews, P.; Thomas, H.; Eckert, J.</div><div class="citationInfo"><span class="NLM_cas:title">Zeitschrift fuer Parasitenkunde</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-28</span>CODEN:
                <span class="NLM_cas:coden">ZEPAA6</span>;
        ISSN:<span class="NLM_cas:issn">0044-3255</span>.
    </div><div class="casAbstract">The fine structure of the tegument of 3 trematode species, S. mansoni, D. dendriticum, and F. hepatica, was studied by means of light scanning (SEM) and transmission electron microscopy (TEM) after in vitro exposure to 0, 1, 10, or 100 μg/mL concns. of the anthelmintic praziquantel  [55268-74-1] for 5, 15, 30, or 60 min.  In S. mansoni and D. dendriticum, the resulting vacuolization of the tegument was confined to numerous small areas scattered all over the surface of the parasites; this finally led to the disruption of the apical tegumental layer.  No changes were found in the tegument of F. hepatica after treatment with praziquantel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxyZgjkvqASrVg90H21EOLACvtfcHk0lgcR_fzraUypg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhsl0%253D&md5=994322f5fc28adf1b2d8003c45a597fd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2FBF00927527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00927527%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DB.%26aulast%3DMehlhorn%26aufirst%3DH.%26aulast%3DAndrews%26aufirst%3DP.%26aulast%3DThomas%26aufirst%3DH.%26aulast%3DEckert%26aufirst%3DJ.%26atitle%3DLight%2520and%2520electron%2520microscopic%2520studies%2520on%2520the%2520effect%2520of%2520praziquantel%2520on%2520Schistosoma%2520mansoni%252C%2520Dicrocoelium%2520dendriticum%252C%2520and%2520Fasciola%2520hepatica%2520%2528Trematoda%2529%2520in%2520vitro%26jtitle%3DZ%2520Parasitenkd.%26date%3D1980%26volume%3D63%26spage%3D113%26epage%3D128%26doi%3D10.1007%2FBF00927527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fetterer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pax, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J. L.</span></span> <span> </span><span class="NLM_article-title">Praziquantel, potassium and 2,4-dinitrophenol: analysis of their action on the musculature of <i>Schistosoma mansoni</i></span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(80)90366-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1016%2F0014-2999%2880%2990366-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=7449814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADyaL3cXkvV2gtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1980&pages=31-38&author=R.+H.+Fettererauthor=R.+A.+Paxauthor=J.+L.+Bennett&title=Praziquantel%2C+potassium+and+2%2C4-dinitrophenol%3A+analysis+of+their+action+on+the+musculature+of+Schistosoma+mansoni&doi=10.1016%2F0014-2999%2880%2990366-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Praziquantel, potassium and 2,4-dinitrophenol:  analysis of their action on the musculature of Schistosoma mansoni</span></div><div class="casAuthors">Fetterer, Raymond H.; Pax, Ralph A.; Bennett, James L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-8</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">The antischistosomal drug praziquantel (PZ)  [55268-74-1] (10-6 M), 60 mM K+, and 2,4-dinitrophenol (DNP)  [51-28-5] induce a rapid contracture of the musculature in adult male S. mansoni.  This event is accompanied, except for DNP, by an increased accumulation of 45Ca2+ in the parasite.  K+-induced contractures had phasic and tonic components, whereas DNP and PZ produced only tonic contracture of the parasite musculature.  The Ca2+ antagonist D-600  [16662-47-8] (10-4 M), as well as La3+ (10 mM) and Co2+ (10 mM), prevented the 45Ca2+ accumulation produced by high K+.  La3+ and Co2+ blocked the tension-increasing effects of high K+; D-600 blocked only the tonic contractures.  D-600 and Co2+ did not prevent the 45Ca2+ increase produced by PZ, but La3+ did.  D-600 did not block the PZ response, but Co2+ and La3+ partially attenuated it.  La3+ also partially attenuated the DNP response.  Co2+ and D-600 prevented sustained contractures in response to DNP.  Thus, although K+, PZ, and DNP have the same final effect on the musculature of S. mansoni, it appears that their effects are not mediated by the same mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrciPgUKYe2JLVg90H21EOLACvtfcHk0lgcR_fzraUypg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXkvV2gtbY%253D&md5=30eebdc9e0eeda34a00ed90504a2fb74</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2880%2990366-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252880%252990366-0%26sid%3Dliteratum%253Aachs%26aulast%3DFetterer%26aufirst%3DR.%2BH.%26aulast%3DPax%26aufirst%3DR.%2BA.%26aulast%3DBennett%26aufirst%3DJ.%2BL.%26atitle%3DPraziquantel%252C%2520potassium%2520and%25202%252C4-dinitrophenol%253A%2520analysis%2520of%2520their%2520action%2520on%2520the%2520musculature%2520of%2520Schistosoma%2520mansoni%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1980%26volume%3D64%26spage%3D31%26epage%3D38%26doi%3D10.1016%2F0014-2999%2880%2990366-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renganathan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cioli, D.</span></span> <span> </span><span class="NLM_article-title">An international initiative on praziquantel use</span>. <i>Parasitol. Today</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1016/S0169-4758(98)01310-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1016%2FS0169-4758%2898%2901310-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=17040826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A280%3ADC%252BD28ngvV2ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1998&pages=390-391&author=E.+Renganathanauthor=D.+Cioli&title=An+international+initiative+on+praziquantel+use&doi=10.1016%2FS0169-4758%2898%2901310-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">An international initiative on praziquantel use</span></div><div class="casAuthors">Renganathan E; Cioli D</div><div class="citationInfo"><span class="NLM_cas:title">Parasitology today (Personal ed.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">390-1</span>
        ISSN:<span class="NLM_cas:issn">0169-4758</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCGDiedPKcpe2mnZh2OgS0fW6udTcc2eaUudtk3IvcUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28ngvV2ltA%253D%253D&md5=0e2b79ee5a5db8204370813aa207d85b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0169-4758%2898%2901310-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-4758%252898%252901310-6%26sid%3Dliteratum%253Aachs%26aulast%3DRenganathan%26aufirst%3DE.%26aulast%3DCioli%26aufirst%3DD.%26atitle%3DAn%2520international%2520initiative%2520on%2520praziquantel%2520use%26jtitle%3DParasitol.%2520Today%26date%3D1998%26volume%3D14%26spage%3D390%26epage%3D391%26doi%3D10.1016%2FS0169-4758%2898%2901310-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span> </span><span class="NLM_article-title">Drugs for Neglected Diseases Initiative.
Acoziborole</span>. <a href="https://dndi.org/research-development/portfolio/acoziborole/" class="extLink">https://dndi.org/research-development/portfolio/acoziborole/</a> (accessed April 10, <span class="NLM_year">2021</span>)</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drugs+for+Neglected+Diseases+Initiative.%0AAcoziborole.+https%3A%2F%2Fdndi.org%2Fresearch-development%2Fportfolio%2Facoziborole%2F+%28accessed+April+10%2C+2021%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DDrugs%2520for%2520Neglected%2520Diseases%2520Initiative.%250AAcoziborole%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klug, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Repurposing Strategies for Neglected Diseases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2569</span>– <span class="NLM_lpage">2575</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1016%2Fj.bmcl.2016.03.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=27080183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVGqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2569-2575&author=D.+M.+Klugauthor=M.+H.+Gelbauthor=M.+P.+Pollastri&title=Repurposing+Strategies+for+Neglected+Diseases&doi=10.1016%2Fj.bmcl.2016.03.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing strategies for tropical disease drug discovery</span></div><div class="casAuthors">Klug, Dana M.; Gelb, Michael H.; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2569-2576</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neglected tropical diseases (NTDs) and other diseases of the developing world, such as malaria, attract research investments that are disproportionately low compared to their impact on human health worldwide.  Therefore, pragmatic methods for launching new drug discovery programs have emerged that repurpose existing chem. matter as new drugs or new starting points for optimization.  In this Digest we describe applications of different repurposing approaches for NTDs, and provide a means by which these approaches may be differentiated from each other.  These include drug repurposing, target repurposing, target class repurposing, and lead repurposing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7WuWi-qOAgbVg90H21EOLACvtfcHk0liOsSZxCOYTMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVGqt7c%253D&md5=e47072a70623e0e3f771880e31578b26</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.103%26sid%3Dliteratum%253Aachs%26aulast%3DKlug%26aufirst%3DD.%2BM.%26aulast%3DGelb%26aufirst%3DM.%2BH.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DRepurposing%2520Strategies%2520for%2520Neglected%2520Diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2569%26epage%3D2575%26doi%3D10.1016%2Fj.bmcl.2016.03.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">11280</span>– <span class="NLM_lpage">11304</span>, <span class="refDoi"> DOI: 10.1021/cr500197d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr500197d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12kurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=11280-11304&author=C.+Merrittauthor=L.+E.+Silvaauthor=A.+L.+Tannerauthor=K.+Stuartauthor=M.+P.+Pollastri&title=Kinases+as+Druggable+Targets+in+Trypanosomatid+Protozoan+Parasites&doi=10.1021%2Fcr500197d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites</span></div><div class="casAuthors">Merritt, Christopher; Silva, Lisseth E.; Tanner, Angela L.; Stuart, Kenneth; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11280-11304</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ZwVA0tDwbrVg90H21EOLACvtfcHk0lgREBe1e7CBsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12kurnJ&md5=960674aae803f0db316c24ef0b5159bc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fcr500197d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr500197d%26sid%3Dliteratum%253Aachs%26aulast%3DMerritt%26aufirst%3DC.%26aulast%3DSilva%26aufirst%3DL.%2BE.%26aulast%3DTanner%26aufirst%3DA.%2BL.%26aulast%3DStuart%26aufirst%3DK.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DKinases%2520as%2520Druggable%2520Targets%2520in%2520Trypanosomatid%2520Protozoan%2520Parasites%26jtitle%3DChem.%2520Rev.%26date%3D2014%26volume%3D114%26spage%3D11280%26epage%3D11304%26doi%3D10.1021%2Fcr500197d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naula, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, J. C.</span></span> <span> </span><span class="NLM_article-title">Protein kinases as drug targets in trypanosomes and <i>Leishmania</i></span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1754</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2005.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1016%2Fj.bbapap.2005.08.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=16198642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlags7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=151-159&author=C.+Naulaauthor=M.+Parsonsauthor=J.+C.+Mottram&title=Protein+kinases+as+drug+targets+in+trypanosomes+and+Leishmania&doi=10.1016%2Fj.bbapap.2005.08.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinases as drug targets in trypanosomes and Leishmania</span></div><div class="casAuthors">Naula, Christina; Parsons, Marilyn; Mottram, Jeremy C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1754</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">151-159</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein kinases represent promising drug targets for a no. of human and animal diseases.  The recent completion of the sequenced genomes of three human-infective trypanosomatid protozoa, Leishmania major, Trypanosoma brucei and Trypanosoma cruzi, has allowed the kinome for each parasite to be defined as 179, 156 and 171 eukaryotic protein kinases resp., that is about one third of the human complement.  The anal. revealed that the trypanosomatids lack members of the receptor-linked or cytosolic tyrosine kinase families, but have an abundance of STE and CMGC family protein kinases likely to be involved in regulating cell cycle control, differentiation and response to stress during their complex life-cycles.  In this review, we examine the prospects for exploiting differences between parasite and mammalian protein kinases to develop novel anti-parasitic chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF-zsVbsp6gbVg90H21EOLACvtfcHk0lgREBe1e7CBsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlags7nJ&md5=f65a9a3b2c5ccd41e54a7a01b609ba44</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2005.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2005.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DNaula%26aufirst%3DC.%26aulast%3DParsons%26aufirst%3DM.%26aulast%3DMottram%26aufirst%3DJ.%2BC.%26atitle%3DProtein%2520kinases%2520as%2520drug%2520targets%2520in%2520trypanosomes%2520and%2520Leishmania%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2005%26volume%3D1754%26spage%3D151%26epage%3D159%26doi%3D10.1016%2Fj.bbapap.2005.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammarton, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, J. C.</span></span> <span> </span><span class="NLM_article-title"><i>Trypanosoma brucei</i> Polo-like Kinase is Essential for Basal Body Duplication, kDNA Segregation and Cytokinesis</span>. <i>Mol. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1229</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2958.2007.05866.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1111%2Fj.1365-2958.2007.05866.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=17662039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWnur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2007&pages=1229-1249&author=T.+C.+Hammartonauthor=S.+Kramerauthor=L.+Tetleyauthor=M.+Boshartauthor=J.+C.+Mottram&title=Trypanosoma+brucei+Polo-like+Kinase+is+Essential+for+Basal+Body+Duplication%2C+kDNA+Segregation+and+Cytokinesis&doi=10.1111%2Fj.1365-2958.2007.05866.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Trypanosoma brucei Polo-like kinase is essential for basal body duplication, kDNA segregation and cytokinesis</span></div><div class="casAuthors">Hammarton, Tansy C.; Kramer, Susanne; Tetley, Laurence; Boshart, Michael; Mottram, Jeremy C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Microbiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1229-1248</span>CODEN:
                <span class="NLM_cas:coden">MOMIEE</span>;
        ISSN:<span class="NLM_cas:issn">0950-382X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinases (PLKs) are conserved eukaryotic cell cycle regulators, which play multiple roles, particularly during mitosis.  The function of Trypanosoma brucei PLK was investigated in procyclic and bloodstream-form parasites.  In procyclic trypanosomes, RNA interference (RNAi) of PLK, or overexpression of TY1-epitope-tagged PLK (PLKty), but not overexpression of a kinase-dead variant, resulted in the accumulation of cells that had divided their nucleus but not their kinetoplast (2N1K cells).  Anal. of basal bodies and flagella in these cells suggested the defect in kinetoplast division arose because of an inhibition of basal body duplication, which occurred when PLK expression levels were altered.  Addnl., a defect in kDNA replication was obsd. in the 2N1K cells.  However, the 2N1K cells obtained by each approach were not equiv.  Following PLK depletion, the single kinetoplast was predominantly located between the two divided nuclei, while in cells overexpressing PLKty, the kinetoplast was mainly found at the posterior end of the cell, suggesting a role for PLK kinase activity in basal body and kinetoplast migration.  PLK RNAi in blood-stream trypanosomes also delayed kinetoplast division, and was further obsd. to inhibit furrow ingression during cytokinesis.  Notably, no addnl. roles were detected for trypanosome PLK in mitosis, setting this protein kinase apart from its counterparts in other eukaryotes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy4NuIRGtYOLVg90H21EOLACvtfcHk0lgdOwee9hcRGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWnur%252FE&md5=2473993f8b21b2f18518840a9b5a0c9c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2958.2007.05866.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2958.2007.05866.x%26sid%3Dliteratum%253Aachs%26aulast%3DHammarton%26aufirst%3DT.%2BC.%26aulast%3DKramer%26aufirst%3DS.%26aulast%3DTetley%26aufirst%3DL.%26aulast%3DBoshart%26aufirst%3DM.%26aulast%3DMottram%26aufirst%3DJ.%2BC.%26atitle%3DTrypanosoma%2520brucei%2520Polo-like%2520Kinase%2520is%2520Essential%2520for%2520Basal%2520Body%2520Duplication%252C%2520kDNA%2520Segregation%2520and%2520Cytokinesis%26jtitle%3DMol.%2520Microbiol.%26date%3D2007%26volume%3D65%26spage%3D1229%26epage%3D1249%26doi%3D10.1111%2Fj.1365-2958.2007.05866.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo-Arratta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seixas, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amata, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordon-Obras, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas-Barros, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colmenarejo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlanga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Identification and Characterization of Hundreds of Potent and Selective Inhibitors of <i>Trypanosoma brucei</i> Growth from a Kinase-Targeted Library Screening Campaign</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e3253</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0003253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1371%2Fjournal.pntd.0003253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=25340575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFeht7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&author=R.+Diazauthor=S.+Luengo-Arrattaauthor=J.+D.+Seixasauthor=E.+Amataauthor=W.+Devineauthor=C.+Cordon-Obrasauthor=D.+I.+Rojas-Barrosauthor=E.+Jimenezauthor=F.+Ortegaauthor=S.+Crouchauthor=G.+Colmenarejoauthor=J.+M.+Fiandorauthor=J.+J.+Martinauthor=M.+Berlangaauthor=S.+Gonzalezauthor=P.+Manzanoauthor=M.+Navarroauthor=M.+P.+Pollastri&title=Identification+and+Characterization+of+Hundreds+of+Potent+and+Selective+Inhibitors+of+Trypanosoma+brucei+Growth+from+a+Kinase-Targeted+Library+Screening+Campaign&doi=10.1371%2Fjournal.pntd.0003253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign</span></div><div class="casAuthors">Diaz, Rosario; Luengo-Arratta, Sandra A.; Seixas, Joao D.; Amata, Emanuele; Devine, William; Cordon-Obras, Carlos; Rojas-Barros, Domingo I.; Jimenez, Elena; Ortega, Fatima; Crouch, Sabrinia; Colmenarejo, Gonzalo; Fiandor, Jose Maria; Martin, Jose Julio; Berlanga, Manuela; Gonzalez, Silvia; Manzano, Pilar; Navarro, Miguel; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e3253/1-e3253/14, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In the interest of identification of new kinase-targeting chemotypes for target and pathway anal. and drug discovery in Trypanosomal brucei, a high-throughput screen of 42,444 focused inhibitors from the GlaxoSmithKline screening collection was performed against parasite cell cultures and counter-screened against human hepatocarcinoma (HepG2) cells.  In this way, we have identified 797 sub-micromolar inhibitors of T. brucei growth that are at least 100-fold selective over HepG2 cells.  Importantly, 242 of these hit compds. acted rapidly in inhibiting cellular growth, 137 showed rapid cidality.  A variety of in silico and in vitro physicochem. and drug metab. properties were assessed, and human kinase selectivity data were obtained, and, based on these data, we prioritized three compds. for pharmacokinetic assessment and demonstrated parasitol. cure of a murine bloodstream infection of T. brucei rhodesiense with one of these compds. (NEU-1053).  This work represents a successful implementation of a unique industrial-academic collaboration model aimed at identification of high quality inhibitors that will provide the parasitol. community with chem. matter that can be utilized to develop kinase-targeting tool compds.  Furthermore these results are expected to provide rich starting points for discovery of kinase-targeting tool compds. for T. brucei, and new HAT therapeutics discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPav6cECtioLVg90H21EOLACvtfcHk0lgdOwee9hcRGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFeht7w%253D&md5=d61b812b1af6aefb0ecdd1fc72c19897</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0003253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0003253%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DR.%26aulast%3DLuengo-Arratta%26aufirst%3DS.%26aulast%3DSeixas%26aufirst%3DJ.%2BD.%26aulast%3DAmata%26aufirst%3DE.%26aulast%3DDevine%26aufirst%3DW.%26aulast%3DCordon-Obras%26aufirst%3DC.%26aulast%3DRojas-Barros%26aufirst%3DD.%2BI.%26aulast%3DJimenez%26aufirst%3DE.%26aulast%3DOrtega%26aufirst%3DF.%26aulast%3DCrouch%26aufirst%3DS.%26aulast%3DColmenarejo%26aufirst%3DG.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DJ.%2BJ.%26aulast%3DBerlanga%26aufirst%3DM.%26aulast%3DGonzalez%26aufirst%3DS.%26aulast%3DManzano%26aufirst%3DP.%26aulast%3DNavarro%26aufirst%3DM.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520Hundreds%2520of%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Trypanosoma%2520brucei%2520Growth%2520from%2520a%2520Kinase-Targeted%2520Library%2520Screening%2520Campaign%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2014%26volume%3D8%26doi%3D10.1371%2Fjournal.pntd.0003253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5992</span>– <span class="NLM_lpage">6000</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1016%2Fj.bmcl.2013.08.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=24054120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5992-6000&author=M.+D.+Shultz&title=The+thermodynamic+basis+for+the+use+of+lipophilic+efficiency+%28LipE%29+in+enthalpic+optimizations&doi=10.1016%2Fj.bmcl.2013.08.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5992-6000</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Approaches to improve the efficiency of mol. optimizations have received great attention and numerous efficiency metrics have been introduced to assist in this effort.  Optimization of properties is equally important to optimization of potency and therefore these metrics contain potency vs. property calcns.  Widespread use of a metric does not guarantee its accuracy and a further understanding of which, if any, metric increases the probability of success was sought.  An anal. of LE, LELP and LipE based on theor. and exptl. data was performed demonstrating that LipE most strongly correlates with compd. quality as defined by enthalpy-driven binding.  The basis for the prioritization of LipE over other metrics in enthalpic optimizations is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobuMO74LdKnbVg90H21EOLACvtfcHk0lhiFmxwwVMJvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P&md5=23d948d1135eeefdfebc60846f28ec2b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.030%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DThe%2520thermodynamic%2520basis%2520for%2520the%2520use%2520of%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520in%2520enthalpic%2520optimizations%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5992%26epage%3D6000%26doi%3D10.1016%2Fj.bmcl.2013.08.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1021/cn100008c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-449&author=T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Moving+beyond+rules%3A+The+development+of+a+central+nervous+system+multiparameter+optimization+%28CNS+MPO%29+approach+to+enable+alignment+of+druglike+properties&doi=10.1021%2Fcn100008c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">435-449</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The interplay among commonly used physicochem. properties in drug design was examd. and utilized to create a prospective design tool focused on the alignment of key druglike attributes.  Using a set of six physicochem. parameters ((a) lipophilicity, calcd. partition coeff. (ClogP); (b) calcd. distribution coeff. at pH = 7.4 (ClogD); (c) mol. wt. (MW); (d) topol. polar surface area (TPSA); (e) no. of hydrogen bond donors (HBD); (f) most basic center (pKa)), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compds. (N = 11 303).  The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates.  This anal. suggests that this algorithm could potentially be used to identify compds. with a higher probability of successfully testing hypotheses in the clinic.  In addn., a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set.  The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chem. design space through a holistic assessment approach.  Based on six physicochem. properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compds. with increased probability of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3Mvkgm_X5bVg90H21EOLACvtfcHk0lhiFmxwwVMJvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D&md5=e94998f65a420be6ee4dec4a987cb983</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fcn100008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100008c%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DMoving%2520beyond%2520rules%253A%2520The%2520development%2520of%2520a%2520central%2520nervous%2520system%2520multiparameter%2520optimization%2520%2528CNS%2520MPO%2529%2520approach%2520to%2520enable%2520alignment%2520of%2520druglike%2520properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D449%26doi%3D10.1021%2Fcn100008c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruciani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carosati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Boeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vianello, R.</span></span> <span> </span><span class="NLM_article-title">MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6970</span>– <span class="NLM_lpage">6979</span>, <span class="refDoi"> DOI: 10.1021/jm050529c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050529c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGis73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6970-6979&author=G.+Crucianiauthor=E.+Carosatiauthor=B.+De+Boeckauthor=K.+Ethirajuluauthor=C.+Mackieauthor=T.+Howeauthor=R.+Vianello&title=MetaSite%3A+Understanding+metabolism+in+human+cytochromes+from+the+perspective+of+the+chemist&doi=10.1021%2Fjm050529c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">MetaSite: Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist</span></div><div class="casAuthors">Cruciani, Gabriele; Carosati, Emanuele; De Boeck, Benoit; Ethirajulu, Kantharaj; Mackie, Claire; Howe, Trevor; Vianello, Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6970-6979</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification of metabolic biotransformations can significantly affect the drug discovery process.  Since bioavailability, activity, toxicity, distribution, and final elimination all depend on metabolic biotransformations, it would be extremely advantageous if this information could be produced early in the discovery phase.  Once obtained, this information can help chemists to judge whether a potential candidate should be eliminated from the pipeline or modified to improve chem. stability or safety of new compds.  The use of in silico methods to predict the site of metab. in phase I cytochrome-mediated reactions is a starting point in any metabolic pathway prediction.  This paper presents a new method, specifically designed for chemists, that provides the cytochrome involved and the site of metab. for any human cytochrome P 450 (CYP) mediated reaction acting on new substrates.  The methodol. can be applied automatically to all the cytochromes for which 3D structure is known and can be used by chemists to detect positions that should be protected in order to avoid metabolic degrdn. or to check the suitability of a new scaffold or prodrug.  The fully automated procedure is also a valuable new tool in early ADME-Tox assays (absorption, distribution, metab., and excretion toxicity assays), where drug safety and metabolic profile patterns must be evaluated as soon, and as early, as possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzNL56jqRMpbVg90H21EOLACvtfcHk0liRyyX48Xt3bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGis73F&md5=0a4576ffbea74e677832b7dbe8e036f0</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm050529c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050529c%26sid%3Dliteratum%253Aachs%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DCarosati%26aufirst%3DE.%26aulast%3DDe%2BBoeck%26aufirst%3DB.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DHowe%26aufirst%3DT.%26aulast%3DVianello%26aufirst%3DR.%26atitle%3DMetaSite%253A%2520Understanding%2520metabolism%2520in%2520human%2520cytochromes%2520from%2520the%2520perspective%2520of%2520the%2520chemist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6970%26epage%3D6979%26doi%3D10.1021%2Fjm050529c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: Increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+Increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0liRyyX48Xt3bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520Increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0lg-Rsf1OU-ODA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barden, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. F.</span></span> <span> </span><span class="NLM_article-title">The blood-brain barrier (BBB) score</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9824</span>– <span class="NLM_lpage">9836</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01220</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01220" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFGqtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9824-9836&author=M.+Guptaauthor=H.+J.+Leeauthor=C.+J.+Bardenauthor=D.+F.+Weaver&title=The+blood-brain+barrier+%28BBB%29+score&doi=10.1021%2Facs.jmedchem.9b01220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The Blood-Brain Barrier (BBB) Score</span></div><div class="casAuthors">Gupta, Mayuri; Lee, Hyeok Jun; Barden, Christopher J.; Weaver, Donald F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9824-9836</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The blood-brain barrier (BBB) protects the brain from the toxic side effects of drugs and exogenous mols.  However, it is crucial that medications developed for neurol. disorders cross into the brain in therapeutic concns.  Understanding the BBB interaction with drug mols. based on physicochem. property space can guide effective and efficient drug design.  An algorithm, designated "BBB Score", composed of stepwise and polynomial piecewise functions, is herein proposed for predicting BBB penetration based on five physicochem. descriptors: no. of arom. rings, heavy atoms, MWHBN (a descriptor comprising mol. wt., hydrogen bond donor, and hydrogen bond acceptors), topol. polar surface area, and pKa.  On the basis of statistical analyses of our results, the BBB Score outperformed (AUC = 0.86) currently employed MPO approaches (MPO, AUC = 0.61; MPO_V2, AUC = 0.67).  Initial evaluation of physicochem. property space using the BBB Score is a valuable addn. to currently available drug design algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5_qEoBbf20LVg90H21EOLACvtfcHk0lg-Rsf1OU-ODA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFGqtbvK&md5=26dd989ea2ca772d72702f4abc47c8fa</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01220%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DBarden%26aufirst%3DC.%2BJ.%26aulast%3DWeaver%26aufirst%3DD.%2BF.%26atitle%3DThe%2520blood-brain%2520barrier%2520%2528BBB%2529%2520score%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9824%26epage%3D9836%26doi%3D10.1021%2Facs.jmedchem.9b01220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernatchez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCall, L.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvet, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klug, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalani, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bag, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buskes, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leed, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncal, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siqueira-Neto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Scaffold and parasite hopping: discovery of new protozoal proliferation inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00453</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00453" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVShsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=249-257&author=B.+Singhauthor=J.+A.+Bernatchezauthor=L.-I.+McCallauthor=C.+M.+Calvetauthor=J.+Ackermannauthor=J.+M.+Souzaauthor=D.+Thomasauthor=E.+M.+Silvaauthor=K.+A.+Bachovchinauthor=D.+M.+Klugauthor=H.+B.+Jalaniauthor=S.+Bagauthor=M.+J.+Buskesauthor=S.+E.+Leedauthor=N.+E.+Roncalauthor=E.+C.+Pennauthor=J.+Erathauthor=A.+Rodriguezauthor=R.+J.+Sciottiauthor=R.+F.+Campbellauthor=J.+H.+McKerrowauthor=J.+Siqueira-Netoauthor=L.+Ferrinsauthor=M.+P.+Pollastri&title=Scaffold+and+parasite+hopping%3A+discovery+of+new+protozoal+proliferation+inhibitors&doi=10.1021%2Facsmedchemlett.9b00453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold and Parasite Hopping: Discovery of New Protozoal Proliferation Inhibitors</span></div><div class="casAuthors">Singh, Baljinder; Bernatchez, Jean A.; McCall, Laura-Isobel; Calvet, Claudia M.; Ackermann, Jasmin; Souza, Julia M.; Thomas, Diane; Silva, Everton M.; Bachovchin, Kelly A.; Klug, Dana M.; Jalani, Hitesh B.; Bag, Seema; Buskes, Melissa J.; Leed, Susan E.; Roncal, Norma E.; Penn, Erica C.; Erath, Jessey; Rodriguez, Ana; Sciotti, Richard J.; Campbell, Robert F.; McKerrow, James; Siqueira-Neto, Jair L.; Ferrins, Lori; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-257</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Utilizing a target repurposing and parasite-hopping approach, we tested a previously reported library of compds. that were active against Trypanosoma brucei, plus 31 new compds., against a variety of protozoan parasites including Trypanosoma cruzi, Leishmania major, Leishmania donovani, and Plasmodium falciparum.  This led to the discovery of several compds. with submicromolar activities and improved physicochem. properties that are early leads toward the development of chemotherapeutic agents against kinetoplastid diseases and malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodxpgfCEC3qLVg90H21EOLACvtfcHk0lgl_aAU6ViifQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVShsA%253D%253D&md5=69a28d4b3a7991e528b3ee474b3e0500</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00453%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DBernatchez%26aufirst%3DJ.%2BA.%26aulast%3DMcCall%26aufirst%3DL.-I.%26aulast%3DCalvet%26aufirst%3DC.%2BM.%26aulast%3DAckermann%26aufirst%3DJ.%26aulast%3DSouza%26aufirst%3DJ.%2BM.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DSilva%26aufirst%3DE.%2BM.%26aulast%3DBachovchin%26aufirst%3DK.%2BA.%26aulast%3DKlug%26aufirst%3DD.%2BM.%26aulast%3DJalani%26aufirst%3DH.%2BB.%26aulast%3DBag%26aufirst%3DS.%26aulast%3DBuskes%26aufirst%3DM.%2BJ.%26aulast%3DLeed%26aufirst%3DS.%2BE.%26aulast%3DRoncal%26aufirst%3DN.%2BE.%26aulast%3DPenn%26aufirst%3DE.%2BC.%26aulast%3DErath%26aufirst%3DJ.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DCampbell%26aufirst%3DR.%2BF.%26aulast%3DMcKerrow%26aufirst%3DJ.%2BH.%26aulast%3DSiqueira-Neto%26aufirst%3DJ.%26aulast%3DFerrins%26aufirst%3DL.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DScaffold%2520and%2520parasite%2520hopping%253A%2520discovery%2520of%2520new%2520protozoal%2520proliferation%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D249%26epage%3D257%26doi%3D10.1021%2Facsmedchemlett.9b00453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Probst, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Sakkary, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A.</span></span> <span> </span><span class="NLM_article-title">Bioactivity of Farnesyltransferase Inhibitors Against <i>Entamoeba histolytica</i> and <i>Schistosoma mansoni</i></span>. <i>Frront. Cell. Infect. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e478</span> <span class="refDoi"> DOI: 10.3389/fcimb.2019.00180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.3389%2Ffcimb.2019.00180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=32039053" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=A.+Probstauthor=T.+N.+Nguyenauthor=N.+El-Sakkaryauthor=D.+Skinnerauthor=B.+M.+Suzukiauthor=F.+S.+Bucknerauthor=M.+H.+Gelbauthor=C.+R.+Caffreyauthor=A.+Debnath&title=Bioactivity+of+Farnesyltransferase+Inhibitors+Against+Entamoeba+histolytica+and+Schistosoma+mansoni&doi=10.3389%2Ffcimb.2019.00180"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3389%2Ffcimb.2019.00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcimb.2019.00180%26sid%3Dliteratum%253Aachs%26aulast%3DProbst%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DT.%2BN.%26aulast%3DEl-Sakkary%26aufirst%3DN.%26aulast%3DSkinner%26aufirst%3DD.%26aulast%3DSuzuki%26aufirst%3DB.%2BM.%26aulast%3DBuckner%26aufirst%3DF.%2BS.%26aulast%3DGelb%26aufirst%3DM.%2BH.%26aulast%3DCaffrey%26aufirst%3DC.%2BR.%26aulast%3DDebnath%26aufirst%3DA.%26atitle%3DBioactivity%2520of%2520Farnesyltransferase%2520Inhibitors%2520Against%2520Entamoeba%2520histolytica%2520and%2520Schistosoma%2520mansoni%26jtitle%3DFrront.%2520Cell.%2520Infect.%2520Microbiol.%26date%3D2019%26volume%3D9%26doi%3D10.3389%2Ffcimb.2019.00180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo-Arreola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Sakkary, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarnagin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meewan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rascón, A. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podust, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashrafi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, C. R.</span></span> <span> </span><span class="NLM_article-title">Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0005680</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0005680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1371%2Fjournal.pntd.0005680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=28704396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKgu7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&author=T.+Longauthor=L.+Rojo-Arreolaauthor=D.+Shiauthor=N.+El-Sakkaryauthor=K.+Jarnaginauthor=F.+Rockauthor=M.+Meewanauthor=A.+A.+Rasc%C3%B3nauthor=L.+Linauthor=K.+A.+Cunninghamauthor=G.+A.+Lemieuxauthor=L.+Podustauthor=R.+Abagyanauthor=K.+Ashrafiauthor=J.+H.+McKerrowauthor=C.+R.+Caffrey&title=Phenotypic%2C+chemical+and+functional+characterization+of+cyclic+nucleotide+phosphodiesterase+4+%28PDE4%29+as+a+potential+anthelmintic+drug+target&doi=10.1371%2Fjournal.pntd.0005680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target</span></div><div class="casAuthors">Long, Thavy; Rojo-Arreola, Liliana; Shi, Da; El-Sakkary, Nelly; Jarnagin, Kurt; Rock, Fernando; Meewan, Maliwan; Rascon, Alberto A.; Lin, Lin; Cunningham, Katherine A.; Lemieux, George A.; Podust, Larissa; Abagyan, Ruben; Ashrafi, Kaveh; McKerrow, James H.; Caffrey, Conor R.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0005680/1-e0005680/27</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background Reliance on just one drug to treat the prevalent tropical disease, schistosomiasis, spurs the search for new drugs and drug targets.  Inhibitors of human cyclic nucleotide phosphodiesterases (huPDEs), including PDE4, are under development as novel drugs to treat a range of chronic indications including asthma, chronic obstructive pulmonary disease and Alzheimer's disease.  One class of huPDE4 inhibitors that has yielded marketed drugs is the benzoxaboroles (Anacor Pharmaceuticals).  Methodol./Principal findings A phenotypic screen involving Schistosoma mansoni and 1,085 benzoxaboroles identified a subset of huPDE4 inhibitors that induced parasite hypermotility and degeneration.  To uncover the putative schistosome PDE4 target, we characterized four PDE4 sequences (SmPDE4A-D) in the parasite's genome and transcriptome, and cloned and recombinantly expressed the catalytic domain of SmPDE4A.  Among a set of benzoxaboroles and catechol inhibitors that differentially inhibit huPDE4, a relationship between the inhibition of SmPDE4A, and parasite hypermotility and degeneration, was measured.  To validate SmPDE4A as the benzoxaborole mol. target, we first generated Caenorhabditis elegans lines that express a cDNA for smpde4a on a pde4(ce268) mutant (hypermotile) background: the smpde4a transgene restored mutant worm motility to that of the wild type.  We then showed that benzoxaborole inhibitors of SmPDE4A that induce hypermotility in the schistosome also elicit a hypermotile response in the C. elegans lines that express the smpde4a transgene, thereby confirming SmPDE4A as the relevant target.  Conclusions/Significance The orthogonal chem., biol. and genetic strategies employed identify SmPDE4A's contribution to parasite motility and degeneration, and its potential as a drug target.  Transgenic C. elegans is highlighted as a potential screening tool to optimize small mol. chemistries to flatworm mol. drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKBmivor-rJLVg90H21EOLACvtfcHk0ljpL6e_uI3kpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKgu7bP&md5=f20bcf6704231669a77645b633c2ca29</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005680%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DT.%26aulast%3DRojo-Arreola%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DEl-Sakkary%26aufirst%3DN.%26aulast%3DJarnagin%26aufirst%3DK.%26aulast%3DRock%26aufirst%3DF.%26aulast%3DMeewan%26aufirst%3DM.%26aulast%3DRasc%25C3%25B3n%26aufirst%3DA.%2BA.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DLemieux%26aufirst%3DG.%2BA.%26aulast%3DPodust%26aufirst%3DL.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DAshrafi%26aufirst%3DK.%26aulast%3DMcKerrow%26aufirst%3DJ.%2BH.%26aulast%3DCaffrey%26aufirst%3DC.%2BR.%26atitle%3DPhenotypic%252C%2520chemical%2520and%2520functional%2520characterization%2520of%2520cyclic%2520nucleotide%2520phosphodiesterase%25204%2520%2528PDE4%2529%2520as%2520a%2520potential%2520anthelmintic%2520drug%2520target%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26doi%3D10.1371%2Fjournal.pntd.0005680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyanaraman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dissous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, C. R.</span></span> <span> </span><span class="NLM_article-title">Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in <i>Schistosoma mansoni</i></span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0004356</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0004356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1371%2Fjournal.pntd.0004356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=26751972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVGiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&author=T.+Longauthor=R.+J.+Neitzauthor=R.+Beasleyauthor=C.+Kalyanaramanauthor=B.+M.+Suzukiauthor=M.+P.+Jacobsonauthor=C.+Dissousauthor=J.+H.+McKerrowauthor=D.+H.+Drewryauthor=W.+J.+Zuercherauthor=R.+Singhauthor=C.+R.+Caffrey&title=Structure-Bioactivity+Relationship+for+Benzimidazole+Thiophene+Inhibitors+of+Polo-Like+Kinase+1+%28PLK1%29%2C+a+Potential+Drug+Target+in+Schistosoma+mansoni&doi=10.1371%2Fjournal.pntd.0004356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-bioactivity relationship for benzimidazole thiophene inhibitors of polo-like kinase 1 (PLK1), a potential drug target in Schistosoma mansoni</span></div><div class="casAuthors">Long, Thavy; Neitz, R. Jeffrey; Beasley, Rachel; Kalyanaraman, Chakrapani; Suzuki, Brian M.; Jacobson, Matthew P.; Dissous, Colette; McKerrow, James H.; Drewry, David H.; Zuercher, William J.; Singh, Rahul; Caffrey, Conor R.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0004356/1-e0004356/21</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">BackgroundSchistosoma flatworm parasites cause schistosomiasis, a chronic and debilitating disease of poverty in developing countries.  Praziquantel is employed for treatment and disease control.  However, its efficacy spectrum is incomplete (less active or inactive against immature stages of the parasite) and there is a concern of drug resistance.  Thus, there is a need to identify new drugs and drug targets.  Methodol./Principal Findings We show that RNA interference (RNAi) of the Schistosoma mansoni ortholog of human polo-like kinase (huPLK)1 elicits a deleterious phenotypic alteration in post-infective larvae (schistosomula or somules).  Phenotypic screening and anal. of schistosomula and adult S. mansoni with small mol. inhibitors of huPLK1 identified a no. of potent anti-schistosomals.  Among these was a GlaxoSmithKline (GSK) benzimidazole thiophene inhibitor that has completed Phase I clin. trials for treatment of solid tumor malignancies.  We then obtained GSKs Published Kinase Inhibitor Sets (PKIS) 1 and 2, and phenotypically screened an expanded series of 38 benzimidazole thiophene PLK1 inhibitors.  Computational anal. of controls and PLK1 inhibitor-treated populations of somules demonstrated a distinctive phenotype distribution.  Using principal component anal. (PCA), the phenotypes exhibited by these populations were mapped, visualized and analyzed through projection to a low-dimensional space.  The phenotype distribution was found to have a distinct shape and topol., which could be elicited using cluster anal.  A structure-activity relationship (SAR) was identified for the benzimidazole thiophenes that held for both somules and adult parasites.  The most potent inhibitors produced marked phenotypic alterations at 1-2 μM within 1 h.  Among these were compds. previously characterized as potent inhibitors of huPLK1 in cell assays.  Conclusions/Significance The reverse genetic and chem. SAR data support a continued investigation of SmPLK1 as a possible drug target and/or the prosecution of the benzimidazole thiophene chemotype as a source of novel anti-schistosomals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdD29YvjLqOLVg90H21EOLACvtfcHk0ljpL6e_uI3kpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVGiurY%253D&md5=9725815b30a5913f9ed25515ef61b3b3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0004356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0004356%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DT.%26aulast%3DNeitz%26aufirst%3DR.%2BJ.%26aulast%3DBeasley%26aufirst%3DR.%26aulast%3DKalyanaraman%26aufirst%3DC.%26aulast%3DSuzuki%26aufirst%3DB.%2BM.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DDissous%26aufirst%3DC.%26aulast%3DMcKerrow%26aufirst%3DJ.%2BH.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DCaffrey%26aufirst%3DC.%2BR.%26atitle%3DStructure-Bioactivity%2520Relationship%2520for%2520Benzimidazole%2520Thiophene%2520Inhibitors%2520of%2520Polo-Like%2520Kinase%25201%2520%2528PLK1%2529%252C%2520a%2520Potential%2520Drug%2520Target%2520in%2520Schistosoma%2520mansoni%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2016%26volume%3D10%26doi%3D10.1371%2Fjournal.pntd.0004356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kyere-Davies, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agyare, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boakye, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, C. R.</span></span> <span> </span><span class="NLM_article-title">Effect of Phenotypic Screening of Extracts and Fractions of <i>Erythrophleum ivorense</i> Leaf and Stem Bark on Immature and Adult Stages of <i>Schistosoma mansoni</i></span>. <i>J. Parasitol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2018</i></span>, <span class="NLM_elocation-id">9431467</span> <span class="refDoi"> DOI: 10.1155/2018/9431467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1155%2F2018%2F9431467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=29977614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Flt12juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2018&publication_year=2018&author=G.+Kyere-Daviesauthor=C.+Agyareauthor=Y.+D.+Boakyeauthor=B.+M.+Suzukiauthor=C.+R.+Caffrey&title=Effect+of+Phenotypic+Screening+of+Extracts+and+Fractions+of+Erythrophleum+ivorense+Leaf+and+Stem+Bark+on+Immature+and+Adult+Stages+of+Schistosoma+mansoni&doi=10.1155%2F2018%2F9431467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Phenotypic Screening of Extracts and Fractions of Erythrophleum ivorense Leaf and Stem Bark on Immature and Adult Stages of Schistosoma mansoni</span></div><div class="casAuthors">Kyere-Davies Gertrude; Agyare Christian; Boakye Yaw Duah; Suzuki Brian M; Caffrey Conor R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of parasitology research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2018</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9431467</span>
        ISSN:<span class="NLM_cas:issn">2090-0023</span>.
    </div><div class="casAbstract">Schistosomiasis is a disease caused by a flatworm parasite that infects people in tropical and subtropical regions of Sub-Saharan Africa, South America, China, and Southeast Asia.  The reliance on just one drug for current treatment emphasizes the need for new chemotherapeutic strategies.  The aim of this study was to determine the phenotypic effects of extracts and fractions of leaf and stem bark of Erythrophleum ivorense (family Euphorbiaceae), a tree that grows in tropical parts of Africa, on two developmental stages of Schistosoma mansoni, namely, postinfective larvae (schistosomula or somules) and adults.  Methanol leaf and stem bark extracts of E. ivorense were successively fractionated with acetone, petroleum ether, ethyl acetate, and methanol.  These fractions were then incubated with somules at 0.3125 to 100 μg/mL and with adults at 1.25 μg/mL.  The acetone fractions of both the methanol leaf and bark of E. ivorense were most active against the somules whereas the petroleum ether fractions showed least activity.  For adult parasites, the acetone fraction of methanol bark extract also elicited phenotypic changes.  The data arising provide the first step in the discovery of new treatments for an endemic infectious disease using locally sourced African medicinal plants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIvDky2mD_DyCEBeYuoi7AfW6udTcc2ebQioguBF4xtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Flt12juw%253D%253D&md5=ff1f872ad10c5e8e17b797d94809bf3a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1155%2F2018%2F9431467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2018%252F9431467%26sid%3Dliteratum%253Aachs%26aulast%3DKyere-Davies%26aufirst%3DG.%26aulast%3DAgyare%26aufirst%3DC.%26aulast%3DBoakye%26aufirst%3DY.%2BD.%26aulast%3DSuzuki%26aufirst%3DB.%2BM.%26aulast%3DCaffrey%26aufirst%3DC.%2BR.%26atitle%3DEffect%2520of%2520Phenotypic%2520Screening%2520of%2520Extracts%2520and%2520Fractions%2520of%2520Erythrophleum%2520ivorense%2520Leaf%2520and%2520Stem%2520Bark%2520on%2520Immature%2520and%2520Adult%2520Stages%2520of%2520Schistosoma%2520mansoni%26jtitle%3DJ.%2520Parasitol.%2520Res.%26date%3D2018%26volume%3D2018%26doi%3D10.1155%2F2018%2F9431467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdulla, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, C. R.</span></span> <span> </span><span class="NLM_article-title"><i>Schistosomiasis Mansoni</i>: Novel Chemotherapy Using a Cysteine Protease Inhibitor</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e14</span> <span class="refDoi"> DOI: 10.1371/journal.pmed.0040014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1371%2Fjournal.pmed.0040014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=17214506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A280%3ADC%252BD2svms1Sjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&author=M.-H.+Abdullaauthor=K.-C.+Limauthor=M.+Sajidauthor=J.+H.+McKerrowauthor=C.+R.+Caffrey&title=Schistosomiasis+Mansoni%3A+Novel+Chemotherapy+Using+a+Cysteine+Protease+Inhibitor&doi=10.1371%2Fjournal.pmed.0040014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor</span></div><div class="casAuthors">Abdulla Maha-Hamadien; Lim Kee-Chong; Sajid Mohammed; McKerrow James H; Caffrey Conor R</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Schistosomiasis is a chronic, debilitating parasitic disease infecting more than 200 million people and is second only to malaria in terms of public health importance.  Due to the lack of a vaccine, patient therapy is heavily reliant on chemotherapy with praziquantel as the World Health Organization-recommended drug, but concerns over drug resistance encourage the search for new drug leads.  METHODS AND FINDINGS:  The efficacy of the vinyl sulfone cysteine protease inhibitor K11777 was tested in the murine model of schistosomiasis mansoni.  Disease parameters measured were worm and egg burdens, and organ pathology including hepato- and splenomegaly, presence of parasite egg-induced granulomas in the liver, and levels of circulating alanine aminotransferase activity as a marker of hepatocellular function.  K11777 (25 mg/kg twice daily [BID]), administered intraperitoneally at the time of parasite migration through the skin and lungs (days 1-14 postinfection [p.i.]), resulted in parasitologic cure (elimination of parasite eggs) in five of seven cases and a resolution of other disease parameters.  K11777 (50 mg/kg BID), administered at the commencement of egg-laying by mature parasites (days 30-37 p.i.), reduced worm and egg burdens, and ameliorated organ pathology.  Using protease class-specific substrates and active-site labeling, one molecular target of K11777 was identified as the gut-associated cathepsin B1 cysteine protease, although other cysteine protease targets are not excluded.  In rodents, dogs, and primates, K11777 is nonmutagenic with satisfactory safety and pharmacokinetic profiles.  CONCLUSIONS:  The significant reduction in parasite burden and pathology by this vinyl sulfone cysteine protease inhibitor validates schistosome cysteine proteases as drug targets and offers the potential of a new direction for chemotherapy of human schistosomiasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfSjig6ZE6a_3jf77P2BG3fW6udTcc2ebQioguBF4xtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svms1Sjug%253D%253D&md5=b32c88c162ddebd16f54672485ebc6e6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0040014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0040014%26sid%3Dliteratum%253Aachs%26aulast%3DAbdulla%26aufirst%3DM.-H.%26aulast%3DLim%26aufirst%3DK.-C.%26aulast%3DSajid%26aufirst%3DM.%26aulast%3DMcKerrow%26aufirst%3DJ.%2BH.%26aulast%3DCaffrey%26aufirst%3DC.%2BR.%26atitle%3DSchistosomiasis%2520Mansoni%253A%2520Novel%2520Chemotherapy%2520Using%2520a%2520Cysteine%2520Protease%2520Inhibitor%26jtitle%3DPLoS%2520Med.%26date%3D2007%26volume%3D4%26doi%3D10.1371%2Fjournal.pmed.0040014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Plasma concentrations of <b>NEU-1207</b> over time after a 5 mg/kg oral dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Predicted metabolites of <b>NEU-1207</b> using MetaSite software.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 3-Position Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (a) 1-methyl-4-pyrazoleboronic acid pinacol ester, K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/water, 85 °C, 4 h (93%). (b) NIS, acetonitrile, 50 °C, 2 h (69%). (c) Tosyl chloride, 4-dimethylaminopyridine (DMAP), triethylamine (TEA), dichloromethane (DCM), rt, 12 h (89%). (d) Aryl boronic acid or pinacol ester, K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/water, 120 °C, μw, 30 min (24–85%). (e) NaOH (2 M aq), dioxane, 150 °C, μw, 1–10 min (10–83%). Ar = aryl group.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Aliphatic 3-Position Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (a) NIS, acetonitrile, 50 °C, 2 h (83%). (b) Tosyl chloride, Et<sub>3</sub>N, DMAP, DCM, rt, 12 h (78%). (c) Boronic ester, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 3:1 dioxane/water, 80 °C, 10 min, μw (56–73%). (d) 1-Methyl-4-pyrazoleboronic acid pinacol ester, K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/water, 85 °C, 4 h (83–93%). (e) NH<sub>4</sub>COO, 10% Pd/C, EtOH, 85 °C, 1.5 h (59–68%). (f) 2 M aq NaOH, dioxane, 150 °C, 15 min, μw (44–75%). (g) HCl, dioxane, 1–3 h, rt (78–97%).</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 5-Position Aromatic and Cyclic Amine Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (a) (3-cyanophenyl)boronic acid, K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/water, 120 °C, μw, 5 min (60%). (b) Aryl boronic acid or pinacol ester, K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/water, 85 °C, 4 h (31–84%). (c) NaOH (2 M aq), dioxane, 150 °C, μw, 1–10 min (10–83%). (d) Amine, LiHMDS (1.0 M in tetrahydrofuran (THF)), RuPhos, RuPhos Pd G1, 65 °C, 5 h (12–30%).</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/medium/jm1c00674_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Plasma concentration versus time profile of <b>29d</b> in mice (<i>n</i> = 3) following a single 10 mg/kg ip dose. The blue dashed line shows the average concentration and the shaded area represents the standard deviation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00674/20210629/images/large/jm1c00674_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00674&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i187">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47162" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47162" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 23 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">World Health Organization</span>. <span> </span><span class="NLM_article-title">Neglected Tropical
Diseases</span>. <a href="http://www.who.int/neglected_diseases/diseases/en/" class="extLink">http://www.who.int/neglected_diseases/diseases/en/</a> (accessed Sept 13, <span class="NLM_year">2016</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=World+Health+Organization&title=Neglected+Tropical%0ADiseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DNeglected%2520Tropical%250ADiseases%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Büscher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamonneau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priotto, G.</span></span> <span> </span><span class="NLM_article-title">Human African Trypanosomiasis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">2397</span>– <span class="NLM_lpage">2409</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)31510-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1016%2FS0140-6736%2817%2931510-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=28673422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A280%3ADC%252BC1cjktFCrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=2397-2409&author=P.+B%C3%BCscherauthor=G.+Cecchiauthor=V.+Jamonneauauthor=G.+Priotto&title=Human+African+Trypanosomiasis&doi=10.1016%2FS0140-6736%2817%2931510-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Human African trypanosomiasis</span></div><div class="casAuthors">Buscher Philippe; Cecchi Giuliano; Jamonneau Vincent; Priotto Gerardo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">10110</span>),
    <span class="NLM_cas:pages">2397-2409</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human African trypanosomiasis (sleeping sickness) is a parasitic infection that almost invariably progresses to death unless treated.  Human African trypanosomiasis caused devastating epidemics during the 20th century.  Thanks to sustained and coordinated efforts over the past 15 years, the number of reported cases has fallen to an historically low level.  Fewer than 3000 cases were reported in 2015, and the disease is targeted for elimination by WHO.  Despite these recent successes, the disease is still endemic in parts of sub-Saharan Africa, where it is a considerable burden on rural communities, most notably in central Africa.  Since patients are also reported from non-endemic countries, human African trypanosomiasis should be considered in differential diagnosis for travellers, tourists, migrants, and expatriates who have visited or lived in endemic areas.  In the absence of a vaccine, disease control relies on case detection and treatment, and vector control.  Available drugs are suboptimal, but ongoing clinical trials provide hope for safer and simpler treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBg2yQ4XqfsRgd2Wuil24tfW6udTcc2ebsmlz27V1dL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjktFCrsw%253D%253D&md5=521e7f5c04b32c04763c6b7a65af6439</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2931510-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252931510-6%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25BCscher%26aufirst%3DP.%26aulast%3DCecchi%26aufirst%3DG.%26aulast%3DJamonneau%26aufirst%3DV.%26aulast%3DPriotto%26aufirst%3DG.%26atitle%3DHuman%2520African%2520Trypanosomiasis%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26spage%3D2397%26epage%3D2409%26doi%3D10.1016%2FS0140-6736%2817%2931510-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehlhorn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, J.</span></span> <span> </span><span class="NLM_article-title">Light and electron microscopic studies on the effect of praziquantel on <i>Schistosoma mansoni</i>, <i>Dicrocoelium dendriticum</i>, and <i>Fasciola hepatica</i> (Trematoda) in vitro</span>. <i>Z Parasitenkd.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1007/BF00927527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1007%2FBF00927527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=7456640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADyaL3MXhsl0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1980&pages=113-128&author=B.+Beckerauthor=H.+Mehlhornauthor=P.+Andrewsauthor=H.+Thomasauthor=J.+Eckert&title=Light+and+electron+microscopic+studies+on+the+effect+of+praziquantel+on+Schistosoma+mansoni%2C+Dicrocoelium+dendriticum%2C+and+Fasciola+hepatica+%28Trematoda%29+in+vitro&doi=10.1007%2FBF00927527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro</span></div><div class="casAuthors">Becker, B.; Mehlhorn, H.; Andrews, P.; Thomas, H.; Eckert, J.</div><div class="citationInfo"><span class="NLM_cas:title">Zeitschrift fuer Parasitenkunde</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-28</span>CODEN:
                <span class="NLM_cas:coden">ZEPAA6</span>;
        ISSN:<span class="NLM_cas:issn">0044-3255</span>.
    </div><div class="casAbstract">The fine structure of the tegument of 3 trematode species, S. mansoni, D. dendriticum, and F. hepatica, was studied by means of light scanning (SEM) and transmission electron microscopy (TEM) after in vitro exposure to 0, 1, 10, or 100 μg/mL concns. of the anthelmintic praziquantel  [55268-74-1] for 5, 15, 30, or 60 min.  In S. mansoni and D. dendriticum, the resulting vacuolization of the tegument was confined to numerous small areas scattered all over the surface of the parasites; this finally led to the disruption of the apical tegumental layer.  No changes were found in the tegument of F. hepatica after treatment with praziquantel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxyZgjkvqASrVg90H21EOLACvtfcHk0ljayxQTU0a06g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhsl0%253D&md5=994322f5fc28adf1b2d8003c45a597fd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2FBF00927527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00927527%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DB.%26aulast%3DMehlhorn%26aufirst%3DH.%26aulast%3DAndrews%26aufirst%3DP.%26aulast%3DThomas%26aufirst%3DH.%26aulast%3DEckert%26aufirst%3DJ.%26atitle%3DLight%2520and%2520electron%2520microscopic%2520studies%2520on%2520the%2520effect%2520of%2520praziquantel%2520on%2520Schistosoma%2520mansoni%252C%2520Dicrocoelium%2520dendriticum%252C%2520and%2520Fasciola%2520hepatica%2520%2528Trematoda%2529%2520in%2520vitro%26jtitle%3DZ%2520Parasitenkd.%26date%3D1980%26volume%3D63%26spage%3D113%26epage%3D128%26doi%3D10.1007%2FBF00927527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fetterer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pax, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J. L.</span></span> <span> </span><span class="NLM_article-title">Praziquantel, potassium and 2,4-dinitrophenol: analysis of their action on the musculature of <i>Schistosoma mansoni</i></span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(80)90366-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1016%2F0014-2999%2880%2990366-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=7449814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADyaL3cXkvV2gtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1980&pages=31-38&author=R.+H.+Fettererauthor=R.+A.+Paxauthor=J.+L.+Bennett&title=Praziquantel%2C+potassium+and+2%2C4-dinitrophenol%3A+analysis+of+their+action+on+the+musculature+of+Schistosoma+mansoni&doi=10.1016%2F0014-2999%2880%2990366-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Praziquantel, potassium and 2,4-dinitrophenol:  analysis of their action on the musculature of Schistosoma mansoni</span></div><div class="casAuthors">Fetterer, Raymond H.; Pax, Ralph A.; Bennett, James L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-8</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">The antischistosomal drug praziquantel (PZ)  [55268-74-1] (10-6 M), 60 mM K+, and 2,4-dinitrophenol (DNP)  [51-28-5] induce a rapid contracture of the musculature in adult male S. mansoni.  This event is accompanied, except for DNP, by an increased accumulation of 45Ca2+ in the parasite.  K+-induced contractures had phasic and tonic components, whereas DNP and PZ produced only tonic contracture of the parasite musculature.  The Ca2+ antagonist D-600  [16662-47-8] (10-4 M), as well as La3+ (10 mM) and Co2+ (10 mM), prevented the 45Ca2+ accumulation produced by high K+.  La3+ and Co2+ blocked the tension-increasing effects of high K+; D-600 blocked only the tonic contractures.  D-600 and Co2+ did not prevent the 45Ca2+ increase produced by PZ, but La3+ did.  D-600 did not block the PZ response, but Co2+ and La3+ partially attenuated it.  La3+ also partially attenuated the DNP response.  Co2+ and D-600 prevented sustained contractures in response to DNP.  Thus, although K+, PZ, and DNP have the same final effect on the musculature of S. mansoni, it appears that their effects are not mediated by the same mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrciPgUKYe2JLVg90H21EOLACvtfcHk0lgTU9nbB2uuAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXkvV2gtbY%253D&md5=30eebdc9e0eeda34a00ed90504a2fb74</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2880%2990366-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252880%252990366-0%26sid%3Dliteratum%253Aachs%26aulast%3DFetterer%26aufirst%3DR.%2BH.%26aulast%3DPax%26aufirst%3DR.%2BA.%26aulast%3DBennett%26aufirst%3DJ.%2BL.%26atitle%3DPraziquantel%252C%2520potassium%2520and%25202%252C4-dinitrophenol%253A%2520analysis%2520of%2520their%2520action%2520on%2520the%2520musculature%2520of%2520Schistosoma%2520mansoni%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1980%26volume%3D64%26spage%3D31%26epage%3D38%26doi%3D10.1016%2F0014-2999%2880%2990366-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renganathan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cioli, D.</span></span> <span> </span><span class="NLM_article-title">An international initiative on praziquantel use</span>. <i>Parasitol. Today</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1016/S0169-4758(98)01310-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1016%2FS0169-4758%2898%2901310-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=17040826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A280%3ADC%252BD28ngvV2ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1998&pages=390-391&author=E.+Renganathanauthor=D.+Cioli&title=An+international+initiative+on+praziquantel+use&doi=10.1016%2FS0169-4758%2898%2901310-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">An international initiative on praziquantel use</span></div><div class="casAuthors">Renganathan E; Cioli D</div><div class="citationInfo"><span class="NLM_cas:title">Parasitology today (Personal ed.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">390-1</span>
        ISSN:<span class="NLM_cas:issn">0169-4758</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCGDiedPKcpe2mnZh2OgS0fW6udTcc2eaTsicCggOXv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28ngvV2ltA%253D%253D&md5=0e2b79ee5a5db8204370813aa207d85b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0169-4758%2898%2901310-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-4758%252898%252901310-6%26sid%3Dliteratum%253Aachs%26aulast%3DRenganathan%26aufirst%3DE.%26aulast%3DCioli%26aufirst%3DD.%26atitle%3DAn%2520international%2520initiative%2520on%2520praziquantel%2520use%26jtitle%3DParasitol.%2520Today%26date%3D1998%26volume%3D14%26spage%3D390%26epage%3D391%26doi%3D10.1016%2FS0169-4758%2898%2901310-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span> </span><span class="NLM_article-title">Drugs for Neglected Diseases Initiative.
Acoziborole</span>. <a href="https://dndi.org/research-development/portfolio/acoziborole/" class="extLink">https://dndi.org/research-development/portfolio/acoziborole/</a> (accessed April 10, <span class="NLM_year">2021</span>)</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drugs+for+Neglected+Diseases+Initiative.%0AAcoziborole.+https%3A%2F%2Fdndi.org%2Fresearch-development%2Fportfolio%2Facoziborole%2F+%28accessed+April+10%2C+2021%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DDrugs%2520for%2520Neglected%2520Diseases%2520Initiative.%250AAcoziborole%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klug, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Repurposing Strategies for Neglected Diseases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2569</span>– <span class="NLM_lpage">2575</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1016%2Fj.bmcl.2016.03.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=27080183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVGqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2569-2575&author=D.+M.+Klugauthor=M.+H.+Gelbauthor=M.+P.+Pollastri&title=Repurposing+Strategies+for+Neglected+Diseases&doi=10.1016%2Fj.bmcl.2016.03.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing strategies for tropical disease drug discovery</span></div><div class="casAuthors">Klug, Dana M.; Gelb, Michael H.; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2569-2576</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neglected tropical diseases (NTDs) and other diseases of the developing world, such as malaria, attract research investments that are disproportionately low compared to their impact on human health worldwide.  Therefore, pragmatic methods for launching new drug discovery programs have emerged that repurpose existing chem. matter as new drugs or new starting points for optimization.  In this Digest we describe applications of different repurposing approaches for NTDs, and provide a means by which these approaches may be differentiated from each other.  These include drug repurposing, target repurposing, target class repurposing, and lead repurposing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7WuWi-qOAgbVg90H21EOLACvtfcHk0lgTU9nbB2uuAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVGqt7c%253D&md5=e47072a70623e0e3f771880e31578b26</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.103%26sid%3Dliteratum%253Aachs%26aulast%3DKlug%26aufirst%3DD.%2BM.%26aulast%3DGelb%26aufirst%3DM.%2BH.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DRepurposing%2520Strategies%2520for%2520Neglected%2520Diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2569%26epage%3D2575%26doi%3D10.1016%2Fj.bmcl.2016.03.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">11280</span>– <span class="NLM_lpage">11304</span>, <span class="refDoi"> DOI: 10.1021/cr500197d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr500197d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12kurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=11280-11304&author=C.+Merrittauthor=L.+E.+Silvaauthor=A.+L.+Tannerauthor=K.+Stuartauthor=M.+P.+Pollastri&title=Kinases+as+Druggable+Targets+in+Trypanosomatid+Protozoan+Parasites&doi=10.1021%2Fcr500197d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites</span></div><div class="casAuthors">Merritt, Christopher; Silva, Lisseth E.; Tanner, Angela L.; Stuart, Kenneth; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11280-11304</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ZwVA0tDwbrVg90H21EOLACvtfcHk0lhWOwPT3ADcqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12kurnJ&md5=960674aae803f0db316c24ef0b5159bc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fcr500197d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr500197d%26sid%3Dliteratum%253Aachs%26aulast%3DMerritt%26aufirst%3DC.%26aulast%3DSilva%26aufirst%3DL.%2BE.%26aulast%3DTanner%26aufirst%3DA.%2BL.%26aulast%3DStuart%26aufirst%3DK.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DKinases%2520as%2520Druggable%2520Targets%2520in%2520Trypanosomatid%2520Protozoan%2520Parasites%26jtitle%3DChem.%2520Rev.%26date%3D2014%26volume%3D114%26spage%3D11280%26epage%3D11304%26doi%3D10.1021%2Fcr500197d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naula, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, J. C.</span></span> <span> </span><span class="NLM_article-title">Protein kinases as drug targets in trypanosomes and <i>Leishmania</i></span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1754</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2005.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1016%2Fj.bbapap.2005.08.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=16198642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlags7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=151-159&author=C.+Naulaauthor=M.+Parsonsauthor=J.+C.+Mottram&title=Protein+kinases+as+drug+targets+in+trypanosomes+and+Leishmania&doi=10.1016%2Fj.bbapap.2005.08.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinases as drug targets in trypanosomes and Leishmania</span></div><div class="casAuthors">Naula, Christina; Parsons, Marilyn; Mottram, Jeremy C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1754</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">151-159</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein kinases represent promising drug targets for a no. of human and animal diseases.  The recent completion of the sequenced genomes of three human-infective trypanosomatid protozoa, Leishmania major, Trypanosoma brucei and Trypanosoma cruzi, has allowed the kinome for each parasite to be defined as 179, 156 and 171 eukaryotic protein kinases resp., that is about one third of the human complement.  The anal. revealed that the trypanosomatids lack members of the receptor-linked or cytosolic tyrosine kinase families, but have an abundance of STE and CMGC family protein kinases likely to be involved in regulating cell cycle control, differentiation and response to stress during their complex life-cycles.  In this review, we examine the prospects for exploiting differences between parasite and mammalian protein kinases to develop novel anti-parasitic chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF-zsVbsp6gbVg90H21EOLACvtfcHk0lhWOwPT3ADcqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlags7nJ&md5=f65a9a3b2c5ccd41e54a7a01b609ba44</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2005.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2005.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DNaula%26aufirst%3DC.%26aulast%3DParsons%26aufirst%3DM.%26aulast%3DMottram%26aufirst%3DJ.%2BC.%26atitle%3DProtein%2520kinases%2520as%2520drug%2520targets%2520in%2520trypanosomes%2520and%2520Leishmania%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2005%26volume%3D1754%26spage%3D151%26epage%3D159%26doi%3D10.1016%2Fj.bbapap.2005.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammarton, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, J. C.</span></span> <span> </span><span class="NLM_article-title"><i>Trypanosoma brucei</i> Polo-like Kinase is Essential for Basal Body Duplication, kDNA Segregation and Cytokinesis</span>. <i>Mol. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1229</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2958.2007.05866.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1111%2Fj.1365-2958.2007.05866.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=17662039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWnur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2007&pages=1229-1249&author=T.+C.+Hammartonauthor=S.+Kramerauthor=L.+Tetleyauthor=M.+Boshartauthor=J.+C.+Mottram&title=Trypanosoma+brucei+Polo-like+Kinase+is+Essential+for+Basal+Body+Duplication%2C+kDNA+Segregation+and+Cytokinesis&doi=10.1111%2Fj.1365-2958.2007.05866.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Trypanosoma brucei Polo-like kinase is essential for basal body duplication, kDNA segregation and cytokinesis</span></div><div class="casAuthors">Hammarton, Tansy C.; Kramer, Susanne; Tetley, Laurence; Boshart, Michael; Mottram, Jeremy C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Microbiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1229-1248</span>CODEN:
                <span class="NLM_cas:coden">MOMIEE</span>;
        ISSN:<span class="NLM_cas:issn">0950-382X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinases (PLKs) are conserved eukaryotic cell cycle regulators, which play multiple roles, particularly during mitosis.  The function of Trypanosoma brucei PLK was investigated in procyclic and bloodstream-form parasites.  In procyclic trypanosomes, RNA interference (RNAi) of PLK, or overexpression of TY1-epitope-tagged PLK (PLKty), but not overexpression of a kinase-dead variant, resulted in the accumulation of cells that had divided their nucleus but not their kinetoplast (2N1K cells).  Anal. of basal bodies and flagella in these cells suggested the defect in kinetoplast division arose because of an inhibition of basal body duplication, which occurred when PLK expression levels were altered.  Addnl., a defect in kDNA replication was obsd. in the 2N1K cells.  However, the 2N1K cells obtained by each approach were not equiv.  Following PLK depletion, the single kinetoplast was predominantly located between the two divided nuclei, while in cells overexpressing PLKty, the kinetoplast was mainly found at the posterior end of the cell, suggesting a role for PLK kinase activity in basal body and kinetoplast migration.  PLK RNAi in blood-stream trypanosomes also delayed kinetoplast division, and was further obsd. to inhibit furrow ingression during cytokinesis.  Notably, no addnl. roles were detected for trypanosome PLK in mitosis, setting this protein kinase apart from its counterparts in other eukaryotes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy4NuIRGtYOLVg90H21EOLACvtfcHk0lj8QYpVYnAG-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWnur%252FE&md5=2473993f8b21b2f18518840a9b5a0c9c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2958.2007.05866.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2958.2007.05866.x%26sid%3Dliteratum%253Aachs%26aulast%3DHammarton%26aufirst%3DT.%2BC.%26aulast%3DKramer%26aufirst%3DS.%26aulast%3DTetley%26aufirst%3DL.%26aulast%3DBoshart%26aufirst%3DM.%26aulast%3DMottram%26aufirst%3DJ.%2BC.%26atitle%3DTrypanosoma%2520brucei%2520Polo-like%2520Kinase%2520is%2520Essential%2520for%2520Basal%2520Body%2520Duplication%252C%2520kDNA%2520Segregation%2520and%2520Cytokinesis%26jtitle%3DMol.%2520Microbiol.%26date%3D2007%26volume%3D65%26spage%3D1229%26epage%3D1249%26doi%3D10.1111%2Fj.1365-2958.2007.05866.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo-Arratta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seixas, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amata, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordon-Obras, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas-Barros, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colmenarejo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlanga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Identification and Characterization of Hundreds of Potent and Selective Inhibitors of <i>Trypanosoma brucei</i> Growth from a Kinase-Targeted Library Screening Campaign</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e3253</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0003253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1371%2Fjournal.pntd.0003253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=25340575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFeht7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&author=R.+Diazauthor=S.+Luengo-Arrattaauthor=J.+D.+Seixasauthor=E.+Amataauthor=W.+Devineauthor=C.+Cordon-Obrasauthor=D.+I.+Rojas-Barrosauthor=E.+Jimenezauthor=F.+Ortegaauthor=S.+Crouchauthor=G.+Colmenarejoauthor=J.+M.+Fiandorauthor=J.+J.+Martinauthor=M.+Berlangaauthor=S.+Gonzalezauthor=P.+Manzanoauthor=M.+Navarroauthor=M.+P.+Pollastri&title=Identification+and+Characterization+of+Hundreds+of+Potent+and+Selective+Inhibitors+of+Trypanosoma+brucei+Growth+from+a+Kinase-Targeted+Library+Screening+Campaign&doi=10.1371%2Fjournal.pntd.0003253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign</span></div><div class="casAuthors">Diaz, Rosario; Luengo-Arratta, Sandra A.; Seixas, Joao D.; Amata, Emanuele; Devine, William; Cordon-Obras, Carlos; Rojas-Barros, Domingo I.; Jimenez, Elena; Ortega, Fatima; Crouch, Sabrinia; Colmenarejo, Gonzalo; Fiandor, Jose Maria; Martin, Jose Julio; Berlanga, Manuela; Gonzalez, Silvia; Manzano, Pilar; Navarro, Miguel; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e3253/1-e3253/14, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In the interest of identification of new kinase-targeting chemotypes for target and pathway anal. and drug discovery in Trypanosomal brucei, a high-throughput screen of 42,444 focused inhibitors from the GlaxoSmithKline screening collection was performed against parasite cell cultures and counter-screened against human hepatocarcinoma (HepG2) cells.  In this way, we have identified 797 sub-micromolar inhibitors of T. brucei growth that are at least 100-fold selective over HepG2 cells.  Importantly, 242 of these hit compds. acted rapidly in inhibiting cellular growth, 137 showed rapid cidality.  A variety of in silico and in vitro physicochem. and drug metab. properties were assessed, and human kinase selectivity data were obtained, and, based on these data, we prioritized three compds. for pharmacokinetic assessment and demonstrated parasitol. cure of a murine bloodstream infection of T. brucei rhodesiense with one of these compds. (NEU-1053).  This work represents a successful implementation of a unique industrial-academic collaboration model aimed at identification of high quality inhibitors that will provide the parasitol. community with chem. matter that can be utilized to develop kinase-targeting tool compds.  Furthermore these results are expected to provide rich starting points for discovery of kinase-targeting tool compds. for T. brucei, and new HAT therapeutics discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPav6cECtioLVg90H21EOLACvtfcHk0lj8QYpVYnAG-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFeht7w%253D&md5=d61b812b1af6aefb0ecdd1fc72c19897</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0003253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0003253%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz%26aufirst%3DR.%26aulast%3DLuengo-Arratta%26aufirst%3DS.%26aulast%3DSeixas%26aufirst%3DJ.%2BD.%26aulast%3DAmata%26aufirst%3DE.%26aulast%3DDevine%26aufirst%3DW.%26aulast%3DCordon-Obras%26aufirst%3DC.%26aulast%3DRojas-Barros%26aufirst%3DD.%2BI.%26aulast%3DJimenez%26aufirst%3DE.%26aulast%3DOrtega%26aufirst%3DF.%26aulast%3DCrouch%26aufirst%3DS.%26aulast%3DColmenarejo%26aufirst%3DG.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DJ.%2BJ.%26aulast%3DBerlanga%26aufirst%3DM.%26aulast%3DGonzalez%26aufirst%3DS.%26aulast%3DManzano%26aufirst%3DP.%26aulast%3DNavarro%26aufirst%3DM.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520Hundreds%2520of%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Trypanosoma%2520brucei%2520Growth%2520from%2520a%2520Kinase-Targeted%2520Library%2520Screening%2520Campaign%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2014%26volume%3D8%26doi%3D10.1371%2Fjournal.pntd.0003253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5992</span>– <span class="NLM_lpage">6000</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1016%2Fj.bmcl.2013.08.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=24054120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5992-6000&author=M.+D.+Shultz&title=The+thermodynamic+basis+for+the+use+of+lipophilic+efficiency+%28LipE%29+in+enthalpic+optimizations&doi=10.1016%2Fj.bmcl.2013.08.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5992-6000</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Approaches to improve the efficiency of mol. optimizations have received great attention and numerous efficiency metrics have been introduced to assist in this effort.  Optimization of properties is equally important to optimization of potency and therefore these metrics contain potency vs. property calcns.  Widespread use of a metric does not guarantee its accuracy and a further understanding of which, if any, metric increases the probability of success was sought.  An anal. of LE, LELP and LipE based on theor. and exptl. data was performed demonstrating that LipE most strongly correlates with compd. quality as defined by enthalpy-driven binding.  The basis for the prioritization of LipE over other metrics in enthalpic optimizations is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobuMO74LdKnbVg90H21EOLACvtfcHk0lgvEMOfuZWtrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P&md5=23d948d1135eeefdfebc60846f28ec2b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.030%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DThe%2520thermodynamic%2520basis%2520for%2520the%2520use%2520of%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520in%2520enthalpic%2520optimizations%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5992%26epage%3D6000%26doi%3D10.1016%2Fj.bmcl.2013.08.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1021/cn100008c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-449&author=T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Moving+beyond+rules%3A+The+development+of+a+central+nervous+system+multiparameter+optimization+%28CNS+MPO%29+approach+to+enable+alignment+of+druglike+properties&doi=10.1021%2Fcn100008c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">435-449</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The interplay among commonly used physicochem. properties in drug design was examd. and utilized to create a prospective design tool focused on the alignment of key druglike attributes.  Using a set of six physicochem. parameters ((a) lipophilicity, calcd. partition coeff. (ClogP); (b) calcd. distribution coeff. at pH = 7.4 (ClogD); (c) mol. wt. (MW); (d) topol. polar surface area (TPSA); (e) no. of hydrogen bond donors (HBD); (f) most basic center (pKa)), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compds. (N = 11 303).  The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates.  This anal. suggests that this algorithm could potentially be used to identify compds. with a higher probability of successfully testing hypotheses in the clinic.  In addn., a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set.  The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chem. design space through a holistic assessment approach.  Based on six physicochem. properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compds. with increased probability of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3Mvkgm_X5bVg90H21EOLACvtfcHk0lgvEMOfuZWtrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D&md5=e94998f65a420be6ee4dec4a987cb983</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fcn100008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100008c%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DMoving%2520beyond%2520rules%253A%2520The%2520development%2520of%2520a%2520central%2520nervous%2520system%2520multiparameter%2520optimization%2520%2528CNS%2520MPO%2529%2520approach%2520to%2520enable%2520alignment%2520of%2520druglike%2520properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D449%26doi%3D10.1021%2Fcn100008c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruciani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carosati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Boeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vianello, R.</span></span> <span> </span><span class="NLM_article-title">MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6970</span>– <span class="NLM_lpage">6979</span>, <span class="refDoi"> DOI: 10.1021/jm050529c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050529c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGis73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6970-6979&author=G.+Crucianiauthor=E.+Carosatiauthor=B.+De+Boeckauthor=K.+Ethirajuluauthor=C.+Mackieauthor=T.+Howeauthor=R.+Vianello&title=MetaSite%3A+Understanding+metabolism+in+human+cytochromes+from+the+perspective+of+the+chemist&doi=10.1021%2Fjm050529c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">MetaSite: Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist</span></div><div class="casAuthors">Cruciani, Gabriele; Carosati, Emanuele; De Boeck, Benoit; Ethirajulu, Kantharaj; Mackie, Claire; Howe, Trevor; Vianello, Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6970-6979</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification of metabolic biotransformations can significantly affect the drug discovery process.  Since bioavailability, activity, toxicity, distribution, and final elimination all depend on metabolic biotransformations, it would be extremely advantageous if this information could be produced early in the discovery phase.  Once obtained, this information can help chemists to judge whether a potential candidate should be eliminated from the pipeline or modified to improve chem. stability or safety of new compds.  The use of in silico methods to predict the site of metab. in phase I cytochrome-mediated reactions is a starting point in any metabolic pathway prediction.  This paper presents a new method, specifically designed for chemists, that provides the cytochrome involved and the site of metab. for any human cytochrome P 450 (CYP) mediated reaction acting on new substrates.  The methodol. can be applied automatically to all the cytochromes for which 3D structure is known and can be used by chemists to detect positions that should be protected in order to avoid metabolic degrdn. or to check the suitability of a new scaffold or prodrug.  The fully automated procedure is also a valuable new tool in early ADME-Tox assays (absorption, distribution, metab., and excretion toxicity assays), where drug safety and metabolic profile patterns must be evaluated as soon, and as early, as possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzNL56jqRMpbVg90H21EOLACvtfcHk0liIWB-BKpohpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGis73F&md5=0a4576ffbea74e677832b7dbe8e036f0</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm050529c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050529c%26sid%3Dliteratum%253Aachs%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DCarosati%26aufirst%3DE.%26aulast%3DDe%2BBoeck%26aufirst%3DB.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DHowe%26aufirst%3DT.%26aulast%3DVianello%26aufirst%3DR.%26atitle%3DMetaSite%253A%2520Understanding%2520metabolism%2520in%2520human%2520cytochromes%2520from%2520the%2520perspective%2520of%2520the%2520chemist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6970%26epage%3D6979%26doi%3D10.1021%2Fjm050529c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: Increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+Increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0liIWB-BKpohpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520Increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0ljgmUAjpWJRRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barden, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. F.</span></span> <span> </span><span class="NLM_article-title">The blood-brain barrier (BBB) score</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9824</span>– <span class="NLM_lpage">9836</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01220</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01220" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFGqtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9824-9836&author=M.+Guptaauthor=H.+J.+Leeauthor=C.+J.+Bardenauthor=D.+F.+Weaver&title=The+blood-brain+barrier+%28BBB%29+score&doi=10.1021%2Facs.jmedchem.9b01220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The Blood-Brain Barrier (BBB) Score</span></div><div class="casAuthors">Gupta, Mayuri; Lee, Hyeok Jun; Barden, Christopher J.; Weaver, Donald F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9824-9836</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The blood-brain barrier (BBB) protects the brain from the toxic side effects of drugs and exogenous mols.  However, it is crucial that medications developed for neurol. disorders cross into the brain in therapeutic concns.  Understanding the BBB interaction with drug mols. based on physicochem. property space can guide effective and efficient drug design.  An algorithm, designated "BBB Score", composed of stepwise and polynomial piecewise functions, is herein proposed for predicting BBB penetration based on five physicochem. descriptors: no. of arom. rings, heavy atoms, MWHBN (a descriptor comprising mol. wt., hydrogen bond donor, and hydrogen bond acceptors), topol. polar surface area, and pKa.  On the basis of statistical analyses of our results, the BBB Score outperformed (AUC = 0.86) currently employed MPO approaches (MPO, AUC = 0.61; MPO_V2, AUC = 0.67).  Initial evaluation of physicochem. property space using the BBB Score is a valuable addn. to currently available drug design algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5_qEoBbf20LVg90H21EOLACvtfcHk0ljgmUAjpWJRRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFGqtbvK&md5=26dd989ea2ca772d72702f4abc47c8fa</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01220%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DBarden%26aufirst%3DC.%2BJ.%26aulast%3DWeaver%26aufirst%3DD.%2BF.%26atitle%3DThe%2520blood-brain%2520barrier%2520%2528BBB%2529%2520score%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9824%26epage%3D9836%26doi%3D10.1021%2Facs.jmedchem.9b01220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernatchez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCall, L.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvet, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klug, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalani, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bag, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buskes, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leed, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncal, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siqueira-Neto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Scaffold and parasite hopping: discovery of new protozoal proliferation inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00453</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00453" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVShsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=249-257&author=B.+Singhauthor=J.+A.+Bernatchezauthor=L.-I.+McCallauthor=C.+M.+Calvetauthor=J.+Ackermannauthor=J.+M.+Souzaauthor=D.+Thomasauthor=E.+M.+Silvaauthor=K.+A.+Bachovchinauthor=D.+M.+Klugauthor=H.+B.+Jalaniauthor=S.+Bagauthor=M.+J.+Buskesauthor=S.+E.+Leedauthor=N.+E.+Roncalauthor=E.+C.+Pennauthor=J.+Erathauthor=A.+Rodriguezauthor=R.+J.+Sciottiauthor=R.+F.+Campbellauthor=J.+H.+McKerrowauthor=J.+Siqueira-Netoauthor=L.+Ferrinsauthor=M.+P.+Pollastri&title=Scaffold+and+parasite+hopping%3A+discovery+of+new+protozoal+proliferation+inhibitors&doi=10.1021%2Facsmedchemlett.9b00453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold and Parasite Hopping: Discovery of New Protozoal Proliferation Inhibitors</span></div><div class="casAuthors">Singh, Baljinder; Bernatchez, Jean A.; McCall, Laura-Isobel; Calvet, Claudia M.; Ackermann, Jasmin; Souza, Julia M.; Thomas, Diane; Silva, Everton M.; Bachovchin, Kelly A.; Klug, Dana M.; Jalani, Hitesh B.; Bag, Seema; Buskes, Melissa J.; Leed, Susan E.; Roncal, Norma E.; Penn, Erica C.; Erath, Jessey; Rodriguez, Ana; Sciotti, Richard J.; Campbell, Robert F.; McKerrow, James; Siqueira-Neto, Jair L.; Ferrins, Lori; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-257</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Utilizing a target repurposing and parasite-hopping approach, we tested a previously reported library of compds. that were active against Trypanosoma brucei, plus 31 new compds., against a variety of protozoan parasites including Trypanosoma cruzi, Leishmania major, Leishmania donovani, and Plasmodium falciparum.  This led to the discovery of several compds. with submicromolar activities and improved physicochem. properties that are early leads toward the development of chemotherapeutic agents against kinetoplastid diseases and malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodxpgfCEC3qLVg90H21EOLACvtfcHk0ljgmUAjpWJRRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVShsA%253D%253D&md5=69a28d4b3a7991e528b3ee474b3e0500</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00453%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DBernatchez%26aufirst%3DJ.%2BA.%26aulast%3DMcCall%26aufirst%3DL.-I.%26aulast%3DCalvet%26aufirst%3DC.%2BM.%26aulast%3DAckermann%26aufirst%3DJ.%26aulast%3DSouza%26aufirst%3DJ.%2BM.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DSilva%26aufirst%3DE.%2BM.%26aulast%3DBachovchin%26aufirst%3DK.%2BA.%26aulast%3DKlug%26aufirst%3DD.%2BM.%26aulast%3DJalani%26aufirst%3DH.%2BB.%26aulast%3DBag%26aufirst%3DS.%26aulast%3DBuskes%26aufirst%3DM.%2BJ.%26aulast%3DLeed%26aufirst%3DS.%2BE.%26aulast%3DRoncal%26aufirst%3DN.%2BE.%26aulast%3DPenn%26aufirst%3DE.%2BC.%26aulast%3DErath%26aufirst%3DJ.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DCampbell%26aufirst%3DR.%2BF.%26aulast%3DMcKerrow%26aufirst%3DJ.%2BH.%26aulast%3DSiqueira-Neto%26aufirst%3DJ.%26aulast%3DFerrins%26aufirst%3DL.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DScaffold%2520and%2520parasite%2520hopping%253A%2520discovery%2520of%2520new%2520protozoal%2520proliferation%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D249%26epage%3D257%26doi%3D10.1021%2Facsmedchemlett.9b00453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Probst, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Sakkary, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, A.</span></span> <span> </span><span class="NLM_article-title">Bioactivity of Farnesyltransferase Inhibitors Against <i>Entamoeba histolytica</i> and <i>Schistosoma mansoni</i></span>. <i>Frront. Cell. Infect. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e478</span> <span class="refDoi"> DOI: 10.3389/fcimb.2019.00180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.3389%2Ffcimb.2019.00180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=32039053" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=A.+Probstauthor=T.+N.+Nguyenauthor=N.+El-Sakkaryauthor=D.+Skinnerauthor=B.+M.+Suzukiauthor=F.+S.+Bucknerauthor=M.+H.+Gelbauthor=C.+R.+Caffreyauthor=A.+Debnath&title=Bioactivity+of+Farnesyltransferase+Inhibitors+Against+Entamoeba+histolytica+and+Schistosoma+mansoni&doi=10.3389%2Ffcimb.2019.00180"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3389%2Ffcimb.2019.00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcimb.2019.00180%26sid%3Dliteratum%253Aachs%26aulast%3DProbst%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DT.%2BN.%26aulast%3DEl-Sakkary%26aufirst%3DN.%26aulast%3DSkinner%26aufirst%3DD.%26aulast%3DSuzuki%26aufirst%3DB.%2BM.%26aulast%3DBuckner%26aufirst%3DF.%2BS.%26aulast%3DGelb%26aufirst%3DM.%2BH.%26aulast%3DCaffrey%26aufirst%3DC.%2BR.%26aulast%3DDebnath%26aufirst%3DA.%26atitle%3DBioactivity%2520of%2520Farnesyltransferase%2520Inhibitors%2520Against%2520Entamoeba%2520histolytica%2520and%2520Schistosoma%2520mansoni%26jtitle%3DFrront.%2520Cell.%2520Infect.%2520Microbiol.%26date%3D2019%26volume%3D9%26doi%3D10.3389%2Ffcimb.2019.00180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo-Arreola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Sakkary, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarnagin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meewan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rascón, A. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podust, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashrafi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, C. R.</span></span> <span> </span><span class="NLM_article-title">Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0005680</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0005680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1371%2Fjournal.pntd.0005680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=28704396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKgu7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&author=T.+Longauthor=L.+Rojo-Arreolaauthor=D.+Shiauthor=N.+El-Sakkaryauthor=K.+Jarnaginauthor=F.+Rockauthor=M.+Meewanauthor=A.+A.+Rasc%C3%B3nauthor=L.+Linauthor=K.+A.+Cunninghamauthor=G.+A.+Lemieuxauthor=L.+Podustauthor=R.+Abagyanauthor=K.+Ashrafiauthor=J.+H.+McKerrowauthor=C.+R.+Caffrey&title=Phenotypic%2C+chemical+and+functional+characterization+of+cyclic+nucleotide+phosphodiesterase+4+%28PDE4%29+as+a+potential+anthelmintic+drug+target&doi=10.1371%2Fjournal.pntd.0005680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target</span></div><div class="casAuthors">Long, Thavy; Rojo-Arreola, Liliana; Shi, Da; El-Sakkary, Nelly; Jarnagin, Kurt; Rock, Fernando; Meewan, Maliwan; Rascon, Alberto A.; Lin, Lin; Cunningham, Katherine A.; Lemieux, George A.; Podust, Larissa; Abagyan, Ruben; Ashrafi, Kaveh; McKerrow, James H.; Caffrey, Conor R.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0005680/1-e0005680/27</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background Reliance on just one drug to treat the prevalent tropical disease, schistosomiasis, spurs the search for new drugs and drug targets.  Inhibitors of human cyclic nucleotide phosphodiesterases (huPDEs), including PDE4, are under development as novel drugs to treat a range of chronic indications including asthma, chronic obstructive pulmonary disease and Alzheimer's disease.  One class of huPDE4 inhibitors that has yielded marketed drugs is the benzoxaboroles (Anacor Pharmaceuticals).  Methodol./Principal findings A phenotypic screen involving Schistosoma mansoni and 1,085 benzoxaboroles identified a subset of huPDE4 inhibitors that induced parasite hypermotility and degeneration.  To uncover the putative schistosome PDE4 target, we characterized four PDE4 sequences (SmPDE4A-D) in the parasite's genome and transcriptome, and cloned and recombinantly expressed the catalytic domain of SmPDE4A.  Among a set of benzoxaboroles and catechol inhibitors that differentially inhibit huPDE4, a relationship between the inhibition of SmPDE4A, and parasite hypermotility and degeneration, was measured.  To validate SmPDE4A as the benzoxaborole mol. target, we first generated Caenorhabditis elegans lines that express a cDNA for smpde4a on a pde4(ce268) mutant (hypermotile) background: the smpde4a transgene restored mutant worm motility to that of the wild type.  We then showed that benzoxaborole inhibitors of SmPDE4A that induce hypermotility in the schistosome also elicit a hypermotile response in the C. elegans lines that express the smpde4a transgene, thereby confirming SmPDE4A as the relevant target.  Conclusions/Significance The orthogonal chem., biol. and genetic strategies employed identify SmPDE4A's contribution to parasite motility and degeneration, and its potential as a drug target.  Transgenic C. elegans is highlighted as a potential screening tool to optimize small mol. chemistries to flatworm mol. drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKBmivor-rJLVg90H21EOLACvtfcHk0ljyorMMpOWy5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKgu7bP&md5=f20bcf6704231669a77645b633c2ca29</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005680%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DT.%26aulast%3DRojo-Arreola%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DEl-Sakkary%26aufirst%3DN.%26aulast%3DJarnagin%26aufirst%3DK.%26aulast%3DRock%26aufirst%3DF.%26aulast%3DMeewan%26aufirst%3DM.%26aulast%3DRasc%25C3%25B3n%26aufirst%3DA.%2BA.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DLemieux%26aufirst%3DG.%2BA.%26aulast%3DPodust%26aufirst%3DL.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DAshrafi%26aufirst%3DK.%26aulast%3DMcKerrow%26aufirst%3DJ.%2BH.%26aulast%3DCaffrey%26aufirst%3DC.%2BR.%26atitle%3DPhenotypic%252C%2520chemical%2520and%2520functional%2520characterization%2520of%2520cyclic%2520nucleotide%2520phosphodiesterase%25204%2520%2528PDE4%2529%2520as%2520a%2520potential%2520anthelmintic%2520drug%2520target%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26doi%3D10.1371%2Fjournal.pntd.0005680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyanaraman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dissous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, C. R.</span></span> <span> </span><span class="NLM_article-title">Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in <i>Schistosoma mansoni</i></span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0004356</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0004356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1371%2Fjournal.pntd.0004356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=26751972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVGiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&author=T.+Longauthor=R.+J.+Neitzauthor=R.+Beasleyauthor=C.+Kalyanaramanauthor=B.+M.+Suzukiauthor=M.+P.+Jacobsonauthor=C.+Dissousauthor=J.+H.+McKerrowauthor=D.+H.+Drewryauthor=W.+J.+Zuercherauthor=R.+Singhauthor=C.+R.+Caffrey&title=Structure-Bioactivity+Relationship+for+Benzimidazole+Thiophene+Inhibitors+of+Polo-Like+Kinase+1+%28PLK1%29%2C+a+Potential+Drug+Target+in+Schistosoma+mansoni&doi=10.1371%2Fjournal.pntd.0004356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-bioactivity relationship for benzimidazole thiophene inhibitors of polo-like kinase 1 (PLK1), a potential drug target in Schistosoma mansoni</span></div><div class="casAuthors">Long, Thavy; Neitz, R. Jeffrey; Beasley, Rachel; Kalyanaraman, Chakrapani; Suzuki, Brian M.; Jacobson, Matthew P.; Dissous, Colette; McKerrow, James H.; Drewry, David H.; Zuercher, William J.; Singh, Rahul; Caffrey, Conor R.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0004356/1-e0004356/21</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">BackgroundSchistosoma flatworm parasites cause schistosomiasis, a chronic and debilitating disease of poverty in developing countries.  Praziquantel is employed for treatment and disease control.  However, its efficacy spectrum is incomplete (less active or inactive against immature stages of the parasite) and there is a concern of drug resistance.  Thus, there is a need to identify new drugs and drug targets.  Methodol./Principal Findings We show that RNA interference (RNAi) of the Schistosoma mansoni ortholog of human polo-like kinase (huPLK)1 elicits a deleterious phenotypic alteration in post-infective larvae (schistosomula or somules).  Phenotypic screening and anal. of schistosomula and adult S. mansoni with small mol. inhibitors of huPLK1 identified a no. of potent anti-schistosomals.  Among these was a GlaxoSmithKline (GSK) benzimidazole thiophene inhibitor that has completed Phase I clin. trials for treatment of solid tumor malignancies.  We then obtained GSKs Published Kinase Inhibitor Sets (PKIS) 1 and 2, and phenotypically screened an expanded series of 38 benzimidazole thiophene PLK1 inhibitors.  Computational anal. of controls and PLK1 inhibitor-treated populations of somules demonstrated a distinctive phenotype distribution.  Using principal component anal. (PCA), the phenotypes exhibited by these populations were mapped, visualized and analyzed through projection to a low-dimensional space.  The phenotype distribution was found to have a distinct shape and topol., which could be elicited using cluster anal.  A structure-activity relationship (SAR) was identified for the benzimidazole thiophenes that held for both somules and adult parasites.  The most potent inhibitors produced marked phenotypic alterations at 1-2 μM within 1 h.  Among these were compds. previously characterized as potent inhibitors of huPLK1 in cell assays.  Conclusions/Significance The reverse genetic and chem. SAR data support a continued investigation of SmPLK1 as a possible drug target and/or the prosecution of the benzimidazole thiophene chemotype as a source of novel anti-schistosomals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdD29YvjLqOLVg90H21EOLACvtfcHk0ljyorMMpOWy5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVGiurY%253D&md5=9725815b30a5913f9ed25515ef61b3b3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0004356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0004356%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DT.%26aulast%3DNeitz%26aufirst%3DR.%2BJ.%26aulast%3DBeasley%26aufirst%3DR.%26aulast%3DKalyanaraman%26aufirst%3DC.%26aulast%3DSuzuki%26aufirst%3DB.%2BM.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DDissous%26aufirst%3DC.%26aulast%3DMcKerrow%26aufirst%3DJ.%2BH.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DCaffrey%26aufirst%3DC.%2BR.%26atitle%3DStructure-Bioactivity%2520Relationship%2520for%2520Benzimidazole%2520Thiophene%2520Inhibitors%2520of%2520Polo-Like%2520Kinase%25201%2520%2528PLK1%2529%252C%2520a%2520Potential%2520Drug%2520Target%2520in%2520Schistosoma%2520mansoni%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2016%26volume%3D10%26doi%3D10.1371%2Fjournal.pntd.0004356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kyere-Davies, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agyare, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boakye, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, C. R.</span></span> <span> </span><span class="NLM_article-title">Effect of Phenotypic Screening of Extracts and Fractions of <i>Erythrophleum ivorense</i> Leaf and Stem Bark on Immature and Adult Stages of <i>Schistosoma mansoni</i></span>. <i>J. Parasitol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2018</i></span>, <span class="NLM_elocation-id">9431467</span> <span class="refDoi"> DOI: 10.1155/2018/9431467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1155%2F2018%2F9431467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=29977614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Flt12juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2018&publication_year=2018&author=G.+Kyere-Daviesauthor=C.+Agyareauthor=Y.+D.+Boakyeauthor=B.+M.+Suzukiauthor=C.+R.+Caffrey&title=Effect+of+Phenotypic+Screening+of+Extracts+and+Fractions+of+Erythrophleum+ivorense+Leaf+and+Stem+Bark+on+Immature+and+Adult+Stages+of+Schistosoma+mansoni&doi=10.1155%2F2018%2F9431467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Phenotypic Screening of Extracts and Fractions of Erythrophleum ivorense Leaf and Stem Bark on Immature and Adult Stages of Schistosoma mansoni</span></div><div class="casAuthors">Kyere-Davies Gertrude; Agyare Christian; Boakye Yaw Duah; Suzuki Brian M; Caffrey Conor R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of parasitology research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2018</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9431467</span>
        ISSN:<span class="NLM_cas:issn">2090-0023</span>.
    </div><div class="casAbstract">Schistosomiasis is a disease caused by a flatworm parasite that infects people in tropical and subtropical regions of Sub-Saharan Africa, South America, China, and Southeast Asia.  The reliance on just one drug for current treatment emphasizes the need for new chemotherapeutic strategies.  The aim of this study was to determine the phenotypic effects of extracts and fractions of leaf and stem bark of Erythrophleum ivorense (family Euphorbiaceae), a tree that grows in tropical parts of Africa, on two developmental stages of Schistosoma mansoni, namely, postinfective larvae (schistosomula or somules) and adults.  Methanol leaf and stem bark extracts of E. ivorense were successively fractionated with acetone, petroleum ether, ethyl acetate, and methanol.  These fractions were then incubated with somules at 0.3125 to 100 μg/mL and with adults at 1.25 μg/mL.  The acetone fractions of both the methanol leaf and bark of E. ivorense were most active against the somules whereas the petroleum ether fractions showed least activity.  For adult parasites, the acetone fraction of methanol bark extract also elicited phenotypic changes.  The data arising provide the first step in the discovery of new treatments for an endemic infectious disease using locally sourced African medicinal plants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIvDky2mD_DyCEBeYuoi7AfW6udTcc2ea2yA2LZQsEErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Flt12juw%253D%253D&md5=ff1f872ad10c5e8e17b797d94809bf3a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1155%2F2018%2F9431467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2018%252F9431467%26sid%3Dliteratum%253Aachs%26aulast%3DKyere-Davies%26aufirst%3DG.%26aulast%3DAgyare%26aufirst%3DC.%26aulast%3DBoakye%26aufirst%3DY.%2BD.%26aulast%3DSuzuki%26aufirst%3DB.%2BM.%26aulast%3DCaffrey%26aufirst%3DC.%2BR.%26atitle%3DEffect%2520of%2520Phenotypic%2520Screening%2520of%2520Extracts%2520and%2520Fractions%2520of%2520Erythrophleum%2520ivorense%2520Leaf%2520and%2520Stem%2520Bark%2520on%2520Immature%2520and%2520Adult%2520Stages%2520of%2520Schistosoma%2520mansoni%26jtitle%3DJ.%2520Parasitol.%2520Res.%26date%3D2018%26volume%3D2018%26doi%3D10.1155%2F2018%2F9431467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdulla, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, C. R.</span></span> <span> </span><span class="NLM_article-title"><i>Schistosomiasis Mansoni</i>: Novel Chemotherapy Using a Cysteine Protease Inhibitor</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e14</span> <span class="refDoi"> DOI: 10.1371/journal.pmed.0040014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=10.1371%2Fjournal.pmed.0040014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=17214506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;key=1%3ACAS%3A280%3ADC%252BD2svms1Sjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&author=M.-H.+Abdullaauthor=K.-C.+Limauthor=M.+Sajidauthor=J.+H.+McKerrowauthor=C.+R.+Caffrey&title=Schistosomiasis+Mansoni%3A+Novel+Chemotherapy+Using+a+Cysteine+Protease+Inhibitor&doi=10.1371%2Fjournal.pmed.0040014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor</span></div><div class="casAuthors">Abdulla Maha-Hamadien; Lim Kee-Chong; Sajid Mohammed; McKerrow James H; Caffrey Conor R</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Schistosomiasis is a chronic, debilitating parasitic disease infecting more than 200 million people and is second only to malaria in terms of public health importance.  Due to the lack of a vaccine, patient therapy is heavily reliant on chemotherapy with praziquantel as the World Health Organization-recommended drug, but concerns over drug resistance encourage the search for new drug leads.  METHODS AND FINDINGS:  The efficacy of the vinyl sulfone cysteine protease inhibitor K11777 was tested in the murine model of schistosomiasis mansoni.  Disease parameters measured were worm and egg burdens, and organ pathology including hepato- and splenomegaly, presence of parasite egg-induced granulomas in the liver, and levels of circulating alanine aminotransferase activity as a marker of hepatocellular function.  K11777 (25 mg/kg twice daily [BID]), administered intraperitoneally at the time of parasite migration through the skin and lungs (days 1-14 postinfection [p.i.]), resulted in parasitologic cure (elimination of parasite eggs) in five of seven cases and a resolution of other disease parameters.  K11777 (50 mg/kg BID), administered at the commencement of egg-laying by mature parasites (days 30-37 p.i.), reduced worm and egg burdens, and ameliorated organ pathology.  Using protease class-specific substrates and active-site labeling, one molecular target of K11777 was identified as the gut-associated cathepsin B1 cysteine protease, although other cysteine protease targets are not excluded.  In rodents, dogs, and primates, K11777 is nonmutagenic with satisfactory safety and pharmacokinetic profiles.  CONCLUSIONS:  The significant reduction in parasite burden and pathology by this vinyl sulfone cysteine protease inhibitor validates schistosome cysteine proteases as drug targets and offers the potential of a new direction for chemotherapy of human schistosomiasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfSjig6ZE6a_3jf77P2BG3fW6udTcc2ea2yA2LZQsEErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svms1Sjug%253D%253D&md5=b32c88c162ddebd16f54672485ebc6e6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0040014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0040014%26sid%3Dliteratum%253Aachs%26aulast%3DAbdulla%26aufirst%3DM.-H.%26aulast%3DLim%26aufirst%3DK.-C.%26aulast%3DSajid%26aufirst%3DM.%26aulast%3DMcKerrow%26aufirst%3DJ.%2BH.%26aulast%3DCaffrey%26aufirst%3DC.%2BR.%26atitle%3DSchistosomiasis%2520Mansoni%253A%2520Novel%2520Chemotherapy%2520Using%2520a%2520Cysteine%2520Protease%2520Inhibitor%26jtitle%3DPLoS%2520Med.%26date%3D2007%26volume%3D4%26doi%3D10.1371%2Fjournal.pmed.0040014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i184"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00674">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_07446"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00674?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00674</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional biological and ADME data, experimental procedures, and characterization (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_001.pdf">jm1c00674_si_001.pdf (477.52 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00674/suppl_file/jm1c00674_si_002.csv">jm1c00674_si_002.csv (4.17 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00674&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00674%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-13%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00674" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799d2fe48573cbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
